




Identifying Glaucoma Susceptibility Genes 




Patricia Stacey Graham 
BSc(Hons), GradDipEd 




Submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy (Medical Studies) 
University of Tasmania, March 2020 
i 
Declaration of Originality 
This thesis contains no material which has been accepted for a degree or diploma by the 
University or any other institution, except by way of background information and duly 
acknowledged in the thesis, and to the best of my knowledge and belief no material previously 
published or written by another person except where due acknowledgement is made in the text 
of the thesis, nor does the thesis contain any material that infringes copyright. 
13/3/2020 
ii 
Authority of access 
This thesis may be made available for loan and limited copying and communication in accordance with 
the Copyright Act 1968. 
13/3/2020 
iii 
Statement of ethical conduct 
The research associated with this thesis abides by the international and Australian codes on 
human experimentation and the guidelines and the rulings of the Ethics Committee of the 
University. 
Ethics Approval Numbers: 
University of Tasmania Human Research Ethics Committee H0014085 




To my parents 
Susie and Micky Lowry 
Who instilled in me the love of learning 
and who would have been so proud 
v 
Acknowledgements 
What a rollercoaster the last four years have been …. it’s been an amazing ride. Rollercoasters are no 
fun alone, and I would sincerely like to thank the following people who kept the ride rolling and to 
those who sat with me in the carriage and didn’t let me fall out. 
To the Australian Government for my Research Training Program Scholarship and to the Menzies 
Institute for supporting me and providing the opportunity to get back into medical research again. 
To my supervisors Professor Kathryn Burdon and Dr Jac Charlesworth; the dynamic duo of supervisory 
teams. Kath, you are a “mentor extraordinaire”. Your intelligence, passion and kindness are the perfect 
combination. You’ve always had the confidence in me that sometimes I didn’t have in myself, and I 
truly appreciate that. Jac, thank you for trusting me with your POAG families and teaching me linkage. 
You are one of the most patient people I know and you have taught me so much. You’ve constantly 
challenged me, which has made me a better scientist. Thank you both for taking me on, teaching me so 
much and getting me to the end. 
To the participants of OGGS and GIST, without whom this study would not have been possible. 
To the researchers, clinicians and statisticians involved with this project and to those who kindly 
provided us with data: Professors John Blangero, Jamie Craig, Joanne Curran, Alex Hewitt, Stuart 
MacGregor, David Mackey, Mary Wirtz, and Dr Tiger Zhou. 
To Sionne and JoJo – my amigos. It’s been the best ride with you the past four years. You have both 
been super patient with my “old school genetics” and getting me up to speed. More importantly, I’ve 
loved our morning chats, procrasti-coffees, lunches in the roundabout, time spent at various sports and 
having the odd celebratory drink. Cheers! 
To the team of bioinformaticians who have taught me so much along the way. Juan, Nick and Bennet, 
I absolutely could not have done this project without you. An extra thank you to Juan for helping me 
troubleshoot my methods and get them up and running. 
To the CompGen team and my “office-kids” in 502 – Ming, Duran, Raj, Kelsie, Alex, Aparna, Emma 
and Van. You’ve kept me young! 
To my friends from outside Menzies. Although many of you never really understood why I would do 
this, you’ve been nothing but supportive. Special thanks to my coffee-buddy, Karen. 
Most importantly, to my family; Al, Jess and Nicki. I could not have done this without your support, 
encouragement and love. I promise – no more mid-life crises …. for a while at least. 
vi 
Abstract 
Glaucoma encompasses a heterogenous group of eye diseases and is the leading cause of 
irreversible blindness worldwide. Death of retinal ganglion cells causes degeneration of the 
optic nerve with resultant loss in vision. Primary open-angle glaucoma (POAG) is the most 
common form of glaucoma. An increase in pressure inside the eye, the intraocular pressure 
(IOP), is the main risk factor for developing POAG. Pressure reducing medication and surgery 
are currently the only preventative measures, and means of slowing the progression of the 
disease, available to those at risk of POAG or already diagnosed with this disease. There is 
currently no cure for glaucoma.  
POAG is a highly heritable, complex disease. Genome-wide association studies (GWAS) have 
identified many common risk variants, each with small effect sizes, which may increase an 
individual’s susceptibility to developing this disease. However, these variants together only 
account for around 3% of the heritability of POAG. Rare variants have been proposed as a 
source of the missing heritability, and the most powerful way to enrich for rare variants is 
through family studies. Linkage studies have identified genes harbouring rare variants which 
cause the disease in around 10% of cases. It is proposed that other, unidentified rare variants 
with large effect sizes, may be important in POAG pathogenesis. 
The clinical intermediate traits of POAG that have been used for successful genetic studies 
include IOP, vertical cup to disc ratio (VCDR) and central corneal thickness (CCT). These 
highly heritable, quantitative traits are measurable in all individuals, regardless of their POAG 
disease status. IOP and VCDR are significantly genetically correlated with POAG disease 
status, making them ideal endophenotypes to use to identify variants and genes involved with 
POAG pathogenesis. CCT is not significantly genetically correlated with POAG, but is a well-
recognised risk factor for the disease, with thinner corneas associated with an increased risk of 
developing POAG. Identifying genes important in corneal development still gives us the 
opportunity to better understand the risk of developing POAG. GWAS have been very 
successful in identifying variants associated with each of these clinical intermediate traits, 
however, only a small proportion of the overall heritability for each trait is accounted for by 
these variants. 
For this study, we hypothesised that rare genetic variants associated with heritable ocular 
clinical traits could be identified in extended pedigrees and would improve our understanding 
vii 
of the genetic susceptibility to POAG. The first aim of this study was to determine the 
contribution of published genetic loci associated with POAG and related traits, to the trait 
variance of the clinical phenotypes in five extended POAG enriched families. The next aim 
was to use linkage analysis to identify regions harbouring potential POAG related risk variants 
in these five families. The final aim was to use in silico tools to investigate genetic variants 
within the most significant peaks identified from the linkage analysis. This study utilised whole 
exome sequencing data from 249 members of five large POAG enriched families, with detailed 
clinical data including IOP, VCDR and CCT measurements, to perform family-based 
association and linkage analyses within a variance components framework. These five 
extended families provide the opportunity to identify rare variants involved in disease due to 
the potential for variants to be enriched by transmission from founder individuals to successive 
generations. 
To identify the previously reported POAG loci, Aim 1 of this study began with a 
comprehensive literature review. To determine whether these loci contributed to the variance 
of the clinical intermediate traits of the families in this study, a family-based association 
analysis was conducted on genetic variants within literature reported regions. Several variants 
within published linkage regions were significantly associated with each of the three traits; 
including a single rare variant within MST1 on chromosome 3 (p = 9.60x10-5) and a haplotype 
within FLRT3 on chromosome 20 (p = 1.17x10-4 to p = 3.18x10-4), which were associated with 
a large increase in IOP in the family members who carry them. FLRT3 lies in a previously 
mapped glaucoma linkage region, GLC1K, and is an ideal candidate gene for further study. 
To identify novel genes associated with POAG and its endophenotypes, Aim 2 focused on 
linkage analyses using whole exome sequencing data, which were conducted for the IOP and 
VCDR traits in the five families. These are both significantly heritable traits, with heritabilities 
calculated at 52% (p = 5.13x10-10) for IOP and 41% (p = 9.0x10-7) for VCDR in the families 
of this study. Identity by descent relationships between family members were calculated 
directly from the whole exome sequencing data using IBDLD, a program specifically designed 
for dense genotyping data. Variance components linkage analysis was conducted using 
SOLAR, including correction for both the ascertainment of the POAG enriched families used 
in this study, and non-normal trait distributions. Linkage peaks reaching significance were 
identified for IOP, but not VCDR. For IOP, peaks on chromosomes 9q34.3 and 15q11.2-13.2 
reached full significance (maximum LOD = 4.25 and 3.40 respectively), and peaks on 
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chromosomes 2q23.1-31.1, 3p13-12.1, 6q24.2-25.1 and 7p11.2-q11.23 reached suggestive 
significance (maximum LOD > 1.86). All but one of the peaks were novel, with the 
chromosome 15 peak completely overlapping the previously identified GLC1I locus. 
Aim 3 involved analysing the identified linkage peaks using in silico strategies. Variants within 
each region were prioritised based on their family-based association results, their effect on 
reducing the linkage peak when included in the linkage model, and predicted in silico 
functional effects. Candidate genes proposed by these analyses were further investigated by a 
pathways analysis and were assessed for association in a large GWAS for IOP. PKP4 and 
FMNL2, on chromosome 2, and HERC2, on chromosome 15, are proposed as promising 
candidate genes associated with increased IOP in the families of this study. FMNL2 has already 
been associated with increased IOP and with POAG in recent GWAS. The identification of 
FMNL2 as a possible risk gene in this study is positive and validates the approach taken in 
using linkage analysis of extended pedigrees as it had already been reported as associated with 
IOP. HERC2 is a novel gene for IOP identified in our current study, and very recently the locus 
has been (independently) identified by GWAS. PKP4 is also a novel gene for IOP and POAG. 
PKP4 and HERC2 require further research in relevant ocular tissues to determine whether they 
are functionally important and whether they could affect IOP regulation. 
This is one of the first studies to conduct linkage analysis using whole exome sequencing data 
on intermediate traits of POAG. This research has identified three candidate genes which may 
be involved with IOP regulation. Currently as the only modifiable risk factor for POAG, IOP 
is an ideal target to develop more effective treatments than are currently available. This 
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1.1 Introduction to glaucoma 
Glaucoma encompasses a group of eye diseases which result in damage to the optic nerve and 
vision loss, and is the leading cause of irreversible blindness worldwide [1, 2]. Glaucoma is 
classified into subtypes based on the age of onset of the disease, the structure of the anterior 
chamber of the eye and whether there are other underlying causes. Secondary glaucoma is 
caused by some medications, trauma to the eye or other eye diseases, such as pseudoexfoliation 
syndrome [3]. Primary forms of glaucoma have no other underlying causes. Primary congenital 
glaucoma (PCG) is a serious condition of infancy, resulting from a developmental defect in the 
eye [4]. Juvenile open-angle glaucoma (JOAG) and primary open-angle glaucoma (POAG) are 
distinguished by their age of onset, with JOAG developing between the ages of 3 and 40 years 
and POAG after the age of 40 years [2, 5]. The “open-angle” refers to a normal angle size 
between the iris and cornea (Figure 1-1a). Primary angle-closure glaucoma (PACG) is 
characterised by an abnormal position of the iris, closing the angle between it and the cornea 
(Figure 1-1b) [3]. Patients with PACG have a physical obstruction to the outflow of aqueous 
humour from the anterior chamber of the eye. Those with POAG do not have the same physical 
obstruction, although they may have resistance to aqueous humour outflow caused by other 
means [3]. POAG is the most common form of glaucoma, making up approximately 75% of 














PCG and JOAG are rare forms of glaucoma and their prevalence is difficult to estimate. POAG 
and PACG account for the majority of glaucoma cases worldwide. In 2010, it was estimated 
that 8.4 million people worldwide were bilaterally blind due to POAG or PACG [2, 6]. With 
an aging worldwide population, this estimate has risen to 11.1 million in 2020 [6]. POAG, on 
its own, currently affects approximately 55 million people [1, 6, 7] and this is projected to rise 
to nearly 80 million by 2040 [1]. Ethnicity affects the prevalence of glaucoma quite 
dramatically. PACG is more prevalent in Asian populations (at approximately 1%) and least 
prevalent in North Americans (< 0.3%) [1]. While approximately 2% of over 40 year olds 
worldwide have POAG, this figure rises to over 4% in those of African heritage [1, 7]. In 
Australia, the prevalence of those with POAG is similar to the worldwide average. In 2020, 
between 200,000 and 300,000 Australians are estimated to be affected by this disease [7, 8]. 
Interestingly, Indigenous Australians have a much lower prevalence of glaucoma than the non-
Indigenous population (1.6% versus 3.4% respectively), even though the Indigenous 
population have more ocular risk factors, such as large optic heads and thinner central corneal 
thickness [8]. With such large numbers of people affected by POAG, the economic burden on 
the health system is great [9]. More importantly, the quality of life decreases for those with a 
visual impairment [9]. As the incidence of POAG increases with age, the elderly are 
Figure 1-1 Cross sectional diagrams of the anterior chamber of the eye showing a) a normal 




Figure 1-2 Cell types of the retina  The retinal ganglion cells (RGC) are in the innermost layer. 
The axons of the RGC converge to form the optic nerve. Source: http://www.salk.edu/news-
release/from-eye-to-brain-salk-researchers-map-functional-connections-between-retinal-neurons-at-
single-cell-resolution/ 
particularly at risk of diminished quality of life. With visual impairment, they risk tripping and 
falling over, losing their independence and increased rates of depression [9]. With an ageing 
worldwide population, the effects of POAG on both economic and personal levels will only 
increase. 
1.3 Pathophysiology of POAG. 
POAG is itself a heterogeneous disease, with a range in the age of onset, amount of optic nerve 
damage, amount of visual field loss, whether the pressure inside the eye is raised and response 
to treatment. Although individuals are affected by POAG differently, there are characteristic 
features of this disease. 
1.4 The optic nerve and optic disc 
The innermost layer of the retina is comprised of retinal ganglion cells (RGC, Figure 1-2). The 
axons of the RGC converge to form the optic nerve, which transmits visual signals to the lateral 
geniculate nucleus, from where information is relayed to the visual cortex of the brain [10]. In 
a healthy eye, there are approximately one million axons in an optic nerve [11]. The optic disc 
is the raised disc on the retina at the point where the optic nerve leaves the eye. The optic cup 
is the depression in the middle of the disc, where the axons converge. This lighter coloured cup 
is surrounded by a pink neuroretinal rim [12]. Together, the cup and rim make up the optic 
disc. Characteristic changes in the optic disc are used for diagnosis and evaluation of the 











1.4.1 Optic nerve damage in POAG 
POAG is a chronic and progressive neurodegenerative disease, affecting the optic nerve of the 
eye [6]. POAG generally affects both eyes, but is often asymmetrical, and one eye may be more 
severely affected than the other [11]. In POAG, there is progressive apoptosis of the RGC with 
a resultant loss of vision. This cell death occurs in a characteristic pattern resulting in loss of 
axons which pass through the upper and lower poles of the optic disc [2]. Mid-peripheral vision 
is the first to be affected. Central vision is not affected until much later in the glaucomatous 
disease process [2, 13]. Death of RGC do not just affect the eye. Disruption of axonal transport 
in these cells also affects the visual centres of the brain [10]. RGC also rely on neurotrophic 
support provided by their brain target neurons as well as their retinal interactions. As RGC 
apoptosis begins, the neurotrophic support diminishes, triggering further RGC death [2]. 
1.4.2 Vertical cup to disc ratio changes in POAG 
Along with vision loss, changes in appearance of the optic disc provide a clear indication of 
glaucomatous damage. As RGCs die, there is a characteristic “cupping” of the centre of the 
disc. Loss of RGC and deformation of connective tissues cause the cup to become deeper and 
wider. The neuroretinal rim surrounding the cup becomes thinner and paler. There may be other 
structural changes such as disc haemorrhages and notching of the neuroretinal rim [2, 10, 11]. 
An important clinical measurement which is used, to determine level of damage, is the cup to 
disc ratio (CDR). This measurement is generally taken in a vertical orientation (VCDR) (Figure 
1-3a). The diameter of the cup divided by the diameter of the whole disc gives a ratio which 
indicates the amount of glaucomatous damage. The more damage there is due to cell death, the 
larger the cup, which leads to a larger ratio (Figure 1-3b). A healthy eye has a VCDR of 
approximately 0.3 and glaucomatous eye is generally considered to be ≥ 0.7 [14]. Asymmetry 
of VCDR of > 0.2 between the two eyes may also be an indication of RGC damage [11]. As 
there is variation in disc size and VCDR in a normal, healthy population, VCDR alone is not 







Figure 1-3 Photographs of the back of the eye showing optic discs a) Vertical cup to disc ratio 
(VCDR) is measured by dividing the diameter of the cup by the diameter of the disc in the vertical 
orientation. b) A comparison of the difference in appearance of a normal optic disc (left) with a 
glaucomatous optic disc (right), which has an enlarged cup and thinner neuroretinal rim. 
Sources: a) http://www.intechopen.com/books/the-mystery-of-glaucoma/the-optic-nerve-in-




















1.4.3 Intraocular pressure 
Many patients with POAG have an elevated intraocular pressure (IOP), which is the pressure 
inside the eye. Generally, a pressure greater than 21mmHg, as measured by tonometry, is 
considered to be high [11]. In these patients, there is often a resistance to aqueous humour 
outflow from the anterior chamber of the eye. In a normal eye, there is a balance of aqueous 
humour secretion by the ciliary body and its drainage through the trabecular meshwork and 
uveoscleral outflow pathways [3] (Figure 1-4), resulting in a normal pressure of between 
11mmHg and 21mmHg [10]. However, in some patients, the trabecular meshwork does not 
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Figure 1-4 Aqueous humour outflow through the eye.  In a healthy eye, intraocular pressure 
is maintained by aqueous humour production in the ciliary body and drainage via the trabecular 
meshwork and uveoscleral pathways. 
Source: https://entokey.com/anatomy-of-the-aqueous-outflow-pathways/  
drain adequately. The mechanism for this resistance is not fully understood, but may involve a 
loss of lining cells or a blockage within the trabecular meshwork [2]. This results in an increase 
in pressure in the anterior chamber of the eye, which causes an increase in pressure in the 
vitreous humour in the posterior chamber, where the optic nerve is located [2]. It is possible 
that increased pressure is responsible for optic nerve damage due to mechanical stress [10, 15]. 
The mechanical stress may affect RGC, the optic disc itself, or other tissues such as the lamina 
cribosa, the tissue which the optic nerve passes through to exit the eye [3]. It has also been 
suggested that an increase in IOP causes an accumulation of reactive oxygen species in the eye, 
and this causes oxidative damage to the RGC [10, 15]. It has still not been determined as to 
which aspect of high IOP is important for progression to POAG; mean IOP, maximum IOP or 













Although most people with POAG do have an elevated IOP, a large percentage (30 – 40%) do 
not [2, 10, 17]. These patients have a normal IOP (≤ 21mm Hg), but similar optic nerve damage 
and visual field losses as those with higher IOP. This is referred to as normal tension glaucoma 
(NTG), to reflect that fact that there is glaucomatous damage with “normal” eye pressure. 
Sometimes, NTG is discussed as though it is a separate form of glaucoma to POAG [13, 18]. 
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Others make the distinction between NTG and high tension glaucoma (HTG) as categories 
within POAG [19]. Often, NTG is included in the general POAG grouping, and projections of 
POAG prevalence worldwide do not make the distinction between NTG and HTG [1, 6, 7]. 
Regardless of how NTG is categorised, it is more common in some ethnic groups than others, 
for example, Japanese have higher prevalence than Caucasians [19, 20]. Aside from patients 
with NTG having optic nerve damage with lower IOP, they also have greater visual field loss, 
for the amount of optic nerve damage, than those with HTG [10]. It has been suggested that 
optic nerve damage may not so much be the result of having a high IOP, but rather the 
difference in pressure between the eye and the brain. This pressure difference, the translaminar 
pressure difference (TPD), is a result of the lamina cribosa tissue separating the pressurised eye 
from the cerebrospinal fluid pressure in the brain [10, 13, 21]. The role of TPD is still not clear, 
as it is difficult gaining accurate intracranial pressure measurements via non-invasive means 
[21]. There are indications that patients with NTG may have lower intracranial pressure 
resulting in a higher TPD than healthy individuals. Also, NTG patients may be more 
susceptible to nerve damage at lower pressures than those with HTG [21]. 
1.5 Diagnosis of POAG 
An early diagnosis of POAG is key to slowing the progression of the disease. Currently, 50% 
of those affected by POAG in developed countries, including Australia, are undiagnosed. This 
figure rises to 90% on a worldwide level [2, 6]. As POAG is initially asymptomatic, painless 
and progresses slowly, diagnosis may not occur until there is substantial vison loss [22]. The 
patients themselves may not notice a loss in vision until the disease is quite advanced, by which 
time the optic disc may be severely damaged [13]. It is estimated that between 30-50% of RGC 
could die before any obvious vision loss has taken place [11, 23], hence the importance of an 
early diagnosis of optic nerve damage.  
To be diagnosed with POAG, a patient needs to be examined by a clinician for optic nerve 
damage and visual field loss. As there is a wide variation in optic disc size and VCDR in the 
population, the importance of repeated measurements taken over time becomes apparent. An 
increase in VCDR may be an indication of early stage optic nerve damage, which may possibly 
be halted before vision loss has occurred. Visual field testing is conducted using perimetry, 
which is often automated, and the clinician looks for specific visual field defects characteristic 
of glaucoma [23]. As perimetry is a subjective test, dependent on patient responses, repeated 
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measurements over time are also important to ensure consistency and to determine the 
progression of vision loss. It is important that VCDR measurements and perimetry results are 
concordant to diagnose POAG, as vision loss alone may be due to other causes [23]. 
Although IOP is not an essential diagnostic criterion for POAG, most patients with POAG do 
have increased eye pressure [2]. Tonometry is routinely used at optometrists, as part of a regular 
eye examination, to measure elevated pressure levels in the eye. An IOP of ≥ 22mHg may not 
necessarily mean that optic nerve damage has occurred, however, referral to an 
ophthalmologist may be indicated to reduce the risk of developing POAG. 
1.6 Treatment of POAG 
Once POAG has been diagnosed, the only proven method to treat it is to reduce the pressure 
inside the eye [24]. Even in NTG patients, who do not have an elevated IOP, reduction in 
pressure has been shown to reduce visual field loss [10, 25]. For patients with high IOP, but no 
glaucomatous damage, administering eye drops can reduce the risk of POAG-related vision 
loss [26]. 
There are several different types of eye drops which are usually the first treatment provided to 
reduce IOP. Some work by increasing outflow of the aqueous humour from the eye and others 
work by decreasing production of aqueous humour [3]. Either way, the purpose is to reduce 
the amount of aqueous humour in the anterior chamber of the eye, to reduce the pressure on 
the optic nerve in the rear of the eye. Although eye drops are well tolerated and with only few 
side effects, patient adherence with regular and continued administration may be an issue [2]. 
Even with regular administration, eye drops alone may not be adequate to halt the progression 
of the glaucoma. There are surgical options to increase aqueous humour outflow and reduce 
IOP; trabeculoplasty is a laser surgery which enlarges drainage channels out of the eye and 
trabeculectomy is a traditional surgical technique which removes part of the trabecular 
meshwork of the eye [10]. The currently available glaucoma treatments are not able to cure the 
disease, but are able to slow down the progression of optic nerve damage and preserve the 
remaining vision to maintain the quality of life for the patient [3]. Neuroprotective treatments 
would be beneficial to protect the optic nerve head from damage, however, as the 




1.7 Risk factors for POAG 
There are several risk factors which increase an individual’s chance of developing POAG. 
Boland and Quigley (2007) [16], provide a comprehensive list of possible risk factors based on 
different categories, such as state of the individual (age, sex and ethnicity), systemic diseases 
and personal behaviours. That study, as well as many others, agree that increased IOP is the 
main and only modifiable risk factor [10, 11, 15, 16, 27-29]. Although an increased IOP is not 
always a symptom of POAG, it is one of the most important risk factors and is the only factor 
which can be treated. 
Age is another important risk factor for the development of POAG. POAG is an adult onset 
disease, usually developing after the age of 40 years [7]. The Blue Mountains Eye Study 
suggests an exponential increase in the prevalence of POAG after the age of 60 years, with less 
than 0.5% developing the disease before the age of 60 years to over 8% for those aged over 80 
years in this population [30]. The increasing of risk as people age may represent a measure of 
various factors, such as length of time exposed to other risk factors, or the deterioration of 
ocular tissues over time, making them more susceptible to glaucomatous damage [16]. 
Ethnicity is another important risk factor for developing POAG. People of African heritage 
develop POAG earlier, do not respond as well to treatments and have a much higher prevalence 
than Caucasians [6, 7, 10, 16]. Over 6% of those with an African heritage will have developed 
POAG by age 65, as compared to only 2% of Caucasians [7]. 
There are also ocular risk factors for the development of POAG. High myopia (short 
sightedness) is one of these [11, 16]. Central corneal thickness (CCT) has also been proposed 
as a risk factor, with the thinner the CCT, the greater the risk of developing POAG [11, 13]. 
However, CCT also affects IOP measurements. IOP is most commonly measured with the 
Goldmann applanation tonometer [31], which may provide inflated IOP measurements in 
individuals with thicker corneas and lower IOP levels in those with thinner corneas. 
Consequently, patients with thicker corneas and higher measured IOP levels are prescribed 
pressure reducing medication more than those with thinner corneas and lower IOP 
measurements. As a result, patients with thinner corneas, who are less medicated, are associated 
with increased risk of developing glaucoma [13, 16]. CCT is a highly heritable ocular measure 
[32], and although it may affect IOP measurements, is still believed to be a risk factor for 
POAG in itself [33]. 
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A large optic disc area (ODA) has also been proposed as a risk factor [2, 16]. The larger discs 
may be more susceptible to nerve damage, although they may potentially contain more nerve 
fibres [16]. Optic cup area and CDR have also been proposed as risk factors for POAG [3, 11], 
however, they are also measures of optic nerve degeneration. Regular examination of patients 
with large optic cups and large CDR, without POAG, will help to determine the amount of risk 
these factors confer [16]. 
Other POAG risk factors have been assessed, such as; smoking, diabetes, body mass index, 
sex, hypertension, alcohol consumption and dietary fat intake. Many of these studies have 
resulted in conflicting and inconclusive results, as reviewed in [13, 15, 18, 27, 34-37], and even 
if some of these prove to be true POAG risk factors, they are unlikely to be as important as the 
other risk factors previously discussed. 
1.8 Family history of POAG 
A family history of POAG is a well-recognised and a very important risk factor for the disease. 
Although it often signifies shared environmental background, the family history also represents 
the genetic background [16]. It has been demonstrated there is a ten-fold increase in the risk of 
POAG if an individual has a close family member with the disease [38]. A study by Wolfs et 
al. (1998) [38], found that a parent or sibling with POAG increases the chance of developing 
the disease to 22% as compared with 2.3% in relatives of non-glaucoma controls. The risks 
may actually be underestimated if the children were too young to have developed POAG at the 
time of the study [22]. Gong et al. (2007) [39], distinguish between inherited and familial forms 
of POAG and suggest that these two forms account for 72% of POAG cases. They define 
inherited POAG as exhibiting a Mendelian inheritance pattern with high penetrance and 
familial POAG exhibiting more complex inheritance patterns with reduced penetrance. 
Sporadic POAG cases are those single patients without affected first or second degree relatives. 
As familial data continues to be collected over time and more information is gathered, the 
definition of the families may change. Classifying POAG into these categories may guide 
genetic studies as well as allowing for those at greater risk of developing the disease to undergo 
appropriate genetic testing [39]. 
The heritability of POAG in three different European ancestry populations, ranged from 42% 
to 81% [40-42]. These heritabilities estimate the amount of phenotypic variation in POAG 
which is due to the genotypic variation. The higher heritability estimate was from a study on 
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large, extended pedigrees [42] and the lower estimate was from a genome-wide association 
study (GWAS) [40] with a twin study providing a heritability estimate mid-way between the 
two [41].  
Several studies have also determined the heritability of some of the intermediate traits involved 
with POAG, such as; intraocular pressure, central corneal thickness, optic disc diameter and 
vertical cup to disc ratio [27, 42-45]. The heritability for these traits are also high, 
demonstrating the importance of genetics in POAG. There is little doubt that genetic 
background is an important risk factor in this disease, at the family level through to the 
population level. Different populations, as represented by different ethnicities, display varying 
prevalence to POAG [7] .Within each ethnic group, there is also the genetic background of 
each family, which is involved in determining an individual’s risk of developing POAG. 
1.9 Genetics of POAG 
Over the last 25 years or so, there has been a wealth of research centred around determining 
the genetic causes of POAG. The use of two distinct approaches has resulted in many genetic 
loci being proposed in POAG pathogenesis. POAG is a genetically complex disease, with both 
causative genes and susceptibility genes identified. 
1.9.1 POAG genes and loci identified by family-based studies. 
Family-based studies identified the first genetic loci linked to POAG. Since the first glaucoma 
locus, GLC1A, was identified in 1993 [46], over 20 more glaucoma loci have been found 
through the use of linkage analysis in families [13, 27]. The major loci are named GLC1A – Q 
and there are several other linkage regions which are un-named [28]. The HUGO gene 
nomenclature committee (HGNC, https://www.genenames.org/) has withdrawn the 
“phenotype only” locus nomenclature and no longer recognises these loci without identified 
causative genes. The online Mendelian inheritance in man catalogue (OMIM, 
https://omim.org/) does still include these loci. In this dissertation these loci will be referred to 
by their original GLC1A - Q nomenclature as a convenient way to refer to previously identified 
genomic locations linked to glaucoma which may not yet have identified causative genes. Loci 
GLC1J, K, M and N are linked with juvenile open-angle glaucoma [47-49]. A locus originally 
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identified in primary congenital glaucoma, and named GLC3A [50], is also recognised as being 
important in the adult onset form of the disease [13, 28].  
These linkage analyses resulted in the identification of large linkage regions, spanning millions 
of base pairs, and it was difficult to identify causative genes. Deeper sequencing was necessary 
to identify if candidate genes within these regions carried deleterious, potentially disease 
causing variants. Seven genes have been identified from within these linkage regions and these 
account for between 5 and 10% of all POAG cases [18, 51, 52]. Considering that the heritability 
of POAG is so high [39, 42], the influence of these genes at a population level, may not be so 
important. However, at the family level, the identification of POAG causative genes has 
allowed family members to assess the risks of developing the disease, undergo genetic testing 
for at risk members and have an earlier intervention with treatments [53]. One of the most 
important genes identified from linkage analysis is myocilin (MYOC), and testing for MYOC 
mutations has demonstrated that at risk individuals can be identified before signs of glaucoma 
are apparent [54]. The identification of POAG causative genes and the biological pathways 
they influence also enable a greater understanding of glaucoma pathogenesis, regardless of the 
process of gene identification [13, 37]. The seven genes which have been identified from 
linkage regions, using family-based studies, are summarised in Table 1-1. Four of the most 
important of these; MYOC, OPTN, TBK1 and CYP1B1 are discussed in more detail below. 
GLC1A was originally identified in a large family with JOAG [46]. The TIGR gene was 
identified from within this locus in 1997 [55], subsequently renamed MYOC, and has since 
become one of the most widely studied glaucoma genes. There is a dedicated online database 
for MYOC (http://www.myocilin.com/) [56], which allows researchers to interrogate specific 
mutations within the gene. Over 180 variants have been described in MYOC. Around 85% of 
these are missense mutations and 40% of variants have been identified as disease causing [56]. 
The majority the variants are in the third exon of the gene [15, 57]. The Gln368STOP mutation 
is the most common MYOC variant and is associated with a later onset form of POAG, with a 
diagnosis after the age of 35 years [58]. MYOC variants are more prevalent and cause a more 
severe form of glaucoma in JOAG cases (22 – 36%) than in POAG (2 - 4%) [19, 28, 53]. 
Increased IOP is a feature of MYOC mutations. MYOC is expressed in all ocular tissues, 
including the trabecular meshwork. It has been proposed that variants in the gene affect protein 
folding and prevent the protein from being secreted, causing accumulation in the trabecular 
meshwork, resulting in increased IOP [15, 19, 28, 53, 57]. Although reduction in pressure is 
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currently the only form of treatment for patients with MYOC mutations, research using 
transgenic mice holds promise for targeted treatments which may prevent the elevation of IOP 
in the first place [53]. 
The second gene to be identified from POAG linkage regions was OPTN in the GLC1E locus 
[59]. Variants in OPTN are associated with NTG. These mutations account for less than 2% of 
NTG cases [19, 28, 57]. OPTN is expressed in several ocular tissues, including the trabecular 
meshwork and retina. The most common mutation, E50K, causes a more severe form of 
glaucoma and at a younger age of onset. Mutations in the OPTN gene may cause abnormal 
protein deposits in the retina and apoptosis of RGC [60]. 
TBK1, in the GLC1P locus, was identified from family studies of NTG [61]. Unlike OPTN, in 
which coding variants cause disease, the TBK1 mutation is a copy number variation. 
Duplications and triplications of TBK1 are responsible for around 1% of NTG cases [57, 62]. 
TBK1 is expressed in the retina and has been shown to bind to OPTN and act in the same 
biological pathway [63, 64]. 
The GLC3A locus was identified in families and linked to PCG [50]. Since then, and with the 
identification of the CYP1B1 gene within this locus, it is now recognised as an important gene 
in the development of JOAG and POAG as well as PCG [65-67]. CYP1B1 is expressed in 
several tissues of the eye and mutations in this gene may be responsible for developmental 
abnormalities [66]. CYP1B1 interacts with MYOC and some carriers with mutations in both 




Table 1-1 Summary of important findings for the seven genes identified from linkage studies of POAG families. 
AD = autosomal dominant, AR = autosomal recessive, POAG = primary open angle glaucoma, NTG = normal tension glaucoma, IOP = intraocular pressure, RGC 












Sheffield el al., 1993 [46] 
Gene: 
Stone el al., 1997 [55] 
AD 
• Encodes a secreted glycoprotein which is expressed in all cells including the trabecular 
meshwork and other ocular tissues. 
• Abnormal myocilin protein may be toxic to trabecular meshwork cells. 
• Many mutations found in gene (>180), ~ 40 are disease causing. GLN368STOP is the 
most common mutation. 
• High IOP a feature of a MYOC mutation. 
• Accounts for 2-4% of POAG and 22-36% of juvenile glaucoma. 
[13, 15, 19, 
28, 37, 51, 




Sarfarazi el al., 1998 [70] 
Gene: 
Rezaie el al., 2002 [59] 
AD 
• Function of protein implicated in tumour necrosis factor-alpha pathway. 
• Expressed in many ocular tissues. 
• Associated with NTG.  
• May be involved with RGC death. 
[13, 15, 19, 
28, 37, 51, 
57, 68, 69] 
ASB10 (GLC1F) 
ankyrin repeat- and socs 
box-containing protein 10 
Locus:Wirtz el al., 1999 [71] 
Gene:Pasutto el al., 2012 [72] 
AD 
• Expressed in several tissues of the eye including RGC, ciliary body and trabecular 
meshwork. 





Monemi el al., 2005 [73] AD, complex 
• Encodes a protein with unknown function which is expressed in all cells. 
• Controversy over the role of WDR36 in glaucoma due to inconsistency of results in 
different studies. 
• May need the involvement of mutation in STI1 to have functional consequence in 
glaucoma. 
[13, 15, 19, 




Pasutto el al., 2009 [74] complex 
• Neurotrophic factor important for neuron survival. 
• Variants in this gene are rare. 
• Inconsistent results in different studies. 
• May be involved with RGC death with high IOP. 
[15, 28, 57, 
68] 
TBK1 (GLC1P) 
TANK-binding kinase 1  
Locus: 
Fingert el al., 2011 [61] 
Gene: 
Fingert et al., 2014 [75] 
complex 
• Copy number variation associated with POAG. Duplication of gene associated with 
NTG. Gene triplication also found associated with POAG. 
• Expressed in ocular tissues. 
• Interacts with OPTN. 




subfamily1, polypeptide 1 
Sarfarazi el al., 1995 [50] AR 
• Expressed in several tissues of the eye. 
• A major locus involved with juvenile glaucoma. 
• Possibly interacts with MYOC in POAG. 




1.9.2 POAG genes and loci identified by population-based studies 
While family-based linkage studies have identified POAG causative genes, population-based 
studies have proposed genes which may be involved with increased susceptibility to POAG. 
GWAS have proven an effective tool in identifying single nucleotide polymorphisms (SNPs) 
which are associated with POAG. The first POAG GWAS was published in 2009 [76], and 
identified six SNPs associated with POAG, although these SNPs did not reach genome-wide 
significance at p < 5x10-8. The CAV1/CAV2 locus was the first to be associated with POAG at 
genome-wide significance and replicated in independent cohorts [77]. Population-based 
candidate gene studies have also proven popular and have replicated findings from GWAS and 
found associations with novel POAG genes [27]. Population-based studies at both the genome-
wide and candidate gene level have been responsible for the identification of more than 74 loci 
which have reached genome-wide significant association with the POAG phenotype [13, 27, 28, 
78]. 
Although many loci have been proposed through GWAS, the genes which may be responsible 
for POAG pathogenesis are still difficult to identify and validate. The majority of associated 
SNPs from GWAS are in non-coding and intergenic regions and usually the nearest gene to that 
SNP is proposed as the associated gene [79]. These proposed genes need to be validated in other 
studies to confirm their involvement in POAG pathogenesis. The alleles of genes identified in 
GWAS may increase the risk of developing POAG, but do not cause the disease on their own. 
Many of these risk alleles and/or particular combinations of them are required to give an 
individual a higher susceptibility of developing POAG. There are also likely to be gene-gene and 
gene-environment interactions of these risk alleles, adding to the complex genetic architecture 
of POAG [51]. While predictive genetic testing is now available for the some of the POAG 
causative genes [53, 80] the complexity of the risk alleles means that predictive testing for 
susceptibility to POAG is still in its early stages. In more recent times, the use of polygenic risk 
scores (PRS) to predict an individual’s risk of developing a disease, is becoming a popular 
method of using GWAS generated data [81]. The use of PRS in complex diseases has great 
potential in the clinical setting, allowing those individuals at greater risk for a particular disease, 
increased monitoring and earlier intervention if necessary [82]. PRS analysis for glaucoma is a 
very recent and exciting development for understanding which SNPs contribute to an increased 
risk of developing this disease. PRS analysis using glaucoma risk loci [83] and IOP loci [84, 85] 
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have only recently been conducted and provide promising research in identifying at risk 
individuals. 
A sample of POAG susceptibility genes, which have been replicated in several population based 
studies, are listed in Table 1-2. Although these loci are all associated with the POAG phenotype, 
it is not yet understood how these genes are involved in the biological pathways which lead to 
POAG pathogenesis. 
Table 1-2 POAG susceptibility genes from population based studies. These are highly replicated 
studies and represent a sample of possible POAG susceptibility genes. 
 
Nearest gene SNP References 
CAV1/CAV2 
caveolin 1/caveolin 2 
rs10258482 [86] 
rs10262524 [86] 
rs1052990 [77, 87] 
rs17588172 [88] 
rs4236601 [77, 87-89] 
rs7795356 [90] 
CDKN2B-AS1 
CDKN2B antisense RNA 1 
rs10120688 [91-94]  
rs1063192  [29, 69, 90, 95-99]  
rs1412829 [91, 95]  
rs2157719 [94, 100] 
rs4977756 [89, 91, 94, 95] 
rs523096  [101, 102] 
rs7049105 [92, 94] 
rs7865618 [101, 103] 
SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of, 1/6 
rs10483727 [29, 69, 89, 90, 94, 95, 97-99, 104-106] 
rs4901977 [103] 
rs146737847 [107] 
rs33912345 [107, 108] 
TMCO1 
transmembrane and coiled-
coil domains 1 
rs4656461 [86, 89, 91, 95, 109] 
rs7518099 [86, 91, 110]  
rs7555523 [66, 86] 
                 Nearest gene = the closest gene to the SNP as identified in the original paper. 
 
Janssen et al. (2013) [13], incorporated 65 POAG associated genes in a biological pathways 
analysis (including the genes in Table 1-2 and the causative genes in Table 1-1), and predicted 
four different molecular networks. The genes from Table 1-2 were divided across all four 
networks, including the separation of the SIX1 and SIX6 genes into two different pathways. SIX6 
was linked with OPTN in a network which included the function of “visual system development”. 
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The pathway which included the function of “ophthalmic disease”, incorporated the MYOC and 
CDKN2B-AS1 genes. The other two pathways did not explicitly state a visual function. The four 
pathways demonstrated intricate webs of interactions of the POAG associated genes, underlying 
the complex genetic nature of this disease. 
1.9.3 Missing heritability in POAG 
Although GWAS have been very successful in proposing POAG associated loci, in total these 
loci only account for around 3% of the heritability of this disease [111]. These are common 
variants each with small effect sizes. The genes identified from linkage studies are rare variants 
with large effect sizes and account for 5-10% of POAG cases [27, 112]. Clearly there is a great 
deal of “missing heritability” for this complex disease. There have been many suggestions 
proposing the reasons as to why the heritabilities of identified variants do not add up to the total 
trait heritability, which for POAG is up to 80% [42]. GWAS may identify many associated loci, 
but they have small effect sizes and do not account for a large amount of the total heritability 
[113-115]. Genotyping arrays used for GWAS use common SNPs and are designed for large 
case-control cohort studies. Structural and copy number variants also have an impact on disease, 
but GWAS are underpowered to find them with statistical significance [113, 114, 116]. The 
TBK1 CNV found in NTG patients (discussed in section 1.9.1 above), was identified from 
linkage analysis [61, 75]. Gene-gene interactions and gene environment interactions are also 
likely to be important in disease risk and progression, as are epigenetic effects [114, 116, 117]. 
These are all likely to account for some of the missing heritability, but none of these are able to 
be assessed with GWAS . Importantly, rare variants with larger effect sizes may account for a 
substantial amount of this missing heritability [113, 117-119]. Figure 1-5 shows the differing 
effect sizes of rare and common variants and that different experimental approaches need to be 
taken to identify them. GWAS are useful in identifying many variants with small effect sizes, 
but different approaches need to be taken to identify rare variants with larger effects. Wainschtein 
et al. (2019) [120], have demonstrated recovery of the gap in heritability when rare variants were 
included from whole-genome sequencing (WGS) data, which were missing from the imputed 
data from SNP arrays. In that study, more than half of the heritability for height was accounted 
for by variants with a minor allele frequency (MAF) between 0.0001 to 0.1. Many of these 
variants were rare and in low linkage disequilibrium (LD) with other genomic variants and would 




Figure 1-5 Identifying genetic variants based on risk allele frequency and genetic effect  
Diagonal lines represent where the most emphasis is on identifying associations. Source: Manolio et al. 
(2009) [113] 
 
The use of linkage analysis is an appropriate method to identify less common variants with large 
effect sizes. It has traditionally been used to identify genes involved with Mendelian disorders, 
diseases in which a single, highly penetrant mutation is causative. Although successful in 
identifying the few, rare POAG causative genes (as discussed in section 1.9.1 above) linkage is 
not commonly used to find genes involved in complex diseases due to the multiple underlying 
genetic effects [121]. POAG is a highly complex, late onset disease and it is difficult obtaining 
families with multiple generations, as parents and siblings may have already died by the time 
family members are diagnosed [18, 28, 52]. As the importance of rare variants in complex 
diseases is becoming better understood [122-124], linkage analysis provides a better tool for 
identification of these variants than GWAS, which is suited to common variants. Families 
provide improved statistical power to search for rare variants affecting disease due to the natural 
enrichment of these variants as they segregate through the generations [125, 126]. Large families 
with many family members affected by POAG provide a valuable resource for finding rare 
variants involved with this disease. 
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1.10 Quantitative clinical traits of POAG 
Part of the missing heritability for POAG, discussed above, may be accounted for by identifying 
variants influencing the quantitative, intermediate traits of POAG  rather than the dichotomous 
disease status itself [37, 42, 68, 117, 126]. The use of these traits, or endophenotypes, has been 
well recognised in psychiatric research as a method of quantifying and deconstructing complex 
diagnoses [127]. Traits such as IOP, VCDR, ODA and CCT offer objective, quantitative data, 
and provide more statistical power for analyses than a subjective, dichotomous POAG diagnosis 
[42]. The use of these traits is becoming more popular, not only to simplify POAG into some of 
its components, but also to gain a better understanding of the biological pathways involved in 
POAG pathogenesis. Complex diseases, such as POAG may have several endophenotypes and 
these endophenotypes may also be linked to diseases other than POAG [37]. 
For a trait to be useful as an endophenotype for a disease, it must be heritable, be genetically 
correlated with the disease of interest, but not cause the disease on its own, and be able to be 
measured in both healthy and diseased individuals [37, 42]. A recent systematic review and meta-
analysis of relevant POAG endophenotypes has shown the heritabilities to be high, with pooled 
estimates for; IOP 0.43 (0.38-0.48), CDR 0.56 (0.44-0.68) and CCT 0.81 (0.73-0.87) [128]. 
Several studies have specifically focused their POAG research on these quantitative traits, for 
example; [29, 93, 105, 110, 129-133]. Heritabilities accounted for by variants identified in 
GWAS specifically conducted on these endophenotypes are greater than those from POAG 
GWAS. The top SNPs from a GWAS using an optic cup measurement explained between 2.1% 
and 3.2% of the variance of POAG in the two independent cohorts of that study [134]. 
Additionally, a GWAS identifying novel IOP loci explained 17% and 9% of variance in the 
EPIC-Norfolk and UK Biobank cohorts respectively, with the latter estimate predicted to be more 
accurate due to decreased IOP measurement error, as multiple measurements were taken [135]. 
Iglesias et al. (2015) [37], have compiled a comprehensive list of the genes, which are the closest 
to GWAS hits, implicated in the POAG endophenotypes and presented them as Venn diagrams 
(Figure 1-6). These diagrams show that there are many genes which have only been implicated 
with individual traits and others which are involved with more than one trait. Although the ocular 
traits are under the control of many genes, the genes may not necessarily be involved with POAG. 
Understanding how they affect POAG pathogenesis will be simplified by knowing which 
quantitative trait they affect. A genetic correlation between the endophenotype and POAG is a 
prerequisite for identifying variants and genes important in POAG pathogenesis. Charlesworth 
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Figure 1-6 Genes implicated in POAG and its intermediate traits. The Venn diagrams 
illustrate the number of loci that show association with (a) optic disc parameters and (b) 
intraocular pressure and central corneal thickness. Genes associated with only one trait are listed 
below the trait name. Genes associated with more than one trait are listed in the overlapping 
regions of the diagram. Genes which have also been associated with POAG are listed in bold. 
Source: Iglesias et al. (2015) [37] 
et al. (2010) [42], demonstrated that IOP and VCDR were genetically correlated with POAG in 
a study on 22 large Caucasian families. Other studies have demonstrated that variants statistically 


















1.11 The use of next generation sequencing technologies to find 
disease causing genes 
Next generation sequencing (NGS) technologies, encompassing whole genome sequencing 
(WGS) and whole exome sequencing (WES), are newer techniques which are being used to 
uncover the genetic causes of disease. With the huge reduction in costs of these technologies in 





disease causing mutations [137]. WGS and WES enable the full spectrum of variants to be 
identified, from common (MAF ≥ 5%) to uncommon (1% ≤ MAF < 5%), rare (MAF < 1%), and 
private (restricted to a family) variants [138, 139]. Using NGS technologies in family-based 
studies provides an exciting opportunity to search for these rare and private variants which may 
be important in disease [138, 140]. 
WES produces sequencing data for the 1% of the genome which is protein coding (~30Mb). 
Although most of the genome is not sequenced, it is believed that many disease causing 
mutations are within these coding regions [139]. So although it is recognised that not all disease 
causing mutations will be identified using WES alone, there is still the potential to find many 
important variants. The cheaper costs associated with WES, compared to WGS, allow for more 
study participants to be sequenced [137]. Although the information which is provided by NGS 
is detailed and valuable, this technology has its limitations. Both WGS and WES produce large 
amounts of data which need to be stored and managed. Specialised bioinformatics skills and 
tools are needed to handle the data and identify variants of interest [141, 142]. Potentially 
deleterious variants need to be identified from within the “noise” of sequencing errors and non-
deleterious mutations. WES has additional limitations as structural variations, for example CNVs 
may not be able to be detected and not all exons are actually sequenced [139]. Although there 
are obvious limitations to NGS technologies, they are outweighed by quality of information 
revealed. NGS provides a more comprehensive genotyping tool than has previously been 
available, and can be used in family-based linkage analyses and population-based association 
studies. 
In POAG research, recent studies using WES have confirmed previous findings and identified 
new variants in genes involved with the disease itself and with the intermediate, clinical traits of 
glaucoma [100, 107, 143-149]. The use of NGS with linkage studies has huge potential for 
accelerating the identification of both common and rare variants in disease. Families with many 
affected members, who are said to be “enriched” for a disease, provide improved statistical power 
for identifying rare variants, as these rare alleles have a 50% chance of being passed from a 
parent to each child [125]. Already, family studies using WES have identified rare variants in 
optic disc parameters of POAG patients [145-147]. New approaches, such as developing identity 
by descent (IBD) algorithms from NGS data, are being established to cope with the increased 
complexity of using NGS information in linkage studies. These are allowing for larger families 
with complex structures to be used [150-152]. 
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1.12 Hypothesis  
POAG is a heterogeneous disease with a complex genetic component. Although there is an 
abundance of literature on suspected POAG risk alleles as well as some rare causative genes, 
very little is known about how these genes affect the pathogenesis of the disease. Researching 
the intermediate traits of POAG may simplify the process of gene identification for this disease. 
Using WES data from large families enriched for POAG, to conduct linkage analyses on these 
intermediate traits, may prove to be a valuable method for finding variants influencing these 
traits. These families may harbour rare, deleterious variants as well as common variants. 
Identification of these variants has the potential to implicate genes and their pathways important 
in the pathogenesis of POAG. Ultimately, with a greater understanding of the genetics of POAG, 
an earlier diagnosis may be possible as well as better, targeted treatments. 
 
The use of extended pedigrees enriched for POAG, to identify genetic variants associated 
with its heritable clinical traits, will provide an improved understanding of the genetic 






To determine the contribution of published genetic variants associated with POAG and 
related traits, to trait variance in five extended POAG enriched families. 
Specifically, this study will use a family-based association analysis on published genetic loci to 
identify variants associated with POAG and its clinical measurements in the families of this 
study. Three sets of variant data will be examined from the association analysis:  
• SNPs reported in the literature as associated with POAG and its intermediate traits 
• 20kb windows around the reported SNPs from the literature 




To identify quantitative trait loci for intermediate POAG traits using linkage analysis in 
five extended pedigrees. 
Specifically, identity by descent will be estimated from whole exome sequencing data and used 
to conduct variance components linkage analysis on five POAG enriched families to identify 
quantitative trait loci for IOP and VCDR. 
 
Aim 3 
To propose candidate genes which may be involved in IOP regulation in the families of this 
study.  
Specifically, this study will use in silico tools to investigate genetic variants within the most 
significant peaks identified from the linkage analysis in Chapter 4, and propose genes which may 







2.1 Ethics approval and consent 
As described previously for these families [71, 153, 154], ethics approval was obtained from the 
Oregon Health and Science University (OHSU) Institutional Review Board (Portland, OR), the 
Human Research Ethics Committees of the Royal Victorian Eye and Ear Hospital (Victoria, 
Australia), and the Human Research Ethics Committee (Tasmania) Network. This study was 
conducted in accordance with the tenets of the Declaration of Helsinki. Written, informed 
consent was obtained from all participants. 
2.2 Families used in this study 
The families used in this study are part of a long standing collaboration of the Oregon Glaucoma 
Genetics Study (OGGS) [71, 153] and the Glaucoma Inheritance Study in Tasmania (GIST) 
[154]. The OGGS families are from the north-western United States of America and the GIST 
families are from the southern Australian island state of Tasmania and all families are of 
European descent. Recruitment of these families in their respective glaucoma studies has been 
previously described in detail [42]. Five pedigrees were selected for this project based on 
contribution to linkage signals in pilot work conducted as part of a NIH funded project in 2006 
(R01 EY010555). That pilot study, and subsequent research using these families [42], included 
extensive relationship testing, conducted by Jac Charlesworth, to ensure correctness of the 
pedigrees prior to the commencement of this study. Table 2-1 provides summary information 
about these families. Three families from the OGGS and two families from the GIST were used. 
These large families span five to seven generations and range in size from 48 individuals in 
family GTAS54 to 201 in family 98002. A total of 531 family members were included in this 
study, with clinical data obtained from over 300 participants. DNA samples, for whole exome 





Table 2-1 Families participating in OGGS and GIST selected for this study. Number of family 













Clinical data (N) 
WES 
(N) IOP VCDR CCT 
93001 OGGS 138 5 49.3 43.2 ± 21.0   84   85 66 57 
95002 OGGS 60 5 51.7 56.8 ± 17.4   40   41 28 36 
98002 OGGS 201 7 51.7 59.5 ± 17.2 107 104 70 91 
GTAS04 GIST 84 6 53.5 59.9 ± 15.4   41   42   9 37 
GTAS54 GIST 48 6 52.1 60.9 ± 13.7   29   29 13 28 
* = informative generations with clinical and/or DNA data 
OGGS = Oregon glaucoma genetics study, GIST = glaucoma inheritance study in Tasmania 
Average age is ± standard deviation. 
IOP = intraocular pressure, VCDR = vertical cup to disc ratio, CCT = central corneal thickness 
WES = whole exome sequencing 
 
Detailed pedigree diagrams of the five families are shown in Figures 2-1 to 2-5 on the following 
pages, indicating POAG disease status as well as the clinical measurements for intraocular 
pressure (IOP), vertical cup to disc ratio (VCDR) and central corneal thickness (CCT). 
Individuals with a medication adjusted IOP (as described below in section 2.5.1) are also 
indicated in these pedigrees. Families 93001, 95002 and 98002 are from the OGGS in America 
and families GTAS04 and GTAS54 are from the GIST in Australia. These families all represent 
the adult onset form of POAG, with diagnosis usually after the age of 40 years for those 
diagnosed. Family members indicated with no POAG status in the pedigree diagrams (Figures 
2-1 to 2-5) were either not clinically assessed for POAG or were too young at their final clinical 
examination to definitively categorise them with a negative diagnosis for POAG. Although the 
POAG status of each individual is shown in the following pedigrees, our study did not use POAG 
as the phenotype of interest. The IOP, VCDR and CCT measurements were used for all of the 
analyses conducted in this study, with POAG status only revealed at the end of the study, when 






Figure 2-1 Family 93001 Identification number = the first string of numbers, I = IOP measurement (mmHg), * = medication adjusted IOP, 
V = vertical cup to disc ratio, C = CCT measurement (μm), nm = not measured, coloured lines represent the same individual appearing more 



























Figure 2-2 Family 95002 Identification number = the first string of numbers, I = IOP measurement (mmHg), * = medication adjusted IOP, 
V = vertical cup to disc ratio, C = CCT measurement (μm), nm = not measured, coloured lines represent the same individual appearing more 





























Figure 2-3 Family 98002 Identification number = the first string of numbers, I = IOP measurement (mmHg), * = medication adjusted IOP, 
V = vertical cup to disc ratio, C = CCT measurement (μm), nm = not measured, coloured lines represent the same individual appearing more 



























Figure 2-4 Family GTAS04  Identification number = the first string of numbers, I = IOP measurement (mmHg), * = medication adjusted IOP, 
V = vertical cup to disc ratio, C = CCT measurement (μm), nm = not measured, coloured lines represent the same individual appearing more than 































Figure 2-5 Family GTAS54  Identification number = the first string of numbers, I = IOP measurement (mmHg), 
* = medication adjusted IOP, V = vertical cup to disc ratio, C = CCT measurement (μm), nm = not measured 































2.2.1 Family 93001 
Family 93001 (Figure 2-1) is a 5 generation family consisting of 138 members. The original 
founders of the family had 7 children, 5 of whom were diagnosed with POAG. In total, 15 
family members were diagnosed with POAG, with a further 11 diagnosed as suspected POAG 
cases at their last clinical examination. Most of the POAG and suspected POAG cases are in 
the 2nd and 3rd generations of the family, with the later generations possibly too young to 
develop POAG by their last examination. Clinical data and DNA samples were obtained from 
most of the direct descendants of those diagnosed with POAG. In total 85 family members 
provided clinical data and 57 provided DNA for sequencing. 
2.2.2 Family 95002 
Family 95002 (Figure 2-2) is the smallest of the American families, with 60 members. This 
family was not descended from the same founder, but were linked together by a couple 
(ID:950021 and ID:950022), both of whom were from POAG enriched families. In total, 14 
family members were diagnosed with POAG plus one suspected POAG case. Two thirds of 
this family provided clinical data and 36 members provided DNA samples. 
2.2.3 Family 98002 
Family 98002 (Figure 2-3) is the largest of the five families involved in this study, with 201 
individuals included. There is one main family, descended from founders ID:9800210 and 
ID:980029. A marriage loop in the 4th generation between two brother and sister pairs is 
indicated in the smaller pedigree diagrams. The POAG cases are spread across this whole 
family with clinical measurements and DNA samples obtained from most of individuals in the 
4th to 7th generations. 
2.2.4 Family GTAS04 
Family GTAS04 (Figure 2-4) is the larger of the two Tasmanian families and demonstrates a 
more complex family structure. The founders in the main part of the pedigree, ID:700004478 
and ID:70000477, had three daughters. Two of these daughters had families with the same 
partner, ID:700004402, and there are POAG affected descendants in both families. The 
partner’s side of the family is linked to the main pedigree and shown in the upper left of Figure 
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2-4, with three additional POAG and one suspected POAG case. Clinical data and DNA 
samples were obtained from most of the individuals with at least suspected POAG, their 
siblings and descendants.  
2.2.5 Family GTAS54 
GTAS54 (Figure 2-5) is the smallest of the five families included in this study, with 48 
individuals, and has a single lineage group. The generations enriched for POAG are the great 
grandchildren of the original founders, ID:700054401 and ID:70005402. In total, 16 were 
diagnosed with at least suspected POAG (included one spouse). Nearly all of the great-
grandchildren of the founders and their descendants provided both clinical data and DNA 
samples for this study.  
2.3 Clinical data 
Clinical data was collected from participants for POAG disease status and for the POAG 
endophenotypes; intraocular pressure (IOP), vertical cup to disc ratio (VCDR) and central 
corneal thickness (CCT) and has been described in detail elsewhere [42, 155]. Briefly, the 
clinical assessment for glaucoma disease status involved assessing the appearance of the optic 
nerve head in conjunction with visual field defects typical of glaucoma. Examination included 
measuring the level of optic nerve head excavation accompanied by thinning of the neuroretinal 
rim, which may also show notching, pitting, Drance-type nerve fibre layer haemorrhages or a 
general loss of retinal fibre layer. For a diagnosis of POAG, the iridocorneal angle was open 
and there was no indication of other causes for the glaucoma, such as trauma, medication use 
or pseudoexfoliation syndrome. The classification of individuals with a definitive versus 
suspected POAG diagnosis is detailed elsewhere [153, 155], and is based on the degree of optic 
nerve cupping and visual field loss.  
IOP was measured with Goldmann applanation tonometry with multiple measurements taken 
over several years for most individuals. The maximum recorded IOP was used as the trait of 
interest in this study. Medical records were accessed for those individuals with a POAG 
diagnosis prior to the study, to obtain any pre-medication IOP data. IOP was measured in 301 
family members. The VCDR, as a measure of optic nerve head excavation and damage, was 
classified using a slit lamp biomicroscope, by one or two clinicians during the clinical 
examination process. Additionally, stereo fundus photographs were taken for future reference 
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and assessed by a third clinician if there was a discrepancy between the examining clinicians. 
The larger VCDR of the two eyes, for each participant, was used as the trait for this study, with 
the maximum measurement recorded used as the trait in this study. VCDR was measured in 
301 family members. CCT was measured with ultrasound pachymetry, with 25 measurements 
taken for each eye at each timepoint. The mean of these measurements was recorded at each 
timepoint and the overall minimum record used as the trait for this study. CCT was measured 
in 186 family members. VCDR and CCT were also measured over multiple time-points. 
2.4 Whole exome sequencing data preparation 
2.4.1 Sequencing, alignment and variant calling 
The DNA sequencing was conducted in the laboratory of our close collaborator, Professor 
Joanne Curran, at the Texas Biomedical Research Institute, USA. DNA samples from 249 
members of five families were extracted from whole blood and prepared for sequencing using 
the Nextera Expanded Exome Enrichment Kit (Illumina: https://sapac.illumina.com
/products/by-type/sequencing-kits/library-prep-kits/truseq-exome.html). 100bp paired-end 
sequencing was conducted on the Illumina HiSeq 2000 platform. The expanded exome kit 
provided 62Mb exome content including 201,121 exons in 20,794 genes, as well as UTRs and 
miRNA sites. The Churchill pipeline [156] was used for sequence alignment. Within this 
pipeline, BWA-MEM (version 0.7.12) [157] was used to align fastq sequences to the hg19 
human reference genome, Picard (version 1.114) (https://broadinstitute.github.io/picard/) was 
used for deduplication, and the Genome Analysis Toolkit (version 3.6) (GATK, 
https://software.broadinstitute.org/gatk/) [158] for local realignment around indels and 
recalibration of base quality scores. The BAM files which were generated were the starting 
point for this research project. A bcbio pipeline (https://github.com/bcbio/bcbio-nextgen) was 
used to call SNPs and indels from the BAM files. The configuration file used for this variant 
calling is provided in Appendix A.1. Within this pipeline, variants were joint called using 
GATK (version 4.0.3.0) [159]. 
2.4.2 Annotating the VCF file 
After variant calling, the resultant VCF file was labelled with quality tags using the GATK 
“Variant Filtration” tool (see Appendix A.2.1). Variants with a depth of coverage (number of 
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filtered reads) of 10 or greater were annotated as “high-coverage”. Variants with a Phred-scaled 
genotype quality score of 20 or greater were annotated as “high-quality”. “High-confidence” 
calls were both high-coverage and high-quality. Conversely, “low-confidence” calls were both 
low-coverage and low-quality. Genotypes could also be assigned low-coverage with high-
quality and high-coverage with low-quality. These quality annotations were used in 
downstream analysis of variants of interest. 
ANNOVAR (April 2018 version) [160, 161] was then used to annotate the vcf file for specific 
gene information, population frequencies in multiple populations, predicted scores of 
deleteriousness and phylogenetic conservation scores. The ANNOVAR command is shown in 
Appendix A.2.2.  
2.5 Traits used in this study 
2.5.1 IOP and IOPMed 
Both an unadjusted maximum IOP measurement (IOP) and a medication adjusted maximum 
IOP measurement (IOPmed) were used in the course of this study. Where possible, IOP 
measurements recorded prior to treatment were used. For those individuals who had 
commenced pressure reducing medication prior to this study, a correction factor was applied 
to the IOP measurement, similar to that applied by Springelkamp et al. (2017) [136]. The 
standard deviation (SD) of the maximum IOP measurements from all 301 participants was 
calculated (SD = 6.1mmHg) and a 1 x SD was added to the IOP measurements for the 29 
individuals who only had post-medication measurements. This trait was called IOPmed, to 
distinguish it from the unadjusted IOP trait.  
2.5.2 VCDR and CCT 
The VCDR and CCT measurements (as described in section 2.3) were used without any form 
of medication adjustment in this study. The raw VCDR measurements were a ratio and ranged 
between 0 and 1. CCT measurements were used in μm. 
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2.6 Variance components analysis of traits 
The Sequential Oligogenic Linkage Analysis Routines (SOLAR) package (version 8.8.1) [162] 
was used to conduct the quantitative genetic and linkage analyses for this project. SOLAR uses 
variance components statistics, which is discussed in detail in Chapter 4. SOLAR was selected 
based on the size of the pedigrees and the computational limits of most of the other packages 
for pedigrees of this size. 
2.6.1 Variance components modelling of traits 
Variance components modelling was conducted using SOLAR to determine the heritability of 
the traits as well as the contribution of the covariates to the phenotypes. Covariates included 
were; age, sex, the interaction of age and sex, age2, and the interaction of age2 and sex. The 
polygenic -screen command calculated the significance of each of the covariates and those 
not reaching a nominal correction significance of p < 0.1 were removed from the final 
polygenic model. Modelling was conducted separately for the full pedigree file, consisting of 
all 531 family members, as well as an adjusted pedigree file, consisting of only the 249 family 
members with WES data. The full pedigree file was used for the measured genotype association 
analysis (MGA) analysis, discussed in section 2.6.3 below. The adjusted pedigree file was used 
for the linkage analysis and is discussed fully in Chapter 4.2.1.3. 
2.6.2 Data transformation 
All traits were normalised prior to the MGA (discussed below). Variance components 
polygenic modelling was performed with all covariates included, unlike the general modelling 
described above. These covariates were included in the model regardless of their significance 
through the polygenic –all –screen command. Residuals for the maximised model were 
computed for each trait. An inverse normal transformation of the residuals was computed using 
the inormal command. The covariate adjusted, inverse normalised residuals were then treated 
as a trait and used in the MGA analyses described below. 
The raw VCDR measurements, which range between 0 and 1, were multiplied by 10 to increase 
the standard deviation of the data, reducing errors in the analysis pipeline. After analysis, all 
results for VCDR were converted back to the true ratios. 
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2.6.3 Measured genotype association (MGA) analysis 
MGA is a test to determine whether the phenotypic means of a trait are affected by genotypic 
differences [163, 164]. Trait means are estimated for each of the genotypes, with an additive 
model used which constrains the heterozygote to be half way between the two homozygotes. 
SNPs are included individually as covariates in the model, scored as a dosage of the minor 
allele. A likelihood ratio test is used to test if the regression co-efficient of each SNP genotype 
differs from zero. Conducting MGA within a variance components framework allows for the 
non-independence of family relationships to be taken into account, which would otherwise 
inflate the p-values [165-167]. MGA uses both genotypic and phenotypic data for each family. 
Any individuals without phenotypic data were not included in the analysis. 
As MGA uses the number of rare alleles, the genotypes in the full VCF file were converted to 
a dosage file representing the number of rare alleles. SNPs and Indels were handled separately 
for this process and subsequent analysis. A custom R script (see Appendix A.3) was used for 
this conversion, as well as running quality control on the data. Variants were filtered based on 
the rarity of the minor allele, with a minor allele copy (MAC) number of less than 5 removed. 
The quality control step removed variants with at least 50% of missing calls. Table 2-3 
summarises the number of SNPs and indels at each of the major stages of the dosage file 
preparation. 
Table 2-2 SNPs and indels remaining at the major stages of dosage file preparation 
 No. SNPs  No. Indels 
Start 429,670 55,499 
After MAC filtering 151,253 25,185 
Final (after quality control) 142,210 22,002 
                  MAC = minor allele copy 
 
The completed dosage file was then used to run the MGA analysis in SOLAR. MGA was run 
separately for each of the three clinical traits; IOP, VCDR and CCT. The commands used for 
this analysis are included in Appendix A.4. The MGA used the full pedigree file listing all 531 
family members and their relationships as well as the full phenotype file. Based on this pedigree 
information, SOLAR was used to calculate a kinship matrix which was used to identify the 
family relationships which were necessary for accurate MGA analysis. MGA was run twice for 
each trait; once using the normalised phenotype values (as described above in section 2.6.2) 
and once on the raw, non-normalised phenotype values. Normalising the traits provides 
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accurate p-values for the association analysis but is not appropriate for determining the 
magnitude of the change in phenotype, due to the transformation of the data. The MGA analysis 
on the raw phenotype values was used to provide beta-values indicating the effect size of each 
allele. 
2.7 Additional information 
2.7.1 R scripts 
R (version 3.3.1) [168] was used to compose most of the custom data manipulation scripts for 
this study. The R package, ggplot2 [169], was used to draw the linkage diagrams in Chapters 
4 and 5. An example linkage diagram script is provided in Appendix A.5. 
2.7.2 Pedigree drawings 




Contribution of reported POAG associated loci with 
IOP, VCDR and CCT in five extended families 
 
3.1 Introduction 
To date there have been hundreds of loci associated with POAG risk; ranging from individual 
SNPs and small indels, to whole genes through to large linkage regions encompassing many 
genes. Some of the loci are well replicated and recognised as true POAG associated loci, for 
example; TMCO1 [12, 66, 86, 89, 91, 95, 109, 136, 171], CDKN2B-AS1 [12, 29, 69, 91, 92, 
94, 111] and SIX1/SIX6 [29, 69, 89, 90, 94, 95, 97, 111, 136], although the function of these 
loci in POAG pathogenesis is still not well understood. Other POAG loci have not been 
replicated in independent studies and their involvement with POAG are not necessarily 
confirmed, for example; UST [172], FREM3 [143] and DERA [172]. Linkage regions, often 
encompassing millions of base pairs, may be family specific, for example; the GLC1D [173], 
GLC1F [71] GLC1L [174] and GLC1P [61] loci. Other linkage regions were identified using 
several families, for example; the GLC1B [175], GLC1H [176] and GLC1I [177] loci. Linkage 
studies have successfully been used as the first stage in identifying regions of the genome of 
interest, allowing for candidate gene studies to follow. MYOC, OPTN, WDR36 and CYP1B1 
have successfully been identified as glaucoma causing genes where linkage studies have 
identified the initial genomic location [46, 50, 70, 73]. However, linkage studies are difficult 
to replicate as the families ascertained for these studies may differ in their size, structure, 
disease phenotype and ethnicity. 
A recognition of the importance identifying loci involved with the clinical intermediate traits 
of disease, rather than the discrete glaucoma disease diagnosis itself, has generated research 
using a variety of strategies. GWAS, candidate gene studies and linkage studies have been 
conducted focussing on IOP, VCDR, CCT and other optic disc measurements, which are 
involved with the POAG disease process either directly, or as a risk factor for the disease [29, 
93, 105, 110, 129-133]. IOP and VCDR have already been identified as ideal endophenotypes 
for POAG in the families of this study [42]. Although CCT was not genetically correlated with 
POAG in these families [42], it is still a recognised risk factor for the disease [2, 13, 178]. As 
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a highly heritable trait, results may still indicate important genes involved in CCT biology, 
although they may not be involved with POAG pathogenesis in these particular families. 
To determine whether POAG loci from the literature are associated with clinical measures in 
the families of this study, firstly, a comprehensive literature review was undertaken, 
encompassing relevant loci from a variety of study types; GWAS, candidate gene studies and 
linkage studies. A family-based association test (measured genotype association; MGA) was 
conducted on these identified loci for each of the intermediate clinical traits measured in the 
families. Association was tested with three loci types; with the published SNP loci, in 20kb 
windows around each SNP, to capture variants in LD with those published, and across POAG 
linkage regions, which encompass much larger regions of the genome. The purpose was not to 
directly compare results from this study with the hundreds of published POAG papers, but to 




3.1.1 Aim of this study  
To determine the contribution of published genetic variants associated with POAG and 
related traits, to trait variance in five extended POAG enriched families. 
Specifically, this study will use a family-based association analysis on published genetic loci 
to identify variants associated with POAG and its clinical measurements in the families of this 
study. Three sets of variant data will be examined from the association analysis:  
• SNPs reported in the literature as associated with POAG and its intermediate traits 
• 20kb windows around the reported SNPs from the literature 




Figure 3-1 outlines the stages involved with conducting a comprehensive literature review of 


















Figure 3-1 Major steps involved with conducting measured genotype association analysis 
from a literature review of POAG loci. Italicised numbers refer to the following sections with 
detailed descriptions of each step. 
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3.2.1 Literature review 
A literature review, to gather information on published POAG loci, was initiated in 2016 and 
concluded in 2018, and included papers published between 1993 and 2018. A PubMed search 
was undertaken, using the following search terms: 
((((((("Glaucoma, Open-Angle/genetics"[Mesh]) OR "POAG"[Title/Abstract]) OR 
"primary open angle glaucoma"[Title/Abstract])) AND ((((("Genetics"[Mesh]) 
OR gene*[Title/Abstract]) OR locus[Title/Abstract]) OR 
loci[Title/Abstract]) OR SNP[Title/Abstract]))) AND "Humans"[Mesh]) AND 
English[Language] 
Additional PubMed searches were also undertaken to ensure a comprehensive literature search. 
((endophenotype) OR intermediate phenotype) AND glaucoma 
(open angle glaucoma) AND genome wide association stud* 
In addition to these searches, other publications were identified from the bibliography sections 
of papers already obtained. Several review articles and meta-analyses were used to ensure 
inclusion of as many relevant loci as possible and these provided many of the loci incorporated 
into the database [13, 27-29, 103, 111, 134, 136, 171, 179].  
Detailed results and information on study participants was extracted from each paper. Studies 
involving participants of European or Caucasian descent were prioritised, to obtain as many 
loci as possible applicable to the families of European descent of this current study. Studies 
involving non-European populations were included if they were a part of larger studies, but 
smaller non-European studies were not prioritised in this literature review.  
3.2.2 Creation of POAG loci database 
Information extracted from the literature review was compiled into a database (Appendix B). 
Loci associated with the POAG clinical status were included as well as the IOP, VCDR and 
CCT clinical traits. Some studies reported associations with optic disc area (ODA) and optic 
cup area (OCA) which, although not included as endophenotypes in this study, are relevant 
traits to assess [29, 180]. The most significant results as reported by the authors were included, 
even if they did not necessarily reach genome-wide significance after Bonferroni correction, to 
ensure important findings were not omitted due to a subjective definition of significance. Some 
variants, for example rs7518099 in TMCO1 and rs10483727 at the SIX1/SIX6 locus, 
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demonstrated association in some studies but not others [29, 91, 93]. Variants were included if 
they were associated with POAG or one of the clinical traits in at least one study. 
The loci included in the database in Appendix B are a comprehensive representation of the 
major POAG and endophenotype loci published in the literature, especially for European 
participants. Major glaucoma linkage regions, designated GLC1A-Q were also included, as 
well as other linkage regions without designated names. The database provides the most 
accurate location of each of the loci as possible, from the original publications. Some papers 
reported microsatellite markers or particular regions of genes (for example the promoter region 
of NPPA [181]) and these were converted to the most accurate base pair positions in the hg19 
reference genome. 
Base pair position and POAG and/or clinical trait associations from the literature were 
extracted from Appendix B and used to test for association in the families. Association in the 
families was tested for variants falling into each of three groups from the literature; SNPs, 20kb 
windows around these SNPs, and linkage regions. Methods for each category varied slightly, 
as outlined below. 
3.2.2.1 SNPs from the literature 
A single list containing each variant’s chromosome number and base pair position was 
generated from Appendix B. There were 448 SNPs identified in the POAG database. The 
VLOOKUP function within Microsoft Excel was used to determine which of these SNPs were 
captured in the whole exome sequencing conducted on the families (as shown in the VCF file 
described in section 2.4.2). The SNPs identified in the family data were tested for association 
separately for the IOP, VCDR and CCT clinical traits. 
3.2.2.2 20kb windows around SNPs from the literature 
To test for association in the 20kb windows around the published SNPs, firstly the loci were 
categorised by their clinical associations in the literature. SNPs were separated into POAG, 
IOP, VCDR, CCT and the combined ODA or OCA groups, as identified by “1” in these 
columns in Appendix B. A BED file, consisting of the chromosome number and a column each 
for the start and stop base pair positions, representing a ±10kb region around each of the SNPs, 
was generated for each clinical trait. Regions were common between BED files if SNPs were 
associated with more than one clinical trait in the literature. Table 3-1 summarises the numbers 
of SNPs represented in each of the 5 BED files.  
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Table 3-1 Number of SNPs with reported associations represented in BED files for POAG 
and its clinical traits 
POAG * IOP VCDR CCT ODA or OCA 
191 108 107 96 110 
POAG* = primary open angle glaucoma, including 13 SNPs identified as associated with normal 
tension glaucoma and 4 loci identified as associated with juvenile open angle glaucoma IOP = 
intraocular pressure, VCDR = vertical cup to disc ratio, CCT = central corneal thickness, ODA = 
optic disc area, OCA = optic cup area 
 
A custom R script (see Appendix C.1.1) was used with each of the BED files to extract variants 
within each region from the family sequencing data. Regions reported in the literature as 
associated with POAG were assessed for association with each of the three clinical traits; IOP, 
VCDR and CCT. Regions reported for each trait were assessed against the same trait in the 
families with the addition of assessing IOP loci for association with CCT and vice versa, due 
to relationship between CCT thickness and IOP measurement (see Chapter 1.7). In addition, 
published ODA and OCA loci were tested for association with VCDR in the families as these 
traits are also related. Table 3-2 shows the analysis plan for examining the family-based 
association data within the 20kb regions around the SNPs. 
Table 3-2 Analysis plan for assessing reported associations against the clinical traits 
measured in the families 
 Family MGA data 





POAG ✓ ✓ ✓ 
IOP ✓  ✓ 
VCDR  ✓  
CCT ✓  ✓ 
ODA or OCA  ✓  
Ticks indicate reported associations assessed against family MGA data for each of the clinical traits. 
POAG* = primary open angle glaucoma, including 13 loci identified as associated with normal 
tension glaucoma and 4 loci identified as associated with juvenile open angle glaucoma IOP = 
intraocular pressure, VCDR = vertical cup to disc ratio, CCT = central corneal thickness, ODA = 
optic disc area, OCA = optic cup area 
 
3.2.2.3 Variants within larger loci and linkage regions 
One BED file was generated for all the larger loci (such as regions of genes) and linkage 
regions, consisting of the chromosome number, start and stop base pair positions as reported 
in Appendix B. No additional windows were added to these regions as they were already broad. 
The same custom R script as used in the 20kb windows discussed above (Appendix C.1.1) was 
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used to extract these 38 larger regions from the family sequencing data. MGA analysis was 
then conducted on these regions for each of the clinical traits; IOP, VCDR and CCT. 
3.2.3 Family-based association testing of published POAG loci 
MGA is a family-based association test conducted within a variance components framework 
(as described in Chapter 2.6.3). MGA analysis was completed separately for IOP, VCDR and 
CCT, providing association data for each variant within the regions identified from the 
literature. Variance components polygenic modelling was conducted on the IOP, VCDR and 
CCT quantitative traits in SOLAR (as described in section 2.6.3) using the full pedigrees to 
calculate empirical kinships. MGA was run for both the normalised and raw trait values, to 
provide accurate association statistics (normalised) as well as effect sizes of each variant 
(untransformed).  
As whole exome sequencing (WES) data was obtained from the families of this study, 
providing the genotyping information for this analysis, only regions captured by the exome 
sequencing were able to be included in the MGA analysis. Reported loci in non-coding and 
intergenic regions were not captured 
3.2.3.1 Significance levels for association testing  
As the association analyses were tested on three different types of loci from the literature; 
SNPs, 20kb windows around SNPs and linkage regions, determining statistical significance 
was calculated accordingly for each. 
The SNPs were tested for association with each of the clinical traits measured in these families. 
A Bonferroni correction was used to adjust for the number of independent loci which were 
captured in the family sequencing data as well as the three clinical traits tested with MGA. The 
20kb windows around the SNPs were only tested for association with the traits as outlined in 
Table 3-2. The linkage regions were tested for association with IOP, VCDR and CCT and were 
combined with the POAG 20kb window regions, as these too were assessed for association 
with each of the three clinical traits. We hypothesised that there would be only one causative 
variant per region and therefore used the number of regions assessed for each trait to correct 
for the number of tests performed. The p-value used for significance used a correction 
accounting for both the number of loci represented and the number of clinical traits analysed 
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for each list of regions (Table 3-2). The p-value used for suggestive significance only corrected 
for the number of loci represented but not the number of traits analysed. 
3.2.3.2 Combine MGA data with annotated VCF files 
To contribute additional information on the variants tested for association, annotations for each 
of the variants were added to the MGA output files. The variants in these regions were 
annotated using ANNOVAR (as described in section 2.4.2), providing information such as 
allele frequencies in different populations and measures of deleteriousness. Variants were also 
annotated for call quality, using GATK (as described in section 2.4.2). Only variants with at 
least 80% high confidence calls were used for further analysis. A custom R script (Appendix 




3.3 Results  
3.3.1 Polygenic modelling of IOP, VCDR and CCT 
Polygenic modelling for each of the clinical traits is displayed in Table 3-3. The three traits 
were all significantly heritable, with p-values ranging from 1.80 x 10-9 to 9.00 x 10-7. CCT was 
the most heritable trait at 84% and the normalised VCDR trait least heritable at 40%. Only the 
non-normalised IOP trait was kurtotic and normalising the trait increased its heritability to 
50%. Age was a significant covariate for each of the clinical traits. Covariates contributed most 
to the variance of VCDR, with 34%, and least to CCT, with 6%. 
Table 3-3 Variance components polygenic modelling of normalised and non-normalised 
POAG clinical traits 
Trait 





Covariates included in 
final model (non-
normalised traits only) 
Proportion of 
variance due to 
covariates (%) 
IOP 44 ± 10 1.83 x 10-8 -3.97 age, age2 18 
IOP_norm 50 ± 10 1.36 x 10-8 -0.19   
VCDR 43 ± 11 9.00 x 10-7 -0.38 age, age2 31 
VCDR_norm 40 ± 11 5.00 x 10-7 -0.19   
CCT 88 ± 12 1.80 x 10-9 -0.37 age 6 
CCT_norm 84 ± 14 2.20 x 10-9 -0.24   
POAG = primary open-angle glaucoma, IOP = intraocular pressure, VCDR = vertical cup to disc 
ratio, CCT = central corneal thickness, norm = normalised trait,  
h2r = heritability, SE = standard error, residual kurtosis = a measure of non-normal trait distribution, 
bold indicates kurtosis exceeding 0.8 threshold 
3.3.2 Significance thresholds for each analysis 
As described in section 3.2.3.1, significance levels were based on the number of loci captured 
in the families’ sequencing data. With 41 SNPs from the literature returned in the family-based 
association data, Bonferroni corrected p-values of 4.1 x 10-4 (0.05 ÷ (41 SNPs x 3 traits)) and 
0.0012 (0.05 ÷ 41 SNPs) were used for significance and suggestive significance respectively. 
For the 20kb windows around the published SNPs, levels of significance were based on the 
combinations identified in the analysis plan in Table 3-2 with the addition of the larger loci and 
linkage regions, which were assessed for all of the clinical traits in the family-based association 
data. The number of loci captured in the family MGA analyses determined the Bonferroni 
correction factor used. Table 3-4 summarises the multiple testing corrections and p-values used 
to determine significance for the analysis of the combined 20kb windows and the larger loci 
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and linkage regions. Significance represents correction for both the number of loci and the 
number of traits tested for association, whereas suggestive significance represents correction 
for the number of loci only.  
Table 3-4 Significance levels used for analysis of family-based association data for 20kb 
windows around published SNPs and larger loci and linkage regions. 




No. loci represented 






POAG and all 
linkage regions 
101 
IOP, VCDR and 
CCT 
1.7 x 10-4 5.0 x 10-4 
IOP 35 IOP and CCT 7.1 x 10-4 1.4 x 10-3 
VCDR 30 VCDR 1.7 x 10-3  
CCT 26 CCT and IOP 9.6 x 10-4 1.9 x 10-3 
ODA or OCA 29 VCDR 1.7 x 10-3  
POAG = primary open-angle glaucoma, IOP = intraocular pressure, VCDR = vertical cup to disc 
ratio, CCT = central corneal thickness, ODA = optic disc area, OCA = optic cup area 
 
 
3.3.3 Association of literature reported POAG SNPs with clinical traits in 
five extended pedigrees 
Out of the 41 variants reported in the literature which were captured in the exome sequencing, 
none were significantly associated with IOP, VCDR or CCT at the Bonferroni corrected 
significance level of p ≤ 4.1 x 10-4 or suggestive significance at p ≤ 0.0012. Table 3-5 identifies 
all the variants which reached nominal significance at p ≤ 0.05 for each of the traits. Five SNPs 
reached nominal significance for IOP, three for VCDR and one for CCT. 
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Table 3-5 Nominally significant measured genotype association results for specific SNPs and indels identified in the literature 
 
 
Chr = chromosome, bp = base pair, ref = reference allele, alt = alternate allele 
5’ UTR - 5’ untranslated region, ncRNA = non-coding RNA, exonic = protein coding region (synonymous unless otherwise indicated) 
Ref = reference allele, Alt = alternate allele 
CADD = combined annotation dependent depletion phred scores (version 1.4), scores ≥ 15 are in bold 
AF = frequency of the variant allele in the 5 families, gnomAD genome NFE = variant allele frequency in non-Finnish Europeans in the gnomAD genome database 
IOP =  intraocular pressure, VCDR = vertical cup to disc ratio, CCT = central corneal thickness 
beta-value = effect size per allele. IOP = pressure inside the eye measured in mmHg, VCDR = between -1.0 and 1.0, CCT = thickness of the central cornea measured in μm 
mac = minor allele copies as used for MGA analysis (both phenotypic and genotypic data required). Maximum copies possible for each endophenotype are; IOP = 490, VCDR = 486, CCT = 296 
POAG = primary open angle glaucoma, NTG = normal tension glaucoma, ODA = optic disc area, OCA, optic cup area 
blank cells represent SNPs not reaching nominal significance for the trait 
 
 
   
Measured genotype association 
From Appendix B 






























2 38,298,139  rs1800440 CYP1B1 
exonic 
p.(Asn > Ser) 
T C 25.00 0.177 0.170           0.0175 -12.01 7.54 51 [182, 183] POAG 
2 38,302,177  rs1056827 CYP1B1 
exonic 
p.(Ala > Ser) 
C A 7.55 0.273 0.306 0.0419 1.48 1.05 135           [182, 183] POAG 
2 38,302,390  rs10012 CYP1B1 
exonic 
p.(Arg > Gly) 
G C 5.13 0.273 0.302 0.0419 1.48 1.05 135           [182] POAG 
2 113,542,960  rs1800587 IL1A 5' UTR G A 2.12 0.321 0.295      0.0354 0.04 2.95 156         [184] POAG 
9 22,003,367  rs1063192 CDKN2B-AS1 
ncRNA 
intronic 
G A 0.99 0.655 0.562 0.0435 -1.31 0.85 319           




9 136,131,415  rs8176743 ABO 
exonic 
p.(Gly > Ser) 
C T 7.49 0.124 0.105 0.0405 1.89 2.37 61           [86] IOP 
9 136,131,461  rs8176741 ABO exonic G A 5.88 0.124 0.105 0.0405 1.89 2.37 61                 [136] 
IOP, VCDR, ODA 
or OCA 
12 104,415,244  rs11553764 GLT8D2 5' UTR C T 8.92 0.092 0.173         0.0305 0.08 1.08 45         [179] CCT 
15 100,692,953  rs72755233 ADAMTS17 
exonic 
p.(Thr > Ile) 
G A 23.10 0.081 0.115         0.0143 -0.09 2.57 38         [171] IOP 
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The nine nominally significant variants represent six genes, with CYP1B1 and ABO with more 
than one associated SNP. All of the variants are common in the general population, as measured 
by the frequency of the variant allele in the gnomAD genome non-Finnish European database 
[185], ranging from 10.5% to over 56% in frequency. The effect size of each of the variants 
was small, as measured by the beta-values. Four of the five SNPs nominally significant for IOP 
were only associated with average increased pressure of around 1 or 2 mmHg per allele with 
the CDKN2B-AS1 variant associated with a reduction in IOP by a similar amount. For VCDR, 
the effect size was similarly small, with two variants associated with increasing and one variant 
associated with decreasing VCDR by less than 0.1. The only nominally significant CCT SNP 
was associated with a decrease in corneal thickness of 12μm per allele. This variant in CYP1B1 
contributes to nearly 8% of the variance in CCT, giving it a larger impact than the other 
variants, which do not exceed 3% each. 
The publications, from which the variants were included in this analysis, are a mixture of 
smaller targeted gene and variant studies and large GWAS. The CDKN2B-AS1 variant, 
rs1063192, is the most replicated variant of these nominally significant associations. Multiple 
publications associated this variant with POAG, normal tension glaucoma (NTG) and the IOP 
endophenotype [29, 69, 90, 95-99]. Most of the nominally significant variants in Table 3-5 
were identified from POAG loci in the literature. The two ABO variants, nominally associated 
with IOP in the family MGA data were identified from published IOP loci [86, 136]. The two 
VCDR variants, rs11553764 and rs72755233, were from publications of different clinical 
traits; CCT and IOP respectively [171, 179]. 
3.3.4 Association of larger POAG loci with clinical traits in five extended 
pedigrees 
Variants within POAG linkage regions combined with the 20kb windows around published 
POAG SNPs yielded significant results when tested for association with IOP, VCDR and CCT 
in the five extended pedigrees. Table 3-6 displays all the variants reaching at least suggestive 
significance for the three traits. The rarer variants from this table (< 50 copies) are also included 
in Table 3-7 which supplements allele frequency information with detail on the number of 
minor alleles present in each of the five families.  
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Table 3-6 Statistically significant measured genotype association results for 20kb windows around published variants and linkage regions identified in the literature 
 
 
Measured genotype association  




Variant ID Gene 
Gene 
region 






































11 130,281,493 rs200759153 ADAMTS8 
exonic 
p.(Pro > Pro) 




















2 97,563,745 rs4243786 FAM178B 5' UTR T C 0.63 0.283 0.264 1.67 x 10-4 -2.12 5.54 138         
GLC1B [175] POAG 
2 97,877,478 rs10194525 ANKRD36 
exonic 
p.(Val > Met) 
G A 22.50 0.432 0.419 3.22 x 10-4 3.44 6.21 211         
2 98,164,184 rs13001728 ANKRD36B 
exonic 
p.(Glu > Asp) 
C G 0.27 0.697 0.679 7.40 x 10-5 2.13 7.49 341         
2 98,206,188 rs1868445 ANKRD36B 5' UTR C G 4.71 0.700 0.692 1.26 x 10-4 2.04 7.31 341         
2 98,206,282 rs28415903 ANKRD36B 5' UTR C T 5.75 0.699 0.691 1.25 x 10-4 2.00 7.24 342         
2 98,206,293 rs1814505 ANKRD36B 5' UTR G A 3.21 0.699 0.691 1.25 x 10-4 2.00 7.24 342         
2 98,273,290 rs11547232 ACTR1B 3' UTR C T 0.06 0.685 0.680 1.06 x 10-4 2.06 7.40 335         
2 197,521,750 rs34133636 CCDC150 
exonic 
p.(Glu > Lys) 
G A 23.20 0.024 0.062     3.81 x 10-4 -0.23 6.69 12     2q33.1 – 33.3 [187] POAG 
3 42,266,360 rs3755809 TRAK1 3' UTR T C 1.09 0.245 0.215         5.74 x 10-6 24.35 9.30 68 
GLC1L [174] POAG 
3 49,725,021 rs114429531 MST1 
exonic 
p.(Arg > His) 
C T 8.07 0.010 <0.001 9.60 x 10-5 9.49 5.28 5         
3 126,178,390 rs1043803 ZXDC 3' UTR A C 4.53 0.608 0.616         4.45 x 10-4 16.24 10.33 184 
GLC1C [153] POAG 3 126,180,121 rs3231 ZXDC 3' UTR C T 6.93 0.606 0.613         1.96 x 10-4 16.98 11.36 183 
3 126,200,403 rs1799398 UROC1 3' UTR A C 1.41 0.606 0.614         1.96 x 10-4 16.98 11.36 183 
5 133,451,564 rs115535840 TCF7 5' UTR G C 12.85 0.024 0.065         3.60 x 10-4 -40.62 14.00 11 




GTT - 19.03 0.737 0.697         3.48 x 10-4 -16.90 9.52 218 
5 149,589,656 rs116239172 SLC6A7 3' UTR C G 0.64 0.046 0.042         4.25 x 10-4 -36.48 8.94 10 
6 167,369,897 rs1044059 RNASET2 5' UTR C A 10.52 0.398 0.457     1.30 x 10-4 -0.08 8.47 191     
6q27 [188] IOP 
6 167,369,992 rs2247325 RNASET2 5' UTR A G 9.95 0.281 0.347     7.90 x 10-5 -0.10 8.30 134     
10 70,742,931 rs12412103 DDX21 3' UTR A G 6.00 0.064 0.050 1.20 x 10-4 -3.60 6.91 32         
10q22 [189] IOP 




Measured genotype association  




Variant ID Gene 
Gene 
region 




































17 6,024,786 rs3809841 WSCD1 3' UTR G T 0.01 0.413 0.431         1.20 x 10-5 -17.73 10.46 128 
  17p13.3-p13.1 [190] POAG 17 8,024,121 rs1442849 HES7 3' UTR C T 11.90 0.291 0.280 
        4.10 x 10-5 -19.03 11.19 80 
17 8,701,799 rs17854013 MFSD6L 
exonic 
p.(Pro > Thr) 
G T 16.17 0.141 0.184 2.43 x 10-4 -2.22 7.04 69         
17 75,495,397 rs9038 SEPT9 3' UTR T C 3.99 0.367 0.406 3.20 x 10-4 1.78 3.78 178           17q25.1-q25.3 [190] POAG 
19 13,010,643 rs9384 GCDH 3' UTR G T 1.10 0.331 0.360         3.23 x 10-4 -16.01 11.33 102 
19p13.2 [191] IOP 
19 13,044,544 rs2974750 FARSA 5' UTR C A 6.52 0.659 0.647         1.11 x 10-4 17.65 13.11 190 
20 14,304,700 rs79295487 FLRT3 3' UTR G A 13.32 0.075 0.012 1.17 x 10-4 4.55 7.18 36         
GLC1K [47] JOAG 20 14,304,785 rs183080338 FLRT3 3' UTR T A 16.07 0.050 0.008 3.18 x 10
-4 5.07 4.73 24         
20 14,307,024 rs8120693 FLRT3 
exonic 
p.(Ala > Thr) 
C T 19.49 0.074 0.012 1.27 x 10-4 4.54 7.00 36         
 
Significant p-values indicated in bold, suggestive significance not bold p-values 
Chr = chromosome, bp = base pair 
3’ UTR = 3’ untranslated region, 5’ UTR - 5’ untranslated region, exonic = protein coding region, includes amino acid change 
Ref = reference allele, Alt = alternate allele 
CADD = combined annotation dependent depletion phred scores (version 1.4), scores ≥ 15 are in bold 
AF = frequency of the variant allele in the 5 families 
gnomAD genome NFE = variant allele frequency in non-Finnish Europeans in the gnomAD genome database  
IOP = intraocular pressure, VCDR = vertical cup to disc ratio, CCT = central corneal thickness 
beta-value = effect size per allele. IOP = pressure inside the eye measured in mmHg, VCDR = between -1.0 and 1.0, CCT = thickness of the central cornea measured in μm 
mac = minor allele copies as used for MGA analysis (both phenotypic and genotypic data required). Maximum copies possible for each endophenotype are; IOP = 490, VCDR = 486, CCT = 296 
POAG = primary open angle glaucoma, JOAG =  juvenile open angle glaucoma, NTG = normal tension glaucoma, ODA = optic disc area, OCA, optic cup area 
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Table 3-7 Minor allele copies per family for variants identified in Table 3-6 with a < 50 copies genotyped in the five families 
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10 115,805,601 - ADRB1 3' UTR C T 10.38 0.010 0.002     3.21 x 10-4 -0.32 2.18 5     1(1) 1(1) 3(3)   5 
11 130,281,493 rs200759153 ADAMTS8 
exonic 
p.(Pro > Pro) 
G A 9.11 0.010 0.003 1.16 x 10-3 7.85 5.59 5         1(1) 1(1)   3(3) 5 
2 197,521,750 rs34133636 CCDC150 
exonic 
p.(Glu.> Lys) 
G A 23.20 0.024 0.062     3.81 x 10-4 -0.23 6.69 12     4(4)  5(5) 1(1) 2(2) 12 
3 49,725,021 rs114429531 MST1 
exonic 
p.(Arg > His) 
C T 8.07 0.010 <0.001 9.60 x 10-5 9.49 5.28 5          3(3) 2(2)   5 
5 133,451,564 rs115535840 TCF7 5' UTR G C 12.85 0.024 0.065         3.60 x 10-4 -40.62 14.00 11 7(6) 3(3) 2(2)   12 
5 149,589,656 rs116239172 SLC6A7 3' UTR C G 0.64 0.046 0.042         4.25 x 10-4 -36.48 8.94 10 4(3) 2(2) 4(4) 4(0) 9(1) 23 
10 70,742,931 rs12412103 DDX21 3' UTR A G 6.00 0.064 0.050 1.20 x 10-4 -3.60 6.91 32         8(8)  21(21) 1(1) 2(2) 32 
10 72,185,254 rs16927606 EIF4EBP2 3' UTR T C 4.79 0.036 0.045         3.92 x 10-4 33.07 5.46 13 6(4) 11(8) 1(1)   18 
20 14,304,700 rs79295487 FLRT3 3' UTR G A 13.32 0.075 0.012 1.17 x 10-4 4.55 7.18 36         12(12) 9(9) 13(12)  3(3) 37 
20 14,304,785 rs183080338 FLRT3 3' UTR T A 16.07 0.050 0.008 3.18 x 10-4 5.07 4.73 24          9(9) 13(12)  3(3) 25 
20 14,307,024 rs8120693 FLRT3 
exonic 
p.(Ala > Thr) 
C T 19.49 0.074 0.012 1.27 x 10-4 4.54 7.00 36         12(12) 9(9) 13(12)  3(3) 37 
 
Significant p-values indicated in bold, suggestive significance not bold p-values 
Chr = chromosome, bp = base pair 
3’ UTR = 3’ untranslated region, 5’ UTR - 5’ untranslated region, exonic = protein coding region, includes amino acid change 
Ref = reference allele, Alt = alternate allele 
CADD = combined annotation dependent depletion phred scores (version 1.4), scores ≥ 15 are in bold 
AF = frequency of the variant allele in the 5 families 
gnomAD genome NFE = variant allele frequency in non-Finnish Europeans in the gnomAD genome database  
IOP =  intraocular pressure, VCDR = vertical cup to disc ratio, CCT = central corneal thickness 
beta-value = effect size per allele. IOP = pressure inside the eye measured in mmHg, VCDR = between -1.0 and 1.0, CCT = thickness of the central cornea measured in μm 
mac = minor allele copies as used for MGA analysis (both phenotypic an genotypic data required). Maximum copies possible for each endophenotype are; IOP = 490, VCDR = 486, CCT = 296 
POAG = primary open angle glaucoma, JOAG =  juvenile open angle glaucoma, NTG = normal tension glaucoma, ODA = optic disc area, OCA, optic cup area  





Of the 31 variants identified (Table 3-6), two were from the 20kb windows around the SNP 
loci from the literature; an unnamed variant upstream from rs1801253 in ADRB1 on 
chromosome 10 and rs200759153 which is within the 20kb window of three variants in 
ADAMTS8 on chromosome 11. The chromosome 10 variant is in a region identified in a study 
of NTG [186] and reached suggestive significance in the VCDR association results. This 
variant is rare in the general population, with a minor allele frequency of only 0.2% and found 
in a total of 5 heterozygous carriers in 3 of the 5 families (see Table 3-7). This variant appears 
protective in these families, as it was associated with an average reduction in the VCDR by 
0.3. This is quite large, considering that as a ratio, the beta-value for VCDR only ranges 
between -1 and 0 or 0 and 1, with negative values representing a protective effect and positive 
values representing a deleterious effect. Although a large effect size, the variance explained in 
VCDR by this variant was relatively small, at only 2%. The chromosome 11 variant, 
rs200759153, demonstrated suggestive significance with IOP and is within the 20kb region 
around ADAMTS8 variants associated with multiple traits in the literature. Another rare SNP 
in the general population, at 0.3%, it was also found in 5 heterozygous carriers across 3 families 
(see Table 3-7). The effect size of this variant was large, with each allele associated with an 
average increase in IOP of nearly 8mmHg in these variant carriers. The variance of the IOP 
trait explained by this SNP was also large, at nearly 6%. 
The remaining 29 variants of at least suggestive significance are within reported linkage 
regions. Although larger loci, such as regions of genes, were included in this analysis, 
associations were not identified within these regions. Most of these variants are within 5’ and 
3’ untranslated regions (UTRs) of genes within the linkage regions. There are 6 non-
synonymous protein coding variants and one deletion encompassing a whole codon. Most of 
the variants are common in the general population, with only 4 variants observed at or below 
1% in the gnomAD NFE database. 
The first of these rare variants identified within the linkage regions in Table 3-6 is rs114429531, 
a protein coding SNP in MST1, significantly associated with IOP in these families. This variant 
was extremely rare observed with a frequency of < 0.001 in the gnomAD database. This non-
synonymous SNP is carried by 5 family members across two families (see Table 3-7) and 
increased IOP by an average of 9.5mmHg per allele. 
A cluster of rare variants was observed in the FLRT3 gene on chromosome 20. The three 
variants were observed at around a 1% frequency in the general population, which increases to 
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between 5 and 7.5% in the families of this study. Two of the variants are located in the 3’ UTR 
of FLRT3 and one is a non-synonymous protein coding SNP. These three variants appear to be 
on the same haplotype, as all the variants are carried by the same individuals in the same 
families (Table 3-7). One of the three variants, rs183080338, which was the only one of the 
three to not to reach full significance, is only carried by 25 individuals (see Table 3-7). Twelve 
members of family 93001 do not carry this variant, but all carry the other 2 variants shared by 
four out of the five families of this study. This region of FLRT3 increased IOP between 4.5 and 
5mmHg per allele in these families, and explains up to 7% of the variance of this trait. Two out 
of the three variants have CADD scores greater than 15, predicting deleterious functional 
effects. The FLRT3 gene lies in the GLC1K region, originally identified from families with 
juvenile open angle glaucoma [47]. 
The remaining significant variants identified in Table 3-6 are more common than those already 
discussed, ranging from 4% through to 70% in the gnomAD genome NFE database. A group 
of these common variants are located in the GLC1B region on chromosome 2 and were 
associated with IOP in this analysis. The first variant in this region, rs4243786, reduced IOP 
by just over 2mmHg in the families of this study. The remaining variants in this region 
increased IOP, with rs10194525 demonstrating the greatest IOP increase. Although this non-
synonymous protein coding SNP only reached suggestive significance, it has an extremely high 
CADD score. The other non-synonymous protein coding SNP in this region, rs13001728, is 
extremely common in both the families and the gnomAD database, at 70% frequency, but has 
a negligible CADD score. This SNP and the remaining variants in the UTRs of the GLC1B 
region are found at a similar frequency in the families and have a similar level of effect to IOP, 
increasing it around 2mmHg on average. Three remaining SNPs reached at least suggestive 
significance for IOP in Table 3-6; rs12412103, rs17854013 and rs9038. These were found 
within three different published linkage regions; one on chromosome 10 and two from 
chromosome 17. Two of these variants are within 3’ UTRs and one, rs17854013, is a non-
synonymous protein coding variant. This latter SNP reduced IOP in these families, as did the 
chromosome 10 variant. These two variants are not as common as the third variant, rs9038, 
which increased IOP by just under 2mmHg in the families. 
Three variants reached at least suggestive significance in the VCDR MGA analysis of the 
linkage regions from the literature. Firstly, rs34133636, a non-synonymous protein coding SNP 
with a high CADD score in the CCDC150 gene. This variant was found less frequently in the 
families than in the gnomAD database and reduced VCDR by 0.23. The remaining two 
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significant SNPs are within 100bp of each other in the 5’ UTR of RNASET2. These variants 
are more common than the other two VCDR variants discussed already and they also reduce 
VCDR by around 0.1, in these families. 
The most significant MGA result in Table 3-6 is for rs3755809, a 3’ UTR SNP in the TRAK1 
gene, which was associated with CCT. This is a common variant, with an allele frequency of 
over 20% in the families and the general population. This variant was associated with an 
increase in CCT thickness by an average of 24μm and explains over 9% of the variance in this 
trait in the families. Other significant CCT MGA results were identified in UTRs on 
chromosome 17. These common variants decreased CCT thickness by around 18μm per allele, 
in these families. The final significant CCT MGA result is rs2974750 on chromosome 19. This 
variant increased CCT in these families, whereas another variant within the same published 
chromosome 19 linkage region, rs9384, decreased CCT at a suggestive level of significance. 
Both these variants are common in these families. Variants associated with increased CCT at a 
suggestive significance threshold, were found on chromosome 3 within a 22kb range within 
the GLC1C linkage region. Variants identified within the GLC1M linkage region decreased 
CCT measurements between 17 and 41μm, on average, in the families of this study. One of 
these variants, rs1160982, the only indel in Table 3-6, is a very common deletion in the protein 
coding region of FBXL21. The other two variants in the GLC1M region are much rarer, with 
less than 5% frequency in the families of this study. They both had a larger effect size of CCT 
reduction, at around 40μm per allele in the family members, although these results were also 
at a suggestive level of significance. Another variant with a large effect size is rs16927606 on 
chromosome 10. This variant was associated with an average increase of CCT by 33μm per 
allele, but is not as common as other alleles, observed at a frequency of less than 4%. 
Table 3-7 shows the rarer variants, from Table 3-6, with less than 50 copies in total across the 
five families. It should be noted that, as described in section 2.6.3, the minor allele copy number 
for the MGA analysis was filtered to at least five copies for each variant. Thus, the extremely 
rare variants have not been included in this analysis. Even the rarest of variants in this analysis, 





The major aim of the overall research presented in this thesis was to use extended families 
enriched for POAG to identify rare variants and propose novel genes which impact the 
endophenotypes of this complex disease. The bulk of the literature on this disease is focused 
on common variants with small effect sizes. There have also been large regions of the genome 
associated with glaucoma, represented by published linkage regions, but with very few 
functional variants identified from within these. Before identifying potentially novel variants 
associated with the endophenotypes in the families of this study, it was important to first 
determine whether variants and regions already recognised in the literature harbour variants 
influencing POAG risk in these families. There are challenges to comparing the outcomes of 
published population and family studies with the family generated data from our study. Many 
different study designs and populations were represented in the literature with the predominant 
association studies favouring the identification of common variants. Even the family data 
included in the literature, as published linkage regions, represented multiple family structures 
and study designs. Most of these published family studies have not found the causative variants 
or genes. However, as a first stage analysis of our family data, prior to identifying potentially 
novel POAG variants and genes, using a family-based association test to determine the impact 
of published variants and regions in our families is a valid approach to take. Thus, recognising 
that there are limitations to the research conducted in this chapter, MGA analysis was used to 
assess whether published POAG loci affected trait variance in IOP, VCDR and CCT in the 
families of this study. 
The first stage involved establishing a database of genetic loci (Appendix B) and testing these 
for association in the five families of this study. Association was analysed for three sets of 
variant data; published SNPs, 20kb windows around these published SNPs and larger loci, 
including linkage regions. 
3.4.1 SNPs from the literature 
Family-based association analysis of the reported SNPs revealed no significant associations 
(Table 3-5). Fewer than 10% of these variants were present in the WES sequencing in the 
families, and of these, none reached statistical significance, with only nine reaching nominal 
significance at p ≤ 0.05. These were all common variants in the families and in the general 
population. Most of the variants identified from the family-based association results had small 
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effect sizes and only accounted for a very small proportion of the variance of the trait. Of the 
SNPs from the literature reaching nominal significance in this study, one variant, rs1800440 in 
CYP1B1, had a larger effect size and explained a greater amount of variance than the other 
variants identified. An effect of reducing CCT by an average of 12μm per allele was observed 
in the families, which is not insubstantial when considering a homozygote for this allele may 
have a 24μm reduction in corneal thickness. This is a large effect size considering the normal 
range for CCT is between 503μm and 565μm [192]. This SNP also is ranked in the top 0.1% 
of deleterious variants by CADD, suggesting it could potentially be of functional significance 
in these families. CYP1B1 was originally identified as the causative gene in the primary 
congenital glaucoma locus GLC3A [50] and since then, has been associated with JOAG and 
POAG [182, 193-195], although there are conflicting findings on the importance of different 
variants in the risk of developing POAG [183]. The lack of association of CYP1B1 with CCT 
in the literature, including several CCT GWAS [179, 196-201] and the fact that this variant 
only reached nominally significance in our study, suggest this variant is not an important 
finding for these families. 
When considered in the context of the non-significant p-values, individually the identified 
variants are unlikely to play an important role in the genetic determination of the POAG traits 
within these families. However, they may contribute in a polygenic fashion. Although beyond 
the scope of this study, polygenic risk score (PRS) analysis is becoming a more popular 
research field and a valuable tool for utilising the rich data obtained from GWAS, which is 
transferable to the clinical setting [81]. The combined effects of many variants, each with small 
effect sizes, may provide an increased risk upon which family specific rare variants contribute. 
PRS studies in large case-control cohorts have recently been published for IOP and POAG [83-
85]. Using the risk alleles identified in those studies to determine the background risk of these 
families would be beneficial to gain a better understanding of the genetic mechanisms 
important to POAG risk in these families. 
3.4.2 20kb around published SNPs 
Investigating the regions around the reported variants from the literature may provide other 
association signals which may be in LD with the variants already identified. Windows 20kb 
around each variant (10kb upstream and downstream) were chosen to provide an appropriately 
sized region which would conceivably contain variants in LD with the published SNPs [79]. 
Only two variants reached suggestive significance within these 20kb window regions; rare 
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variants in ADRB1 and ADAMTS8 (Table 3-6). Although the ADRB1 variant may be important 
in the 5 individuals it was identified in, it only explains around 2% of the variance of the VCDR 
trait, thus is not a major variant in the families overall. This variant was identified downstream 
from rs1801253, which was implicated in NTG in Japanese glaucoma patients [186]. That 
study investigated polymorphisms associated with glaucoma and IOP, but not VCDR, which 
is the associated endophenotype in our study. In the families of our study, the identified variant 
has a protective effect, associated with an average decrease of 0.3 in VCDR. 
The synonymous coding SNP, rs200759153, was identified within the 20kb windows of four 
ADAMTS8 variants. These four variants have been associated with each of the clinical traits 
measured in the literature as well as optic cup area [103, 136, 179]. This SNP was associated 
with IOP at a suggestive level of significance in this study. This is another rare variant, 
contributing nearly 6% to the variance in IOP, associated with an average increase in IOP 
nearly 8mmHg in the families of this study. Several variants have been identified in ADAMTS8 
as associated with the clinical intermediate traits of POAG, and this gene has only very recently 
been associated with POAG itself [83]. Interestingly, of the five variant carriers of rs200759153 
in the families of this study, two had been diagnosed with POAG and two had a suspected 
POAG diagnosis at the time of examination. The fifth person had not developed POAG at their 
last clinical examination, but they were only 40 years old at the time and may have developed 
glaucoma since. As the families of this study are enriched for POAG, this finding may represent 
an incidental finding. However, this SNP may represent a true association of a variant 
important in the progression from ocular hypertension to POAG. Further research on the 
association of this rare ADAMST8 variant and the gene itself with POAG is needed to elucidate 
this finding. 
3.4.3 Linkage regions from the literature 
The published variants themselves and the 20kb windows around them only yielded 2 variants 
at a suggestive level of significance in the family-based association analysis. The linkage 
regions identified in the literature were associated with several variants reaching full statistical 
significance (Table 3-6). These regions total around a tenth of the genome (>300 million base 
pairs), in comparison to the 20kb windows (< 10 million base pairs) even though a large 
proportion of these regions had not been sequenced in the WES of these families. The greater 
number of variants with significant associations in the linkage regions, compared to the 20kb 
window regions, may be a reflection of the size of the linkage regions themselves, and the 
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increased chance of observing significant results or an increase in relevance of these regions in 
the families of this study, or a combination of both of these. Importantly, the significance 
thresholds determined previously (sections 3.2.3.1 and 3.3.2) were based on a hypothesis of 
one causal variant per linkage region. We have used that threshold, but in some cases have 
presented results for more than one significant result per linkage region, for example seven 
variants from the GLC1B locus (Table 3-6). Although more than one variant may have been 
identified in a linkage region, they would be considered to be on the same haplotype, with only 
one causative variant. Haplotype analysis would need to be conducted to confirm these 
findings, however, in the context of this study, it is hypothesised that only one variant per 
linkage region per trait would be functional. 
3.4.3.1 IOP associated variants within linkage regions 
Several significant associations were observed with IOP in these families in four different 
linkage regions from the literature. GLC1B on chromosome 2 was originally identified in 
families with POAG with low to moderate IOP levels [175]. The MGA results from our study 
have identified a haplotype of significant variants for increased IOP, although this increase is 
only around 2mmHg in the families. Most of these variants are extremely common, at around 
70%. Possibly the most interesting variant associated with IOP in the families within the 
GLC1B region, is rs10194525, a missense mutation with a high CADD score. Although only 
reaching suggestive significance, this variant had a slightly larger effect size, associated with 
an average IOP increase of nearly 3.5mmHg per allele, and contributed to over 6% of the trait 
variance. Of the variants identified within the GLC1B linkage region, rs10194525 is the most 
likely functional variant in the families of this study. 
A variant identified here and worth further consideration is rs114429531 in MST1. Extremely 
rare in the general population, it was associated with a large average increase of 9.5mmHg per 
allele, in IOP. This variant, observed at 0.2% in the gnomAD NFE database, was identified in 
five individuals across two families (Table 3-7). Four of the five individuals had a POAG 
diagnosis, with one person without a POAG diagnosis at their last clinical examination. Similar 
to the ADAMTS8 variant already discussed, this correlation of the MST1 variant with POAG 
diagnosis may just be a coincidental finding or it may represent a true association of a variant 
associated with increased IOP and progression to POAG. In a study on differentially expressed 
genes coding for carbohydrate binding proteins in eyes affected by glaucoma [202], MST1 was 
found to be downregulated in POAG trabecular meshwork cells compared to normal cells. As 
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the trabecular meshwork is critical for aqueous humour outflow, dysregulation of the cells can 
cause IOP to increase [2, 3, 203]. Further research is necessary to determine whether the MST1 
gene itself is involved with IOP regulation and if so, whether this rare variant affects the 
functioning of the gene. GLC1L is the linkage region from the literature which encompasses 
MST1. The GLC1L region was identified in a Tasmanian family (different to the Tasmanian 
families of our study) who also carried a myocilin (MYOC) mutation, and association between 
the linkage region and MYOC was proposed [174]. The MST1 variant and another in TRAK1 
(Table 3-6), discussed with the CCT variants later, are significant in the families of this study, 
but not likely to be causative variants in the Tasmanian family in which the GLC1L region was 
identified with an autosomal dominant inheritance pattern. The same family as used to identify 
the GLC1L linkage region, in a later study was also used to identify a locus on chromosome 
10 associated with maximum IOP [189]. In the families of our study, a variant found within 
this linkage region, rs12412103, was associated with decreased IOP rather than increased. Most 
of the 32 copies of this variant are carried in Family 98002, one of the American families (Table 
3-7). 
An association of three variants with within the FLRT3 gene on chromosome 20 has been 
identified with IOP. These are uncommon variants (MAF of 0.8% and 1.2% in gnomAD NFE) 
enriched in the families of this study (MAF of 5% and 7.5% respectively) (Tables 3-6 and 3-7). 
Two of these variants have CADD scores exceeding 15, with rs8120693, a missense SNP, 
predicted to be most deleterious of the three variants, with a CADD score of nearly 20. The 
three variants in FLRT3 associated with IOP in this study are located in the GLC1K linkage 
region, one of the identified JOAG loci. JOAG is often more severe with higher IOP levels and 
greater progression of visual field loss than POAG [203]. GLC1K was originally identified in 
25 pedigrees with JOAG [47] and the region refined further with four candidate genes excluded 
[204]. FLRT3 was not one of the genes assessed in the Sud et al. (2008) [204] study and the 
role that this gene may possibly play in IOP regulation is currently unknown.  
3.4.3.2 VCDR associated variants within linkage regions 
Only three variants reached at least suggestive significance for association with VCDR in the 
linkage regions from the literature (Table 3-6). A missense variant in CCDC150 had the highest 
CADD score (23.2), of all the variants associated within published POAG loci and was 
identified in 12 individuals across four of the five families of this study (Table 3-7). Although 
only reaching suggestive significance, it was associated with a reduction in VCDR of over 0.2 
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and accounted for nearly 7% of the variance of this trait. The other two VCDR associated 
variants reached full statistical significance and accounted for a larger proportion of the 
variance (over 8%), but had smaller effect sizes, associated with a reduction in VCDR by an 
average of 0.1 or less in the family members. These two variants are very common RNASET2 
variants which are within a published IOP linkage region on chromosome 6 [188]. 
Interestingly, this locus was not replicated in a later study by the same group [191] where they 
identified another IOP linkage region, this time on chromosome 19. The three VCDR 
associated variants are unlikely to play an important role in POAG pathogenesis within the 
families, as the variants are common and associated with a reduction in VCDR, rather than an 
increase which is observed during POAG pathogenesis. 
3.4.3.3 CCT associated variants within linkage regions 
CCT associated results were identified across 6 linkage regions from the literature, including 
POAG, JOAG and IOP loci [48, 153, 174, 189-191]. None of the 11 genes associated with 
CCT in these families had been implicated with POAG or its clinical traits in those of European 
descent, as represented by their absence from the POAG loci database (Appendix B). Most of 
the variants are common, with half of variants associated with a decrease in CCT thickness in 
these families. As thinner corneas are associated with increased risk of POAG [2, 13, 178], 
variants associated with a thinner CCT are more relevant to POAG pathogenesis. Although 
only reaching suggestive significance, two less common variants; rs115535840 and 
rs116239172, within the GLC1M linkage region had large effect sizes and accounted for a 
large proportion of the trait variance (Table 3-6). The first variant was associated with an 
average 41μm thinner cornea and accounted for 14% of the CCT trait variance in these families 
and the second; with an average 36μm thinner cornea and accounting for 9% of the variance. 
Unfortunately, although the latter variant in the SLC6A7 gene was identified in 23 individuals 
across all of the families, CCT phenotyping data was only obtained for 10 of these family 
members, meaning association testing could only be undertaken on these 10 individuals (Table 
3-7). It would be interesting to determine if having the full CCT phenotyping data would 
strengthen the observed association signal. The GLC1M locus, within which these variants are 
located, was identified in a single family from the Philippines with many family members 
affected by JOAG [48]. This locus was refined further and NRG2 excluded as a candidate gene 
[205]. It is unlikely that the variants associated in our study were causative variants in the 
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original study, but they are still of interest and may be involved with determining CCT in the 
families here. 
The four statistically significant CCT associations in Table 3-6 were identified within three 
linkage regions from the literature and were associated with both thicker (rs3755809 and 
rs2974750) and thinner (rs3809841 and rs1442849) corneas. They are all common variants in 
the general population with moderate effect sizes of ±18μm to 24μm and accounted for 9% to 
13% of the CCT variance. These variants, as well as the ones only reaching suggestive 
significance, may be true genetic determinants for CCT, but may not be involved in POAG 
pathogenesis in the families of this study, as CCT is not genetically correlated with POAG in 
these families [42]. It is still important to identify genetic determinants of CCT to gain a better 
understanding of the biological pathways important in corneal development, as thinner corneas 
are associated with a greater risk of developing glaucoma [2, 13, 178], other corneal diseases 
such as keratoconus [179] and progression of ocular hypertension to POAG [206, 207]. 
3.4.4 Contribution to trait variance 
CCT is the most heritable of the three traits (Table 3-3), and as such there is more variance 
available, allowing for larger effects of the identified variants. The CCT variants identified in 
this study demonstrated this, with the greatest beta-values and with the most contribution to 
the trait variance when compared to the IOP and VCDR variants (Table 3-6). Across all of the 
traits in this study, the variants with the largest effect sizes were the rarer ones, occurring less 
than 1% in the general population. Chen et al., 2014 also found stronger family-based 
association results with rarer variants [208]. Considering how rare some of the variants are, the 
proportion of variance to which they contribute is large. For example, the IOP associated 
variant in MST1 (rs114429531) was only identified in five individuals but contributed to over 
5% of the IOP trait variance, which is a similar proportion to the contribution of rs4243786 in 
the FAM178B gene, which has 138 copies of the allele in the families. The largest contribution 
to trait variance of a single variant is rs115535840 in TCF7, in which 11 copies of this allele 
contributed to 14% of variance in CCT. 
3.4.5 Strengths and limitations 
A limitation of this study is CCT measures were only available for a subset of family members 
(148 sequenced individuals; primarily from the American families), due to these measurements 
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only being implemented as a routine clinical measurement several years after the initiation of 
these studies. This decreased the power of the family-based association analyses for this trait, 
although this was somewhat balanced by the boost from the increased heritability. However, 
this was for the CCT trait only. Most of the family members with genotypic data also had 
complete IOP and VCDR phenotypic data (see Table 2.1 Figures 2-1 to 2-5). The MGA 
analysis itself was run as an additive model, with the heterozygous genotype considered 
halfway between the two homozygotes [167]. This may be an appropriate model for many 
variants, but is unlikely to be the best model for every variant tested. As the association analysis 
was performed on each variant independently, without any form of conditional analysis, 
interpretation of the results needs to be considered carefully. Variances cannot be added 
together or assumed to be independent for different loci, as there may be interactions between 
loci. For example, the cluster of IOP associations on chromosome 2, within the ANKRD36B 
and ACTR1B genes (Table 3-6), are assumed to be a haplotype, with an average pressure 
increase of 2mmHg and around 7% contribution to the trait variance for the whole haplotype, 
not each individual variant. However, without testing, it cannot be assumed that this haplotype 
is independent of other IOP associations identified in the table. 
The purpose of the study presented in this chapter was to determine whether POAG associated 
loci from the literature contribute to trait variance in the families of this study. An important 
limitation of this study is that only the protein coding regions as captured by exome sequencing 
could be assessed. To overcome this, whole genome sequencing would be required as the 
majority of associations detected by GWAS are in non-coding regions [79]. SNP array analysis 
could also be conducted, followed by imputation to provide similar data to that analysed in 
GWAS [209, 210]. However, increased genotyping of variants would be accompanied by an 
increase in the multiple testing penalty. The fact that only 10% of the SNP loci from the 
literature were represented in the family genotype data demonstrates the inability to determine 
the contribution of non-coding variants to trait variance in these families. However, the 
financial considerations limiting sequencing to exomes only, allowed for many more family 
members to be sequenced than if whole genome sequencing was conducted instead. 
A strength of this study is the size and complexity of the families and quantity of family 
members who have contributed both phenotypic and genotypic data. The use of families allows 
for the identification of rare variants due to enrichment of these variants as they segregate 
through the generations of the family [211]. Although some of the rare variants presented in 
this chapter have demonstrated enrichment in the five families overall (Table 3-7), they are not 
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confined to a single family, but spread over multiple families. For example, the MST1 variant, 
which is extremely rare in the gnomAD genome NFE database (MAF < 0.001), was present in 
two of the five families. Due to the rarity of this variant, this result is unexpected. Although 
this may be a genuine result in these families, it may actually represent a sequencing error and 
all of the variants would need validating by sequencing in the laboratory before being 
prioritised further. Some of the less rare variants, for example the three FLRT3 variants, which 
are also enriched in these families when compared to the gnomAD database (Table 3-7), 
provide confidence that genuine enrichment has occurred as it would be unlikely to obtain 
erroneous sequencing results across 3 variants. 
3.4.6 Conclusion 
Overall, the study presented in this chapter did identify variants affecting trait variance for IOP, 
VCDR and CCT. However, individually, some of these effects were small and unlikely to be 
the main contributors to trait variation and POAG risk in these families. A future PRS analysis 
may determine the underlying risk these common variants contribute in the families of this 
study. There were rare variants identified with larger effect sizes and  these need to be validated 
in the laboratory before prioritising further. Variants worth further consideration are 
rs114429531 in MST1 and the FLRT3 region for IOP, and rs115535840 (TCF7) and 
rs116239172 (SLC6A7) for CCT. Recognising that IOP is a true POAG endophenotype but 
CCT is only a risk factor means that the CCT variants identified may not be involved with 
POAG pathogenesis, but may still be useful to gain an understanding of corneal development. 
As IOP is currently the only modifiable risk factor for POAG and the primary target for 
treatment, it is important to identify genes which may be implicated with this POAG 
endophenotype. A better understanding of the pathways leading to increased IOP will 






Variance components linkage analysis of whole-exome 
sequencing data in five extended pedigrees 
 
4.1 Introduction 
Conducting linkage analysis using quantitative intermediate traits of POAG has the potential 
to identify genes important in POAG pathogenesis [37, 42, 68, 117]. Quantitative traits provide 
objective data for analysis, which is more powerful than a more subjective dichotomous disease 
status based on reaching threshold trait values. Early linkage studies focussed on this discrete 
diagnosis of glaucoma disease status [46, 153, 175] but more recently, the value of using 
quantitative traits has been recognised [42, 133, 188, 191, 212]. Phenotypic variation in the 
quantitative trait due to genotypic variation is necessary to identify a quantitative trait locus 
(QTL), the region of DNA where the genotypic variation occurs. The quantitative traits in this 
study have previously been assessed as suitable endophenotypes for glaucoma [42], with IOP 
and VCDR demonstrating statistically significant correlation with POAG. This correlation with 
POAG is important, as the purpose of this research is to identify QTLs which are not only 
important in the trait itself, but also involved in POAG pathogenesis. 
Linkage analysis which uses variance components methods are suitable for quantitative traits 
involved with complex disease, such as glaucoma [162]. Multiple loci can be assessed in large, 
complex pedigrees, with larger pedigrees providing more power for linkage than smaller 
pedigrees [167, 213]. Variance components methods partition the phenotypic variation of a 
trait into its components consisting of an additive polygenic component and random 
environmental effects component, as shown in equation (1). 




e                                                   (1) 
Variance is represented as 𝜎2 with p, g and e denoting phenotypic, genetic and environmental 
components respectively. Equation (2) is an extension of the basic variance components model 
with covariance of family members included. Covariance takes into account the specific 
relationships between family members. 
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Ω = 2ϕ𝜎2a + I𝜎
2
e                                                 (2) 
The phenotypic covariance, Ω, is partitioned into its additive genetic and environmental 
components. The genetic component represents the contribution of additive genetic variance 
anywhere in the genome (𝜎2a) including the coefficient of relationship (2ϕ), describing the 
familial relationship between each pair of individuals. Phenotypes are expected to be more 
similar the more closely related the individuals. The environmental component, which is 
expected to be unshared in large families, is reflected with the included identity matrix (I). 
To conduct linkage analysis within a variance components methodology, a further extension to 
equation (2) is needed. Equation (3) demonstrates this additional level of allele sharing 
information. 




e                                               (3) 
Rather than only including an additive genetic effect, which encompasses any number of loci 
across the genome, QTL specific variance is incorporated (𝜎2qtl) which accounts for allele 
sharing information between relatives. Identity by descent (IBD) matrices describe the 
measured amount of allele sharing between individuals in a family; the closer the relationship, 
the more allele sharing at a locus is expected. IBD measures shared alleles which are inherited, 
without mutation or recombination, from a common ancestor. This is in contrast to measuring 
identity by state (IBS), where relatives might share the same alleles, but these alleles may have 
entered the family from multiple founders. Alleles inherited IBD are expected to be rarer than 
those inherited IBS, as they must be inherited from a common ancestor without any alteration. 
Alleles inherited IBS can potentially come from multiple family members and are not as useful 
for localising QTLs as the information gained from alleles inherited IBD. The proportion of 
alleles inherited IBD at the specific QTL is represented by the П matrix for that genomic 
location. Residual additive genetic effects, outside of the QTL, are represented by 2ϕ𝜎2a in 
equation (3). In this way, QTL specific variance is partitioned from the total genetic variance 
and allows for the identification of which QTLs contribute most to the total trait variance. 
An accurate measure of IBD is crucial for successful linkage analysis with variants components 
methods [162]. Multipoint IBD estimation, where IBD at a location is calculated based on 
surrounding marker information, is better than single point estimation for identifying QTLs 
using variants components linkage analysis [214]. Early linkage studies used around 400 
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microsatellite markers across the whole genome for IBD estimation. In contrast, SNP arrays 
and next generation sequencing technologies such as WES can produce many thousands of 
markers. Microsatellite markers were originally chosen because of their high heterogeneity due 
to varying allelic lengths, in contrast to biallelic SNP markers which are a single base pair in 
length, restricting their allelic diversity. The information content provided by these markers is 
critical to successful IBD estimation and linkage analysis [215]. Research comparing the use 
of microsatellite markers with SNP array markers has determined that a higher density of SNP 
markers is comparable to and may exceed the use of lower density microsatellites in linkage 
analysis [216-218]. However, the LD of these high density SNPs needs to be considered, as 
SNPs in high LD may inflate LOD scores [218].  
Conducting linkage analysis from WES data, rather than SNP array data, provides the 
advantage of potentially being able to identify any functional exonic variants themselves. Gazal 
et al. (2016), compared the performance of linkage analysis conducted using WES sequencing 
with that using SNP arrays and found them similar, with the WES sequencing proving to be 
more cost effective in being able to reduce the numbers of candidate variants than using SNP 
arrays [219]. 
Different methods and algorithms need to be used when calculating IBD from high density 
SNP data than microsatellite data. Computationally, algorithms which are suitable for IBD 
estimation with few markers or small families may not be suitable for the dense data generated 
from WES in large, extended families [220, 221].  
 
 
4.1.1 Aim of this study 
To identify quantitative trait loci for intermediate POAG traits using linkage analysis in 
five extended pedigrees. 
Specifically, identity by descent will be estimated from whole exome sequencing data and used 
to conduct variance components linkage analysis on five POAG enriched families to identify 
quantitative trait loci for IOP and VCDR.  
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4.2 Methods 
4.2.1 Preparation of WES data for multipoint linkage analysis 
Sequencing and variant calling of the exome data was discussed in Chapter 2. The variant call 
format (VCF) file generated contained 435,975 biallelic SNPs and was the starting point for 
preparation of files suitable for conducting variance components linkage analysis. Only 
biallelic SNPs were used for identity by descent estimation, due to the requirements of the 
chosen program. The steps taken to prepare the VCF data for linkage analysis are summarised 















Figure 4-1 The major data manipulation steps prior to variance components linkage analysis 





4.2.1.1 Filter VCF file 
Biallelic SNPs were extracted from the full VCF file obtained after variant calling. This VCF 
file was first labelled with quality annotations using the GATK “Variant Filtration” tool (as 
described in Chapter 2.4.2). Only variants with “high-confidence” calls were selected for 
linkage analysis. A custom R script was used to set the poor quality variant calls to missing 
(see Appendix D.1). This same R script was used to calculate the number of observations of 
each variant. Variants were deleted if observed less than eight times across all five families. 
Inclusion of very rare SNPs may affect identity by descent (IBD) estimation and subsequent 
linkage analysis [222]. Nearly three-quarters of the SNPs were filtered out in this stage. This 
figure includes variants which were genuinely rare and also variants which were artificially 
rare due to the blanking out of variants annotated as “low”. 
Only the autosomal variants were considered in our study and the different methods which are 
required for the sex chromosomes is for a future study. PLINK (version 1.9) [223] was used to 
remove X and Y chromosome variants. PLINK was also used to remove variants with missing 
genotypes exceeding 5%. This threshold was chosen as it was the same threshold used for 
identity by descent estimation (see section 4.2.1.3). At the same time, variants which deviated 
considerably from Hardy-Weinberg equilibrium were also removed. Only founders were 
considered in this test. A threshold of p < 0.001 for the Hardy-Weinberg equilibrium exact test 
was used, as it allowed for a slight deviation from Hardy-Weinberg equilibrium, which may 
occur with genuine associations of variants with traits. Appendix D2 shows the PLINK 
commands used for this stage of the filtering. 
Table 4-1 summarises the VCF file filtering stages discussed above. At the conclusion of 
filtering the initial VCF file, 67,605 biallelic SNPs remained, all of high-coverage (depth ≥ 10) 
and high-quality (genotype quality score ≥ 20).  
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Number of SNPs 
remaining 
Filtering program 
Initial VCF file   435,975  
Remove very rare 
SNPs 
MAC < 8 321,823 114,152 
R script to set poor 
quality calls to missing 
and to filter out rare SNPs 
Remove X and Y 
chromosome SNPs 
 2,347 111,805 PLINK 
Remove missing 
genotypes 
> 5% missing 42,153 69,652 PLINK 
Remove SNPs which 
deviate from Hardy-
Weinberg equilibrium 
p-value < 0.001 2,047 67,605 PLINK 




Filtered vcf file from 4.2.1.1 
Subset vcf into individual chromosomes 
(bcftools) 
Create ped and map files 
(PLINK) 
Mendelian error checking 
(PedCheck) 
Modify ped and map files 
(R and Excel) 
4.2.1.2 Mendelian error checking 
The filtered VCF file was checked for Mendelian inconsistencies using the PedCheck program 
(version 1.1) [224]. PedCheck was run for each chromosome individually, with loops to 
automate the process (see Appendix D.3). The process of file preparation for PedCheck is 














Figure 4-2 Preparation of files for Mendelian error checking. Programs used for each stage are 
in brackets. 
 
Firstly, bcftools (version 1.8) [225] was used to subset the filtered VCF file into VCF files of 
individual chromosomes (see Appendix D.3.1). PLINK was used to create ped and map files 
from these individual chromosome VCF files (see Appendix D.3.2) The PLINK produced map 
files were concatenated, adjusted to 1 column with a unique chromosome_base-pair 
identification number and then subset again into individual chromosome map files (see 
Appendix D.3.3). The PLINK produced ped files were adjusted to the requirements of the 
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PedCheck program using R. As there was one ped file per chromosome, this step was 
streamlined using a loop within the R script (see Appendix D.3.4). 
After file preparation, PedCheck was used to run Mendelian error checking (see Appendix  
D.3.5). PedCheck was used to check for inconsistencies between parent-offspring 
relationships, as well as inconsistencies beyond the basic nuclear family, by using a “genotype-
elimination” algorithm recursively [224]. Results of Mendelian error checking, with the 
number of markers with errors per chromosome, are presented in Table 4-2. 









1 6960 187 2.7 
2 4494 79 1.8 
3 3645 63 1.7 
4 2872 36 1.3 
5 3324 46 1.4 
6 3201 16 0.5 
7 3613 73 2.0 
8 2610 52 2.0 
9 2714 54 2.0 
10 3015 39 1.3 
11 4196 87 2.1 
12 3501 51 1.5 
13 1363 9 0.7 
14 2162 48 2.2 
15 2255 55 2.4 
16 2963 35 1.2 
17 3878 55 1.4 
18 1203 18 1.5 
19 4767 117 2.5 
20 1978 22 1.1 
21 987 11 1.1 
22 1904 36 1.9 
Total 67605 1189  
 
Variants identified as Mendelian errors were excluded from all five families, even if the error 
did not occur in all of the families, to allow for consistency of variants used for linkage analysis. 
Names of the error SNPs were extracted from the PedCheck output and PLINK was used to 
remove these SNPs from the previously filtered VCF files (see Appendix D.3.6). 
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After removing the identified variants from the VCF files, the Mendelian error checking 
procedure was repeated, to confirm that no Mendelian inconsistencies still existed. Once this 
was confirmed, the individual chromosome VCF files were concatenated into one full VCF 
file, using bcftools. After Mendelian error checking, 66,416 variants remained. 
4.2.1.3 Identity by descent (IBD) estimations 
IBD estimations were performed using IBDLD (version 3.38) [152, 226]. This program is 
designed for dense genotype data and estimates IBD allele sharing between each pair of 
individuals in all of the pedigrees. An extension of the hidden Markov model is used for 
multipoint IBD estimation which includes calculations of linkage disequilibrium (LD), thus 
LD pruning of dense genotype data is not necessary. The GIBDLD method, within IBDLD, 
was recommended over the similar LD-RR method, due to a known issue with distant 
relationships in the latter method (Mark Abney, personal communication). The GIBDLD 
method does not require detailed pedigree information and is able to calculate IBDs between 
members within the same pedigrees and between pedigrees. 
Preparation of the files for IBD estimation is described in Appendix D.4. Firstly, PLINK was 
used to create map and ped files from the corrected filtered VCF file (see Appendix D.4.1). 
PLINK used the SHAPEIT recombination map (https://mathgen.stats.ox.ac.uk/genetics_
software/shapeit/shapeit.html#gmap) to include centi-Morgan (cM) positions for each of the 
variants in the map file output. The map file was then adjusted using Excel, to meet the input 
requirements of the IBDLD program (see Appendix D.4.2). A custom R script (Appendix 
D.4.3) was used to modify the PLINK output ped file to the appropriate pedigree file format 
for IBDLD. 
The IBDLD program required optimisation for several parameters and the full command is 
provided in Appendix D.4.4. Optimisation of the parameters was based on the detailed 
information provided in the IBDLD software documentation with additional recommendations 
provided by the authors (personal communication). As only variants of high coverage and high 
confidence were used (see section 4.2.1.1), a minimum call rate of 95% per variant was set as 
the threshold for IBD computation. The -rars (“remove adjacent redundant SNPs”) parameter 
was used to ensure that the remaining SNPs all contributed to IBD estimation. This parameter 
removed SNPs in full LD with each other which did not provide additional information for LD 
modelling. A total of 241 SNPs were excluded in this initial stage, leaving 66,175 SNPs 
remaining for IBD estimation. The -ploci and -dist parameters were used for the LD 
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calculations prior to IBD estimations. LD was calculated from one end of the chromosome to 
the other (smallest base pair position through to largest), and -ploci 50 -dist 2 used 50 
previous SNPs within a 2cM window for these LD calculations. The -hiddenstates parameter 
was set to 9, which is the appropriate setting for relatedness estimations in large pedigrees. The 
-ibd parameter was set to 2, which outputs IBD sharing at each locus as well as the Δ7 of the 
nine condensed identity coefficients, as defined by Jacquard (1972) [227]. The Δ7 coefficient 
refers to the probability of both alleles being inherited IBD at each locus and is a requirement 
for the use of the multipoint IBD files in the SOLAR program. IBDLD was run on the 66,175 
filtered and Mendelian error corrected SNPs. IBD estimation was conditional on all of the SNPs 
on the chromosome and output files for each chromosome were obtained. IBD estimates for 
each chromosome were output as zipped text files and these were used to generate the 
multipoint identity by descent (MIBD) matrices. 
4.2.1.4 Generate multipoint identity by descent (MIBD) matrices  
Output from the IBDLD program was converted to MIBD matrices specific for the linkage 
analysis protocol. A custom awk script (see Appendix D.5.1) was used to extract the multipoint 
IBD data from the zipped IBDLD output files which were generated per chromosome. The map 
file required for this process was a modification of the map file used for the IBDLD program. 
The map file for IBDLD estimation was too dense to use for linkage analysis and the density 
of markers was reduced to 1 SNP per cM (see Appendices D.5.2 and D.5.3 for the modification 
details).  
The awk script used for generating MIBD files (Appendix D.5.1) also required access to a 
numerical index of the study participants, consistent with the indexing which occurs when 
linkage analysis is conducted. These index files were generated when the pedigree file was 
loaded into the linkage program. More details about the pedigree file and linkage program are 
provided in section 4.2.2. 
To generate MIBD files, the custom awk script (Appendix D.5.1) was used to combine IBD 
information from IBDLD output files with pedigree index numbers and marker locations. A 
loop command was used to streamline this process (Appendix D.5.4). One MIBD matrix was 
generated for each marker in the map file. A further processing step of the MIBD matrices was 
conducted, which scaled the MIBD matrices to ensure individual values did not greatly exceed 
1. A custom C++ program, grm (version 0.3-48-g7550b77, written and provided by Juan 
Peralta, University of Texas Rio Grande Valley), was used for this purpose using the 
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approaches previously described [228, 229]. The command to run this program is detailed in 
Appendix D.5.5. The default tolerance threshold of 1x10-6 was used to ensure that no MIBD 
value exceeded 1.00000. Use of the MIBD matrices is detailed further in section 4.2.2. 
4.2.1.5 Generate an empirical kinship (phi2) file 
An empirical kinship matrix file, containing accurate family relationships, was necessary for 
the linkage analysis. As the IBDLD program was used to determine pairwise IBD, from which 
MIBD matrices were derived, this program was also used for the empirical kinship calculations. 
As well as producing IBD estimations per chromosome, the IBDLD program also generated 
genome-wide empirical kinship data. Appendix D.6 outlines the preparation of the phi2 file. 
Details of the use of the phi2 file are provided section 4.2.2. 
4.2.2 Multipoint linkage analysis with ascertainment correction 
Variance components multipoint linkage analysis was conducted using SOLAR [162] with the 
MIBD and phi2 matrices described above (section 4.2.1.4 and 4.2.1.5 respectively). Linkage 
was conducted on the IOP, IOPmed and VCDR traits (see section 2.5.1 for description of traits) 
on 249 members of the five families. CCT was not included in this analysis as there were not 
enough individuals with CCT measurements in each of the families to conduct a robust 
analysis.  
The pedigree file used did not provide parental or family information (these 3 fields were 
zeroed out) for each of the 249 sequenced individuals of this study. Thus only each individual’s 
unique identification number and sex were included in the pedigree file. This allowed for the 
use of the phi2 file to provide familial information based on calculated empirical kinship values 
from the IBDLD program (section 4.2.1.5). The phenotype file also provided personal and trait 
data on only the 249 sequenced individuals. A null model, a model with no linkage elements 
included, was first created with polygenic modelling. The modelling for linkage analysis 
differed from the polygenic modelling described in Chapter 2 prior to MGA (Chapter 2.6.1) as 
that modelling used the full pedigree file, including all family relationships, from which 
SOLAR generated a kinship matrix to conduct MGA. The linkage analysis discussed in this 
chapter used a pedigree file without family relationships with the IBDLD-generated empirical 
kinship matrix. 
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The linkage analysis was conducted with ascertainment correction. An ascertainment 
correction is used to correct for a potential distortion of data when families are non-randomly 
ascertained. As discussed previously (Chapter 2.2) the five families from OGGS and GIST 
recruited in this study were enriched for POAG. Their phenotypic measurements, such as IOP, 
may not represent measurements as observed in the general population. Mean IOP 
measurements may be higher in the families than the general population and the variance may 
be lower, if there is less representation of individuals with normal IOP in the families. By 
constraining the linkage analysis to the population means, including effects of covariates, a 
more accurate representation of the linkage patterns of that trait may be observed. 
To provide a population ascertainment correction for linkage analysis conducted on the POAG 
endophenotypes, data from the Melbourne Visual Impairment Project (MVIP) was used [230]. 
This population based study provided data for participants aged 40 and over and clinical 
examinations including IOP and VCDR measurements were conducted in a similar manner to 
those of the OGGS and GIST. Table 4-3 compares age, IOP and VCDR data between the 
families involved with this study and the MVIP population. Overall, the families of this study 
were younger than the MVIP participants, had higher IOP and slightly larger VCDR. 
Table 4-3 Comparison of mean age, IOP and VCDR measures between the families of this 
study and the Melbourne Visual Impairment Project 
 
 Families MVIP 
Mean age (years) 54.68 ± 19.21 (312) 58.19 ± 12.35 (4363) 
Mean IOP (mmHg) 20.18 ± 2.51 (301) 15.43 ± 3.34 (3691) 
Mean VCDR 0.44 ± 0.25 (301) 0.45 ± 0.20 (3451) 
IOP = intraocular pressure, VCDR = vertical cup to disc ratio,  
each mean is ± the standard deviation 
Numbers in brackets refer to the number of participants with data available 
 
Polygenic analysis of the MVIP data provided the beta-values (coefficients) for the covariates, 
as observed in an unrelated, generally healthy population. Data from this population was used 
to constrain the mean for each trait, as well as the interactions of the covariates. The values to 
be constrained were included in a tcl (tool command language) script within SOLAR (see 
Appendices D.7 and D.8). The polygenic modelling was conducted with these constraints in 
place and the resultant null model used for the linkage analysis. By constraining these values 
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for multipoint linkage analysis, a more realistic indication of where the family data sits, in 
relation to the general population, is obtained.  
To conduct the linkage analysis, the trait was specified and chromosomes selected 
(chromosome all or chromosome 1-22 will run linkage across all autosomes). The interval 
between markers can also be selected, with an interval of 1 meaning that each marker in the 
map file will be used. For this analysis, an interval of 1 was used to gain maximal linkage 
information (at a maximum of 1 SNP per cM). The multipoint scanning was first set at 
multipoint 3 2, meaning that a first pass across the genome searched for the largest QTL 
with a minimum LOD of 3 or more. If a QTL meeting this criterion was identified, a second 
pass across the genome was undertaken, with largest QTL fixed (removed) from the subsequent 
pass. The QTL specific variance, is represented by П𝜎2qtl in equation 3 in the introduction to 
this chapter. It is partitioned from the total genetic variance and allows for QTLs to be identified 
individually in successive passes. This continued until the LOD of the largest QTL did not 
reach 2. The commands used to conduct the linkage analysis using SOLAR are provided in 
Appendix D.9. 
4.2.3 Empirical LOD adjustment 
Variance components linkage analysis is sensitive to the distribution of the data, where a non-
normal distribution may amplify the size of a linkage peak by increasing type 1 errors [212, 
231]. An empirical LOD adjustment can be performed on non-normally distributed data and 
provides a constant, which when multiplied by the observed LOD scores, gives a more accurate 
indication of the expected LOD score under a normal distribution. A constant of less than 1 
indicates the data is inflated and requires adjusting. After polygenic modelling and 
ascertainment correction, a LOD adjustment calculation was run with 10,000 replications for 
each trait with high kurtosis. The lodadj -calc command within SOLAR simulates a 
distribution of LOD scores which would be expected under the null hypothesis of no linkage. 
Each replication calculates a LOD for a simulated marker unlinked to the trait. SOLAR 
conducts a regression analysis of the observed LOD scores against the simulated LOD scores 
providing the LOD adjustment constant. If this constant is less than 1, it is multiplied by the 
observed LOD scores to more accurately reflect the LOD scores which would be obtained had 
the distribution been normal. 
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As the lodadj function in SOLAR does not currently support empirical LOD adjustment using 
the ped file without family associations (as described in section 4.2.4), the full ped file, with 
the all family and parental information, was used for this analysis. Empirical LOD adjustment 
was conducted on the IOP and IOPmed traits. 
4.2.4 Significance of linkage analysis 
Linkage plots were drawn highlighting both significance and suggestive significance levels. A 
LOD score of 3.3 was used for full significance and 1.86 used for suggestive significance, as 





4.3.1 Polygenic modelling of zeroed ped file 
Polygenic modelling for each of the traits used for linkage analysis are shown in Table 4-3. 
The same ped file which was used to generate the IBDLD matrices (section 4.2.1.3) was used 
for this modelling. All of the traits were significantly heritable, with IOPmed more heritable 
than the unadjusted IOP trait by an order of magnitude in the p-value. Age was a significant 
covariate for each of the traits, with age2 also significant for both of the IOP traits. Both of the 
IOP traits were kurtotic, indicating a non-normal distribution of phenotypic measures. 
Table 4-4 Variance components polygenic modelling of POAG clinical traits used for linkage 
analysis. 
Trait 





Covariates included in 
final model (non-
normalised traits only) 
Proportion of 
variance due to 
covariates (%) 
IOP 43 ± 11 1.20 x 10-6 -3.44 age, age2 20 
IOPmed 50 ± 11 2.00 x 10-7 -2.32 age, age2 27 
VCDR 41 ± 13 3.91 x 10-5 -0.55 age 33 
POAG = primary open-angle glaucoma, IOP = intraocular pressure, VCDR = vertical cup to disc 
ratio, CCT = central corneal thickness, norm = normalised trait,  
h2r = heritability, SE = standard error, residual kurtosis = a measure of non-normal distribution, bold 
indicates kurtosis exceeding 0.8 threshold 
 
4.3.2 LOD adjustment 
LOD adjustment was conducted for the ascertainment corrected IOP and IOPmed traits, due to 
their high kurtosis (see Table 4-3). The resultant adjustment constants were 0.63 for IOP and 
0.59 for IOPmed. LOD scores from the linkage analyses were multiplied by these constants to 
adjust for inflation due to the non-normal distributions of these traits. LOD adjustment was not 
necessary for the VCDR trait. 
4.3.3 Multipoint linkage analysis for intraocular pressure 
Variance components multipoint linkage analyses for the ascertainment corrected IOP and 
IOPmed traits are shown in Figure 4-3, including the application of LOD adjustments which 
reduced the linkage peaks accordingly. 
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Figure 4-3 Variance components multipoint linkage analysis 
for chromosomes 1 to 22 for intraocular pressure traits. 
Intraocular pressure was unaltered (IOP) or medication adjusted 
(IOPmed). Location (cM) = centimorgan location along each 
chromosome, LOD = logarithm of the odds, with the red dashed 
line indicating a significance level of 3.3 and the grey dashed line, 
a significance level of 1.86 
81 
The linkage plots are very similar between IOP and IOPmed, with peaks identified in the same 
regions (Figure 4-3). Two peaks reached full statistical significance for IOPmed, at LOD = 3.3, 
on chromosomes 9 and 15. These two peaks reached suggestive significance for IOP. Peaks 
reaching suggestive significance for both intraocular pressure traits were identified on 
chromosome 2, 6 and 7, with a peak on chromosome 3 only reaching suggestive significance 
for IOPmed. Overall, the IOPmed trait generated larger peaks for the linkage analyses. The 
chromosome 2 peak was the only major peak with a slightly lower maximum LOD score for 
the IOPmed trait (0.2 lower for IOPmed). This peak was also narrower for IOPmed, with a 
single peak, whereas the IOP plot shows a broader peak with additional minor peaks. 
 
4.3.4 Multiple passes for intraocular pressure 
Multiple linkage passes were conducted for IOP and IOPmed, to determine whether subsequent 
linkage signals were independent of previously detected QTLs. Figures 4-4 and 4-5 show the 
multiple passes for IOP and IOPmed respectively. Both traits fulfilled the criteria for four 
passes until there were no peaks reaching a maximum LOD score of 2. Both traits also followed 
the same order of conditioning on the QTLs, with chromosome 9 the largest peak in the first 
pass, followed by chromosome 6 in the second pass and chromosome 2 in the third pass. When 
conditioned on chromosome 7 in the fourth pass, no peaks remained with a LOD score of 2 in 
the final pass for either trait. Figures 4-4 and 4-5 show that conditioning on the largest QTL 






IOP pass 1 vs pass 2 
IOP pass 2 vs pass 3 
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Figure 4-4 Passes 1 to 4, drawn in pairs, of variance components multipoint linkage analysis 
for IOP for chromosomes 1 to 22 Location (cM) =  centimorgan location along each chromosome, 
LOD = logarithm of the odds, with the red dashed line indicating a significance level of 3.3 and the 
grey dashed line, a significance level of 1.86 
 




IOPmed pass 1 vs pass 2 
IOPmed pass 2 vs pass 3 
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Figure 4-5 Passes 1 to 4, drawn in pairs, of variance components multipoint linkage analysis 
for IOPmed for chromosomes 1 to 22 Location (cM) =  centimorgan location along each 
chromosome, LOD = logarithm of the odds, with the red dashed line indicating a significance level 
of 3.3 and the grey dashed line, a significance level of 1.86 
 
  
IOPmed pass 3 vs pass 4 
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4.3.5 Multipoint linkage analysis for VCDR  
Variance components multipoint linkage analysis was also conducted on the VCDR trait 
(Figure 4-6). This trait was ascertainment corrected and did not require LOD adjustment. One 
peak, on chromosome 7, reached suggestive significance (maximum LOD = 2.5), but no QTLs 
were identified reaching full significance for this trait. 
 
Figure 4-6 Variance components multipoint linkage analysis for chromosomes 1 to 22 for 
VCDR Location (cM) =  centimorgan location along each chromosome, LOD = logarithm of the 






Variance components multipoint linkage analysis of WES data was used to identify several 
QTLs for IOP in the five extended pedigrees of this study. Results for VCDR are not so clear 
cut, but possibly at least one suggestive QTL has been identified in this study. This is the first 
study to identify QTLs of POAG endophenotypes from WES. Although linkage analysis of 
quantitative endophenotypes, rather than a discrete POAG diagnosis, have proven to be 
successful in identifying QTLs, microsatellites and SNP genotyping panels are more 
commonly used to conduct the linkage analyses, with deeper sequencing conducted once QTLs 
have been identified [104, 133, 233]. An advantage of using WES data for the linkage analysis 
itself, rather than microsatellites or SNP array data, is that once a QTL has been identified, the 
WES data itself can be interrogated for variants with potential functional relevance. Although 
there are limitations to using WES in linkage studies; only a small portion of the genome is 
sequenced and predominantly only protein coding regions can be interrogated, there is still a 
great potential for identifying variants affecting disease. Although linkage analysis has been 
conducted from WES in other disease phenotypes [234-238], the use of WES in such large 
families and for endophenotypes of POAG, makes this study unique.  
Using WES data for linkage analysis required optimisation at several steps to ensure accurate 
and appropriate data flow from one step to the next. WES data, representing the protein coding 
regions of the genome, is extremely dense in some areas and non-existent in other areas of the 
genome [239, 240], providing a new set of challenges for data preparation, analysis and 
interpretation. Previous studies using WES for linkage analysis pruned the variants to select 
common SNPs with high heterozygosity and in low LD with each other [234-238]. Our study 
used a different strategy, using all biallelic SNPs with MAF > 1.5% (see section 4.2.1.1), 
regardless of heterozygosity, and instead of LD pruning the SNPs, using the IBDLD program 
to condition on the existing LD to estimate IBD [152]. Other members of our group have 
compared the use of IBDLD for generating empirical kinships with those generated by SOLAR 
from reported pedigree relationships, and found them to be comparable and appropriate to use 
when sufficient genotype data are available [241]. The use of IBDLD to generate MIBD 
matrices for linkage analysis in SOLAR had also been conducted in our group, and linkage 
regions identified for plasma triglyceride levels [228]. These studies provided confidence that 
using IBDLD to estimate IBD between each of the members of the extended pedigrees and 
generating an empirical kinship matrix to use for the linkage analyses, was an appropriate 
method to use. 
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Heritability modelling on the endophenotypes used for linkage analysis in this study have 
shown that they were all significantly heritable (Table 4-3) indicating there was enough total 
additive genetic variance to separate into specific QTL variances, as represented by П𝜎2qtl. 
in equation (3) from section 4.1. The heritabilities for IOP (43%), IOPmed (50%) and VCDR 
(41%) in this study are well within the broad range for heritabilities for these endophenotypes 
which have been recently reviewed [128]. There is a great deal of variability in the literature 
on the heritabilities of these traits as they are dependent on the study design, sample size, 
method of analysis and included covariates. In our study, age was a common significant 
covariate to all three endophenotypes, with age2 also significant in the pressure traits. This is 
unsurprising, as the risk of POAG increases with age in the general population [10, 16, 27, 29]. 
Two important corrections were applied to the linkage analyses in this study; ascertainment 
correction and empirical LOD adjustment. Ascertainment correction constrains the trait mean 
and standard deviation as well as those of the covariates to that of an unascertained population 
[167], in this case, from the Melbourne Visual Impairment Project [230]. Ascertainment 
correction magnifies potential differences between the families of this study, who were 
recruited due to enrichment of POAG, and the general population. An individual with high IOP 
will appear more extreme when compared to the general population than within a family which 
has a high average IOP. Ascertainment correction provides a more accurate representation of 
the linkage analyses where the families are considered not in isolation, but as part of a general 
population. The LOD adjustment was an important correction to make for the IOP and IOPmed 
linkage analyses. The correction factors which were calculated, 0.63 for IOP and 0.59 for 
IOPmed, suggest an inflation of LOD scores due to the non-normal distribution of these traits 
[212, 231]. Multiplying all LOD scores by the correction factor reduced the resultant linkage 
analyses by over a third, but provides confidence that peaks reaching significance are true 
representations of QTLs for these traits. 
Our study used an adjustment for those family members who were already using pressure 
reducing medication prior to entering our study (see Chapter 2.5.1). A normal IOP of 
≤ 21mmHg, in a person prescribed eye drops to reduce pressure, represents successful 
treatment, but this individual then is categorised as having healthy pressure, when genetically, 
they contribute to the group with high pressures. By applying an adjustment to IOP 
measurements for these individuals, a truer representation of their “unmedicated” IOP is 
attained, leading to a more extreme IOP phenotype measure. The adjustment used in our study 
was the addition of a standard deviation of the IOP pressure of all the measured family members 
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(SD = 6.1mmHg). This value is comparable to, and possibly underestimates, the effects of 
pressure reducing medication, which has demonstrated a reduction in IOP of over 8mmHg 
[242, 243]. Springelkamp et al. (2017), also adjusted for a “pre-medication IOP value” in their 
GWAS, by multiplying the IOP measurements by a factor of 1.3 [136]. It is difficult to 
determine which is the better method of adjustment; ours used the addition of a constant, 
meaning that each family member who was on pressure reducing medication prior to the start 
of the study had their IOP measurements increased by the same amount, regardless of their 
starting IOP measurement. Multiplication by a factor of 1.3 in the other study [136] increases 
lower pressures by a smaller amount and the larger pressures become much more inflated. Most 
of the medication adjusted family members in our study also had very high VCDR measures 
(≥ 0.8) and associated vision loss representing a more extreme phenotype.  
The results presented for the unadjusted versus the adjusted pressure traits were very similar 
(Figure 4-3), with peaks identified in the same locations. The major difference between the two 
is that the IOPmed trait demonstrated enlarged peaks for chromosomes 9 and 15, reaching full 
statistical significance, whereas these peaks only reached suggestive significance for the IOP 
trait. The other difference is the chromosome 2 linkage region was narrower and tighter at the 
peak for IOPmed than IOP. When the multiple passes were assessed for these two traits, again 
they were very similar (Figures 4-4 and 4-5). The order in which the QTLs were conditioned 
were identical between the two traits, and more importantly, there was no loss in linkage signal 
of the major peaks between successive passes. This suggests that each peak is an independent 
QTL and not inflated due to epistatic effects. We believe that the IOPmed trait more accurately 
reflects the participants’ IOP measures when the effects of pressure reducing medication have 
been considered. Also, this trait has a greater heritability (Table 4-4), with greater statistical 
significance, providing more power for variance components analysis. Consequently, the QTLs 
for the IOPmed trait was chosen for further analysis, which is discussed in Chapter 5. 
A small methodological artefact, which may have been generated in the IBD estimations and/or 
the linkage analyses conducted in this study, was seen with the slight rises in linkage signal 
which occur at the end of chromosomes 12, 13, 15 17, 20, 21 and 22 (Figure 4-3). The start of 
the chromosomes was less affected by this artefact, although small effects on chromosomes 5 
and 13 were observed. The chromosome 15 QTL, which starts at a significant LOD score for 
IOPmed, is unlikely to be purely artefactual, due to the difference between its size and shape 
compared with the equivalent position in the other chromosomes. This peak is discussed in 
detail in Chapter 5. 
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Most of the linkage regions identified in this study are novel, with one peak completely 
overlapping a previously identified POAG locus (Figure 4-7). The peak on chromosome 15 
completely overlaps the GLC1I locus, originally identified in 15 families with an early onset 
form of POAG [177]. A more recent study from the same group replicated the finding at the 
GLC1I locus, using age of onset in an ordered subset analysis [233]. Interestingly, the linkage 
peak in those studies was a very similar shape to the peak in our study, with the locus occurring 








MYOC CYP1B1 WDR36 
ASB10 OPTN 
Figure 4-7 Linkage analysis of the IOPmed trait overlayed with published 
POAG and IOP linkage regions and genes identified from linkage studies.  
Location (cM) = centimorgan location along each chromosome, LOD = 
logarithm of the odds score. Pink rectangles represent published linkage regions 
detailed in Appendix B, circles represent genes identified from linkage studies 
(not drawn to scale) 
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The linkage analysis conducted for VCDR, which was ascertainment corrected but did not 
require LOD adjustment, did not identify any QTLs reaching full significance (Figure 4-6). 
One peak, on chromosome 7 reached suggestive significance. Although on the same 
chromosome as one of the intraocular pressure QTLs identified, these peaks do not overlap. 
This QTL is novel and does not overlap any published POAG or VCDR linkage regions. The 
lack of linkage signals in the VCDR analysis may be due to the nature of the VCDR 
measurements. These measurements only range between 0.1 and 1.0 with a VCDR of 1.0 
representing advanced optic nerve damage, where the optic nerve has degenerated so much that 
the optic cup has enlarged to encompass the whole optic disc [14]. Although quantitative, the 
VCDR measurements are more categorical in nature, with increments of 0.1, and not as 
continuous as the IOP measurements. These VCDR ratios were multiplied by 10 to increase 
the standard deviation within this trait for analysis using SOLAR, but even with this 
adjustment, there was very little range within the data. An alternative approach would be to use 
SOLAR to model VCDR as a discrete trait, instead of quantitative. A threshold of ≥ 0.7 could 
be set for the VCDR measurements, being the threshold commonly used for POAG diagnosis 
[14], allowing for all family members to be classed in two groups. Although not as powerful 
as a quantitative linkage analysis [167, 244], this may prove to be more powerful than the 
analysis already undertaken. It would also be possible to conduct the linkage analysis using 
other programs specifically designed for categorical data. For example, the Bayesian approach 
of Brisbin et al. (2010), was developed for conducting linkage analysis on ordinal and 
categorical traits in complex pedigrees [245]. However, for the purposes of this study, the 
VCDR linkage analysis was left at this point, with the identification of a suggestive QTL on 
chromosome 7. 
The use of WES data has successfully identified several QTLs for IOP in the five large, 
extended families of this study. Further work on identifying each family’s contribution to each 
of these QTLs as well as finding variants with potential functional relevance within these QTLs 








Identification of variants within linkage peaks 
and proposal of novel IOP genes 
 
5.1 Introduction 
In the previous chapter, quantitative trait loci (QTLs) for intraocular pressure (IOP) were 
identified in five families. These peaks reduced the genome-wide search space to provide the 
opportunity to find variants and genes involved in IOP regulation, which may also be involved 
in POAG pathogenesis in these families. Although previous linkage analyses have identified 
over 20 regions associated with glaucoma or its endophenotypes [13, 27], the causative variants 
or genes have not been identified in most of these regions. These linkage analyses were 
conducted using microsatellite or SNP array markers resulting in the identification of large 
regions, but the genes within these regions could only be proposed as possible candidate genes. 
Deeper sequencing was required to determine if the candidate genes carried deleterious, 
potentially disease causing variants. Before the advent of next generation DNA sequencing 
technologies, identifying these variants from within the many genes within linkage regions was 
difficult, time consuming and expensive. It often took years to identify the glaucoma causing 
genes; MYOC and OPTN were reported as the causative genes four years after their linkage 
regions were published [46, 55, 59, 70] and ASB10 was not identified until 13 years after the 
linkage region was published [71, 72]. Most of the linkage regions for glaucoma have not had 
causative genes identified at all. 
Our study has identified six QTLs for IOP (Chapter 4) and the next stage was to interrogate 
these regions and identify variants and genes which may be important in IOP regulation. Exome 
sequencing data was used directly to conduct the linkage analysis. The advantage this provided 
was to enable the identified QTLs to be examined for functional exonic variants, without 
needing to conduct additional sequencing. Selected variants could then be included in the 
linkage model, as covariates, to determine their effects on the linkage peaks. Almasy and 
Blangero (2004) [246], describe this linkage conditional on measured genotype approach. 
Variants to be tested are coded as measured genotypes, with the dosage of the variant (0,1 or 
2) in each individual used as the covariate, similar to that used in MGA (Chapter 2.6.3). 
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Linkage can then be conducted conditional on this measured genotype, which is included as a 
fixed effect on the trait mean and not a component of the trait variance [167]. The effect of the 
measured genotype reduces the variance available for the linkage component of the analysis. 
If the measured genotype accounts for much of the fixed effects of the mean, less variance is 
available for the linkage component and the LOD score of the linkage region is markedly 
reduced. If there are several variants affecting a peak, the measured genotype of one variant 
may not be sufficient to reduce the variance available and consequently the peak may not be 
affected, or only reduced slightly. It should be noted that this method is not able to determine 
whether the variant being tested is a variant with potential functional relevance, or whether it 
is on the same haplotype as the functional variant [246]. 
Prioritised variants were then assessed using in silico tools to predict which genes might be 
involved with IOP regulation in the families of this study. Complex diseases are likely to result 
from involvement of both common and rare variants [119]. The families used in this study, 
which are enriched for POAG, are ideal to use to search for rare variants influencing this 
complex disease, due to the potential of enrichment of rare variants as they segregate through 
the generations. Using families ascertained for a disease as well as using endophenotypes of 
the disease both increase the power to identify functional variants [211]. To identify variants 
influencing IOP, we selected the linkage regions identified in Chapter 4 using the IOPmed trait, 




5.1.1 Aim of this study 
To propose candidate genes which may be involved in IOP regulation in the families of 
this study.  
Specifically, this study will use in silico tools to investigate genetic variants within the most 
significant peaks identified from the linkage analysis in Chapter 4, and propose genes which 





Linkage peaks identified for the IOPmed trait, in Chapter 4, were selected for further 
investigation in this study if they reached at least suggestive significance at a LOD of 1.86 
based on the Lander and Kruglyak significance criteria for linkage proposed in 1995 [232]. 
Linkage peaks on chromosomes; 2, 3, 6, 7, 9 and 15 fulfilled this criterion, with chromosomes 
9 and 15 peaks also being significant at the genome-wide level (LOD ≥ 3.3). 
5.2.1 Defining linkage intervals 
For each of the linkage peaks reaching a LOD score of at least 1.86, the boundaries of the peak 
interval were defined as the cM position where the LOD dropped to 0.59; which is equivalent 
to a nominal p-value of 0.05 [232, 247]. All variants within the boundaries were then extracted 
from the original bcbio called VCF file, to ensure all of the sequenced variants were included 
in the linkage intervals. This VCF file was generated prior to Mendelian error checking 
(described in Chapter 4.2.1.2), hence some of these variants may have had errors. The full VCF 
file was intentionally not checked with PedCheck, as we did not wish to discount any variants 
which may have included a minor sequencing or calling error. However, all variants of interest 
were checked manually to ensure there were no Mendelian errors. These variants were 
annotated using ANNOVAR as described in Chapter 2.4.2.  
5.2.2 Family contribution to linkage peaks 
The first stage in narrowing down the number of variants for further analysis was to determine 
the contribution of each family to the linkage peaks. Variants found predominantly within those 
families were then prioritised further. Based on the number of individuals and the trait 
heritability there was insufficient power to analyse pedigrees individually. Accordingly, to 
retain sufficient heritability to conduct the analyses, the per-family contributions were 
determined by conducting linkage analysis on four families at a time, with a single family 
excluded for each analysis. A marked reduction of the linkage peak when a family was 
excluded is indicative of the contribution of that family to the IOPmed linkage at that peak. 




5.2.3 Measured genotype association analysis 
MGA was conducted for the IOPmed trait on the variants within the intervals for each of the 
linkage regions. MGA, a family-based association test, is described fully in Chapter 2.6.3. A 
maximum of 10% of low confidence and missing calls per variant (as defined in Chapter 2.4.2) 
was required for inclusion in the MGA analysis. 
5.2.4 Linkage conditional on measured genotype 
Individual variants were included in the linkage model as a covariate, prior to ascertainment 
correction, to determine their contribution to the linkage peak, as described by Almasy and 
Blangero, (2004) [246]. Variants were added individually, or in combination with other 
variants. The genotypes of each individual, for the variant of interest, were scored as a dosage, 
based on the number of copies present; with 0 for non-carriers, 1 for heterozygous carriers and 
2 for homozygous variant carriers. Linkage conditional on the measured genotype of the variant 
of interest was then conducted. All the linkage analyses were conducted on the IOPmed trait, 
with both an ascertainment correction and a LOD adjustment applied (see Chapter 4.2.2 and 
4.2.3) 
5.2.5 Prioritisation of variants for further analysis 
Variants identified from within the linkage intervals on each chromosome were prioritised 
based on the following criteria. 
5.2.5.1 Presence in families contributing to the linkage peak 
Variants were prioritised if they were present predominantly in the family or families 
contributing to the linkage peak (see section 5.2.2). As this study has focussed on rare variants, 
there was an expectation that the same rare variant would not be identified in multiple unrelated 
families. For each variant, at least 90% of the calls must have been identified in one of the 
families contributing to the peak. A strict 100% threshold was not chosen to allow for possible 
sequencing or calling errors, which may occur with joint-calling across multiple families, so as 




5.2.5.2 MGA results 
Variants were prioritised if p-values were less than or equal to 0.05 in the MGA analysis (see 
section 5.2.3). 
5.2.5.3 Reduction in LOD score  
Variants fulfilling both criteria above were tested for linkage conditional on their measured 
genotype (see section 5.2.4). Variants were prioritised if they reduced the LOD score of the 
linkage peak by a minimum of 1 LOD unit.  
5.2.6 Additional variants 
Variants were also assessed if they were in the majority of the same individuals as those already 
prioritised. The purpose of assessing these variants was to determine if the haplotype 
encompassing prioritised variants could also be harbouring other, potentially deleterious, 
variants in linkage. 
5.2.7 Further analysis of prioritised variants and genes 
Prioritised and additional variants were assessed further for potential functional affects at both 
the variant and gene level.  
5.2.7.1 Functional annotations and conservation 
The UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) was used to 
determine which mRNA transcripts, eQTL sites and miRNA binding sites (for 3’ UTR 
variants) and active promoter regions (for 5’ UTR variants) overlap with the variant location. 
Conservation of variant sites was assessed with ANNOVAR annotations (Chapter 2.4.2) for 
Genomic Evolutionary Rate Profiling (GERP) and followed with UCSC’s GERP track for any 
missing annotations. The Human Splicing Finder v3.1 (http://www.umd.be/HSF/) was used to 
assess whether the identified variants could potentially affect splicing of mRNA transcripts.  
5.2.7.2 Gene expression in ocular tissues 
Two ocular tissue datasets were used to assess the expression of prioritised genes in ocular 
tissues. We accessed a gene expression dataset (provided by Prof. Jamie Craig and Dr Tiger 
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Zhou, Flinders University) generated from human ocular tissues (referred to as “in-house 
RNAseq data”). The method for generating this RNAseq data is described in detail by 
Macgregor et al, (2018) [248]. Briefly, RNA was extracted from 48 samples obtained from the 
donated eyes of 16 individuals. Nine distinct ocular tissues were used, including the trabecular 
meshwork and ciliary body. Sequencing was undertaken using an Illumina platform and 
mapped to the hg19 human reference genome. Normalised counts per million (CPM) data were 
collected from the transcripts of 21,962 RefSeq protein coding genes. 
Gene expression data for the same ocular tissues was also accessed from Ocular Tissue 
Database (OTD, https://genome.uiowa.edu/otdb/), which uses data generated from the pooled 
samples from six individuals. The OTD uses a normalised “PLIER” score to display gene 
expression results obtained from microarray data [249].  
5.2.7.3 Gene interaction analysis 
To determine whether there was evidence for known (published) gene/gene product 
interactions between the prioritised genes and previously identified IOP or POAG associated 
genes, we used the custom pathway generation functionality in Ingenuity Pathway Analysis 
(IPA, Winter 2019 Release, QIAGEN Inc) [250]. The IPA knowledge base was used to identify 
any published interactions between prioritised genes from this current study and a combined 
set of 129 previously identified IOP genes from Danford et al. (2017) [251] and POAG genes 
identified in Janssen et al. (2013) [13].  
5.2.7.4 Significance of prioritised regions in GWAS data 
Prioritised regions from this study were tested for significance in the recent IOP and glaucoma 
meta-analyses conducted by MacGregor et al. (2018) [248]. These meta-analyses were 
published after the literature review was completed for our current study (see Chapter 3.3.1) 
and as such, those findings were not included in the POAG database (Appendix B). We 
accessed the GWAS summary statistics (provided by Prof. Stuart MacGregor, Queensland 
Institute of Medical Research) to assess our prioritised variants in a large population of 
individuals including glaucoma cases. The IOP GWAS was conducted on participants from the 
UK Biobank (n=103,914) and the International Glaucoma Genetic Consortium (n=29,578). 
Regions from our study were also tested for significance in glaucoma cases (n=11,018) and 
controls (n=126,069), from the UK Biobank and the Australian and New Zealand Registry of 
Advanced Glaucoma. This was a combined glaucoma dataset which included, but was not 
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limited to POAG cases. LocusZoom (http://locuszoom.org/) was used to visualise the GWAS 
data for each of the prioritised regions identified in this current study. The 1000 Genomes 







5.3.1 Linkage intervals 
As discussed in Chapter 4 there were six linkage peaks for IOPmed that exceeded the LOD 
threshold for suggestive linkage and were therefore selected for further investigation. Table 
5-1 shows the identified linkage peaks, their maximum LOD scores and the positions of the 
intervals used to select variants for evaluation. 
Table 5-1 IOPmed linkage peaks and linkage intervals for analysis of variants within peaks 
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  137,593,099  
  
  141,111,553  
9q34.3 
3.40  15 4 
  





    20,743,796  
  
    31,197,564  
15q11.2-13.2 
2.89    7 83 
  





    53,103,371  
  
    77,756,724  
7p11.2-q11.23 
2.64    2 176 
  





  147,345,425  
  
  174,774,366  
2q23.1-31.1 
2.19    3 103 
  





    71,408,319  
  
    86,116,240  
3p13-12.1 
2.00    6 155 
  





  142,539,730  
  
  151,859,314  
6q24.2-25.1 
        Chr = chromosome, cM = centimorgan, bp = base pair 
 
5.3.2 Family contribution to linkage peaks 
Table 5-2 shows the effects of excluding individual families, from the linkage analysis, on the 
maximum LOD score for each of the linkage peaks for the IOPmed trait. Figure 5-1 displays 
the effects of family exclusion across the whole chromosome for each of the chromosomes 
identified with linkage peaks. Four out of the five families contributed to the six linkage peaks. 
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GTAS04 was the only family whose exclusion from the linkage analysis did not reduce any of 
the linkage peaks. The whole chromosome 7 peak was dramatically reduced when a single 
family, 98002, was excluded from the linkage analysis (Figure 5-1d). Conversely, the peak on 
chromosome 6 had minor contributions from four families (Figure 5-1c). Each of the four 
families was the major contributor to at least one linkage peak; Family 93001 to chromosome 
9 (Figure 5-1e), Family 95002 to chromosome 15 (Figure 5-1f), Family 98002 to chromosomes 
2 and 7 (Figure 5-1a and d) and GTAS54 to chromosome 3 (Figure 5-1b). 
 
Table 5-2 Family contributions to linkage peaks. LOD scores for the 5 families together and 
for each family excluded individually.  Families were included in the table if their exclusion from 
the linkage analysis resulted in a reduction in maximum LOD score. Numbers in bold represent the 
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Figure 5-1 Effect of excluding individual families on the six linkage peaks for IOPmed.  Individual families are only shown if there was a reduction in 
peak LOD score when that family was excluded from the linkage analysis. Chromosomes: 2 a), 3 b), 6 c), 7 d), 9 e), and 15 f), five families together = blue, 
exclusion of individual families: 93001 = pink, 95002 = green, 98002 = red, GTAS54 = purple. Location (cM) = centimorgan location along each 


























a) Chromosome 2 b) Chromosome 3 c) Chromosome 6 
d) Chromosome 7 e) Chromosome 9 
f) Chromosome 15 
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5.3.3 Prioritised variants across all linkage intervals 
Variants prioritised (using the criteria in section 5.2.5) across all of the linkage intervals are 
shown in Table 5-3. Appendix E displays all of the variants with MGA results of p ≤ 0.05, and 
indicates those found predominantly in a single family. These variants were tested for linkage 
conditional on their measured genotype. The chromosome 6 linkage interval was the only one 
in which a variant fulfilling all of the prioritisation criteria could not be identified. Prioritised 
variants per linkage interval ranged from a single variant (for chromosome 15) through to five 
for chromosome 2. Merged cells in Table 5-3 represent variants identified in the same 
individuals. As the MGA was conducted using a dosage of the minor allele as a covariate, it is 
impossible to distinguish between the effects of the variants occurring in the same individuals, 
including variants identified in different genes. Variants identified in identical family members 
were found in the chromosome 2, 7 and 9 linkage intervals. The MGA analysis requires both 
phenotypic and genotypic data, and those individuals without IOP measurements were not 
included in this analysis. This is demonstrated in Table 5-3, with differing minor allele copy 
(MAC) numbers in the MGA analysis and in the family specific MAC columns. One 
homozygous carrier of the RIF1 variants and a heterozygous carrier of the CALN1 variants, 






Table 5-3 Prioritised variants across all linkage intervals 
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Gene 
region 


































2 152,317,669 rs116443402 RIF1 exonic  G A   0.3    0.020 
0.072 0.0215 1.71 1.74 34   36  
2 152,331,995 rs372957656 RIF1 3' UTR GTTG -   1.6    0.020 
2 158,177,675 rs749173309 ERMN 3' UTR C A   3.5 < 0.001 0.012 0.0012 7.99 3.27 6  6   
2 166,810,232 rs572065013 TTC21B 5' UTR G A   6.4    0.004 
0.018 0.0079 5.02 3.96 9    9 
2 172,953,525 rs186854626 DLX1 3' UTR C T   9.9    0.002 
3 73,437,185 rs61732653 PDZRN3 exonic  A G   8.7    0.012 0.020 0.0117 4.47 3.59 10   1 9 
3 75,471,002 rs184945375 FAM86DP ncRNA C T 3.4    0.004 0.020 0.0190 4.24 2.82 10    10 
7 71,249,529 - CALN1 3' UTR G C   1.7    * 
0.028 0.0148 4.28 2.86 13   14  
7 71,249,770 - CALN1 3' UTR T -   3.3 < 0.001 
9 139,296,703 - ENTR1 3' UTR G A   1.3    * 
0.030 0.0066 5.18 4.91 15 15    
9 140,342,693 rs746921357 NSMF 3’UTR G A 10.0    0.001 
15 28,474,713 - HERC2 exonic  C T 10.0    * 0.010 0.0005 10.34 4.58 5  5   
Chr = chromosome, bp = base pair 
3’ UTR - 3’ untranslated region, 5’ UTR - 5’ untranslated region, exonic = protein coding region (synonymous) 
Ref = reference allele, Alt = alternate allele 
CADD = combined annotation dependent depletion phred scores (version 1.4) 
gnomAD genome NFE = variant allele frequency in non-Finnish Europeans in the gnomAD genome database. * = variant not found in this database 
AF = frequency of the variant allele in the 5 families 
MGA = measured genotype association analysis 
beta-value = effect size per allele for IOP, measured in mmHg,  
MAC = minor allele copies as used for MGA analysis.  
Family specific MAC = minor allele copies in each family. May differ from MAC used for MGA if IOP information was not also available  
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Of the prioritised variants in Table 5-3, none were non-synonymous and were three 
synonymous protein coding variants; in RIF1, PDZRN3 and HERC2. Most were 3’ UTR 
variants, including the two deletions. None of the 3’ UTR variants overlapped identified 
miRNA sites or eQTL sites. The one 5’ UTR variant, in TTC21B, lies within the active 
promoter of this gene within a region of multiple transcription factor binding sites. Most of the 
prioritised variants had low CADD scores, with only the NSMF and HERC2 SNPs reaching 
scores in the top 10% for predicted deleteriousness. Variants other than those in RIF1 were 
much rarer in the gnomAD database, observed at or below 1% in the European population. 
Several variants were novel or observed at a frequency of below 0.1% in this database. The 
frequency of these variants was much higher in the five families, ranging from 1% for the 
HERC2 variant to over 7% for the RIF1 variants. All of the variants in Table 5-5 were 
associated with an increase in IOP, ranging from an average 1.7mmHg for each allele of the 
RIF1 variants, through to over 10mmHg per allele for the HERC2 variant. In fact, all of the 
variants, other than the RIF1 variants, were associated with a minimum of 4mmHg increase in 
IOP, per allele. The contribution to the IOPmed trait variance, per allele, ranged from just under 
2% to nearly 5%. This variance explained was not correlated with the number of alleles present 
in the families; the HERC2 variant found only in five individuals contributed to the same 
amount of IOP variance as the ENTR1 variant and nearly three times the variance of the RIF1 
variants, found in many more family members. Of all the variants in Table 5-3, the HERC2 
variant was found in the fewest individuals, but was associated with the largest average increase 





5.3.3.1 Evolutionary conservation and predicted splicing effects of variants 
Table 5-4 shows GERP conservation scores and predicted splicing effects of both the 
prioritised (section 5.2.5) and additional (section 5.2.6) variants. Positive GERP values predict 
more evolutionarily conserved base pair positions, with maximum score possible of 6.18, and 
negative values predict the more neutral positions. Zero GERP scores represent a non-
meaningful estimate due to poor alignment. The results displayed in this table are detailed in 
the relevant sections on the linkage regions below. 
 
Table 5-4 Conservation scores and predicted splicing effects of prioritised and additional 









2 152,317,669 rs116443402 RIF1 exonic G A  -0.1 no 
2 152,331,995 rs372957656 RIF1 3' UTR GTTG -   0.0 New ESS site 
2 152,417,767 rs115631125* NEB exonic C A -10.9 ESE site broken 
2 153,378,462 rs138926754* FMNL2 exonic T C   -2.6 ESE site broken 
2 158,177,675 rs749173309 ERMN 3' UTR C A    3.3 ESE site broken 
2 159,536,990 rs148782148* PKP4 
# exonic 
p.(Asp > Val) 
A T   5.5 
ESE site broken 
New ESS site 
2 166,810,232 rs572065013 TTC21B 5' UTR G A -4.9 no 
2 172,953,525 rs186854626 DLX1 3' UTR C T   3.7 
ESE site broken 
New ESS site 
3 73,437,185 rs61732653 PDZRN3 exonic A G -8.9 ESE site broken 
3 75,471,002 rs184945375 FAM86DP ncRNA C T  -2.3 ESE site broken 
7 71,249,529 - CALN1 3' UTR G C  1.7 ESE site broken 
7 71,249,770 - CALN1 3' UTR T -  2.7 ESE site broken 
9 139,296,703 - ENTR1 3' UTR G A -2.7 New ESS site 
9 140,342,693 rs746921357 NSMF 3’UTR G A -0.3 ESE site broken 
15 28,474,713 - HERC2 exonic C T  0.2 no 
 
* = additional variants (from section 5.2.6) which are discussed in the relevant section on their loci 
below. 
Chr = chromosome, bp = base pair 
3’ UTR - 3’ untranslated region, 5’ UTR - 5’ untranslated region, exonic = protein coding region 
(synonymous unless otherwise indicated), # = non-synonymous variant 
Ref = reference allele, Alt = alternate allele 
GERP = Genomic Evolutionary Rate Profiling score 
Potential splicing alteration = as identified using the Human Splicing Finder v3.1 




5.3.3.2 Gene expression in ocular tissues 
Expression of the genes identified from prioritised (section 5.2.5) and additional (section 5.2.6) 
variants in the ocular tissue database (OTD) and our in-house RNAseq dataset are shown in 
Table 5-5. These gene expression results are discussed in the relevant sections on the linkage 
regions below. 
 
Table 5-5 Gene expression of prioritised and additional genes in IOP relevant ocular tissues 
 
 Ocular Tissue Database 
(PLIER score) 
In-house RNAseq 
(counts per million) 
Chr Gene HGNC ID CB TM CB TM 
2 RIF1 23207 40.3800 59.2821 11.7138 38.0609 
2 NEB * 7720 25.8328 128.7910 0.4436 44.0060 
2 FMNL2 * 18267 64.6647 77.1831 16.2269 48.3394 
2 ERMN 29208 -- -- 0.4959 1.1282 
2 PKP4 * 9026 158.2350 115.8910 184.2291 47.4201 
2 TTC21B 25660 34.5452 58.7574 8.0150 18.8125 
2 DLX1 2914 40.4993 34.8669 0.4999 0.6300 
3 PDZRN3 17704 51.2939 26.7320 74.1244 88.6112 
3 FAM86DP 32659 22.5021 10.7506 5.2495 5.9587 
7 CALN1 13248 22.9616 16.9850 0.8475 0.4130 
9 ENTR1 10667 58.9830 41.1306 24.7005 23.3657 
9 NSMF 29843 -- -- 75.5354 127.2043 
15 HERC2 4868 33.2641 48.7907 87.7595 103.2685 
 
* = additional genes (from section 5.2.6) which are discussed in the relevant section on their loci 
below. 
Chr = chromosome, HGNC ID = HUGO gene nomenclature committee identification number  





5.3.4 Analysis of individual linkage intervals 
Each of the linkage intervals is discussed in detail below, in the order of descending maximum 
LOD score of the peaks (as shown in Table 5-1). 
5.3.4.1 Chromosome 9q34.3 linkage interval 
The chromosome 9 linkage peak was the most significant of all six IOP linkage peaks identified 
and reached full statistical significance with a LOD score of 4.25. Table 5-2 and Figure 5-1e 
both indicate that family 93001 contributed most to this peak with family 98002 making a 
minor contribution. Two variants fulfilled the criteria for prioritisation; in ENTR1 (novel 
variant located at chr9:139296703) and NSMF (rs746921357), which were identified in the 
same 15 individuals from family 93001 (Table 5-3). Inclusion of the measured genotype of 
these variants in the linkage model reduced the maximum LOD score by over 1, but did not 
account for the majority of the peak (Figure 5-2). As with the MGA results, variants identified 
in the same individuals result in identical linkage peaks, thus one plot represents both variants. 
Both of these variants were in the 3’ UTR regions of their genes. Both were rare variants, with 
the ENTR1 variant not observed in the gnomAD database and the NSMF variant with a minor 
allele frequency of 0.001. These variants were associated with over 5mmHg average IOP 
increase and contributed to nearly 5% of the trait variance. Both of these variants were 
predicted to affect splicing but neither of them are at evolutionarily conserved sites (Table 5-4). 
NSMF was not included in the OTD, but showed high expression in our in-house RNAseq 
dataset, in both the ciliary body and trabecular meshwork (Table 5-5). In fact, NSMF had the 
highest expression in the trabecular meshwork of all the assessed genes. ENTR1 was expressed 
at lower levels than NSMF in our RNAseq dataset and showed expression in the OTD at a 
similar level to other assessed genes. Neither of these genes were found to interact with any of 
the published genes assessed in the IPA analysis and did not reach significance in the published 



















5.3.4.2 Chromosome 15q11.2-13.2 linkage interval 
The major contribution to the chromosome 15 peak was predicted to be from family 95002. 
Table 5-2 shows a reduction by a LOD score of 2 when this family was excluded from the 
linkage analysis. Figure 5-1f displays the whole linkage peak reduction, also showing a minor 
contribution to the linkage peak from families 93001 and GTAS54. The HERC2 variant (novel 
variant located at chr15: 28474713) was identified in five members of family 95002 (Table 
5-3) and was the only variant which fulfilled the prioritisation criteria. This synonymous SNP 
had the most significant MGA p-value of all the variants which were found predominantly in 
a single family (Appendix E) and had not been observed in the gnomAD database. This variant 
was associated with a 10mmHg increase in IOP, the largest increase of all the variants identified 
contributing to the linkage peaks. The variance explained by this SNP, at 4.6%, was the second 
highest in Table 5-3. When the linkage analysis was conducted, conditional on the measured 
genotype of the HERC2 variant, the LOD score of the peak was reduced by 2, the greatest 
amount of all the variants assessed (Figure 5-3). In fact, this LOD reduction was almost 
identical to the linkage analysis when family 95002 was excluded (Figure 5-4). 
Figure 5-2 Linkage conditional on measured genotype of ENTR1 or NSMF variants. Location 
(cM) = centimorgan location along each chromosome, LOD = logarithm of the odds, with the red dashed 






















Figure 5-4 Linkage conditional on measured genotype of the HERC2 variant compared to the 
exclusion of family 95002. Location (cM) = centimorgan location along each chromosome, LOD = 
logarithm of the odds, with the red dashed line indicating a significance level of 3.3 and the grey 
dashed line, a significance level of 1.86 
  
Figure 5-3 Linkage conditional on measured genotype of the HERC2 variant. Location (cM) 
= centimorgan location along each chromosome, LOD = logarithm of the odds, with the red dashed 
line indicating a significance level of 3.3 and the grey dashed line, a significance level of 1.86 
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The HERC2 variant was not predicted to affect mRNA splicing and was not at an evolutionarily 
conserved site (Table 5-4). HERC2 was expressed in the relevant ocular tissues in both the 
OTD and the RNAseq dataset (Table 5-5). The expression levels in both tissues of our in-house 
dataset were the second highest of all the assessed genes. The IPA analysis identified a protein 
interaction between HERC2 and TP53 [252], which was one of the POAG genes from the 
Janssen et al. (2013) dataset [13].  
When the regions in and around HERC2 was assessed in the MacGregor et al. (2018) [248], 
meta-analyses dataset the lead SNP reached suggestive significance (p < 10-5) in the IOP 
GWAS. Figure 5-5 shows a LocusZoom plot of HERC2 and surrounding genes, with the lead 
SNP reaching a significance of p = 2.56x10-6. This SNP was associated with a slight increase 
in IOP (beta-value = 0.07mmHg) and is located in an intronic region of HERC2. This SNP did 
not reach suggestive significance in the glaucoma GWAS, at p = 5.44x10-4.  
 
Figure 5-5 LocusZoom plot of part of the chromosome 15 linkage interval from the IOP 
GWAS, showing HERC2. The purple diamond represents the top statistically associated SNP. 
Pairwise correlations (r2) between the top SNP and neighbouring SNPs are illustrated in different 




5.3.4.3 Chromosome 7p11.2-q11.23 linkage interval 
The chromosome 7 linkage peak was the only peak to show involvement of only one family; 
98002, the largest of the five families (Table 5-2 and Figure 5-1d). A SNP and indel (novel 
variants located at chr7: 71249529 and chr7: 71249770 respectively), only 250bp apart, in the 
3’ UTR region of CALN1 were the only variants to fulfil the prioritisation criteria (Table 5-3). 
Both variants were extremely rare in the general population; the SNP had not been observed in 
gnomAD and the indel was seen with a frequency of less than 0.001. These variants are carried 
by 14 members of family 98002, 13 of whom had IOP phenotype data and contributed to the 
MGA results. These variants were associated with over 4mmHg increase in IOP and nearly 3% 
of the trait’s variance. Figure 5-6 shows the effect of including the measured genotype of these 











Figure 5-6 Linkage conditional on the measured genotype of the CALN1 variants in family 
98002. Location (cM) = centimorgan location along each chromosome, LOD = logarithm of the odds, 
with the red dashed line indicating a significance level of 3.3 and the grey dashed line, a significance 
level of 1.86 
 
The CALN1 variants were both predicted to affect mRNA splicing, and are both at 
evolutionarily conserved sites (Table 5-4). CALN1 demonstrated a low level of expression in 
relevant ocular tissues in both datasets, especially in our RNAseq dataset, where the expression 
was minimal (Table 5-5). No interactions between this gene and the IOP and POAG genes 
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tested with IPA were identified and it did not reach significance in the published IOP and 
glaucoma meta-analyses. 
5.3.4.4 Chromosome 2q23.1-31.1 linkage interval 
The chromosome 2 linkage interval had five variants which fulfilled all the of the prioritisation 
criteria (Table 5-3). Three families contributed to this peak (Table 5-2 and Figure 5-1) and at 
least one variant in each of these families was identified which reduced the LOD score by a 
minimum of 1 when linkage was conducted conditional on their measured genotype. Figure 
5-7 shows the effects of including the measured genotypes of these prioritised variants in the 
linkage model. A single line represents both of the RIF1 variants (Figure 5-7b) as well as the 
TTC21B and DLX1 SNPs (Figure 5-7c). Conducting linkage conditional on the measured 
genotypes of the variants from the three families together resulted in a complete reduction of 






















 Figure 5-7 Linkage conditional on measured genotype of a) ERMN, b) RIF1, c) TTC21B or DLX1 variants and d) 
combined RIF1, ERMN and TTC21B or DLX1 variants Location (cM) = centimorgan location along each chromosome, 






The ERMN variant (rs rs749173309) was identified in 6 members of family 95002 (Table 5-3). 
Although this variant was found in the fewest number of individuals in the chromosome 2 
linkage interval, it was associated with the greatest effect size, with an average 8mmHg 
increase in IOP per allele. This was also the rarest of the prioritised chromosome 2 variants, 
observed at a frequency of less than 0.0003 in the gnomAD NFE database. This variant also 
had the greatest reduction in maximum LOD of the chromosome 2 variants when linkage was 
conducted conditional on their measured genotype (Figure 5-2a). The ERMN variant was at an 
evolutionarily conserved site, with a GERP score of 3.3, and was also predicted to affect mRNA 
splicing by breaking an exonic splicing enhancer (ESE) site (Table 5-4). ERMN was not found 
in the OTD and it only showed minimal expression in the ciliary body and trabecular meshwork 
of our in-house RNAseq dataset (Table 5-5). This gene was not found to interact with any of 
the published genes assessed in the IPA analysis and did not reach significance in the published 
IOP and glaucoma meta-analyses. 
 
Family 98002 
Two variants in RIF1, less than 15kb apart, were identified in 34 members of family 98002 
(two homozygous carriers resulted in a MAC of 36, Table 5-3). One of these variants is a 
synonymous SNP (rs116443402) and the other a deletion in the 3’ UTR (rs372957656). These 
variants were more common than other prioritised variants in the general population, observed 
at a frequency of 0.02 in the gnomAD database. The RIF1 variants are associated with a 
1.7mmHg increase in IOP, a much smaller effect size than the ERMN variant. They also 
account for less trait variance (Table 5-3). The reduction in the linkage peak, conditional on 
the measured genotype of the RIF1 variants (Figure 5-7b) is also not as great as that for the 
ERMN variant. 
Two additional variants, in NEB (rs115631125) and FMNL2 (rs138926754), were both found 
in the same individuals as the RIF1 variants (Table 5-6). Although the MGA p-values of the 
variants in these genes were greater than 0.05, we hypothesised that there may be additional 





Table 5-6 Additional variants identified in the same individuals as the RIF1 variants in Family 98002 
                      Variants in bold are additional to those already shown in Table 5-3 (not bold)




Variant ID Gene 
Gene 
region 


































2 152,317,669 rs116443402 RIF1 exonic  G A   0.3    0.020 
0.072 0.0215 1.71 1.74 34   36  
2 152,331,995 rs372957656 RIF1 3' UTR GTTG -   1.6    0.020 
2 152,417,767 rs115631125 NEB exonic C A < 0.1    0.004 0.042 0.2047 1.24 0.70 20   21  
2 153,378,462 rs138926754 FMNL2 exonic T C 10.9    0.029 0.058 0.1857 0.34 0.45 28 1  25 3 
 
Chr = chromosome, bp = base pair 
3’ UTR - 3’ untranslated region, 5’ UTR - 5’ untranslated region, exonic = protein coding region (synonymous) 
Ref = reference allele, Alt = alternate allele 
CADD = combined annotation dependent depletion phred scores (version 1.4) 
gnomAD genome NFE = variant allele frequency in non-Finnish Europeans in the gnomAD genome database.  
AF = frequency of the variant allele in the 5 families 
MGA = measured genotype association analysis 
beta-value = effect size per allele; pressure inside the eye measured in mmHg,  
MAC = minor allele copies as used for MGA analysis.  




Figure 5-8 shows comparisons of linkage conditional on the measured genotypes of the RIF1 
variants with NEB (Figure 5-8a) and FMNL2 (Figure 5-8b) variants. Both of these variants 
have very similar effects on the chromosome 2 peak as the RIF1 variants, reducing the 



















Figure 5-8 Linkage conditional on the measured genotype of the RIF1 variants versus the 
NEB variant (a) and FMNL2 variant (b). Location (cM) = centimorgan location along each 







Of the members of Family 98002 shown in Table 5-6 carrying variants in the RIF1, NEB and 
FMNL2 genes, 19 were carriers common for all the variants across the 3 genes. When linkage 
was conducted using the measured genotypes of only the 19 members of Family 98002 who 
carry the variants in these three genes, the maximum LOD score was reduced even further than 
for the RIF1 variants alone (Figure 5-9). This suggests that these 19 family members were 
driving the peak, and the additional family members who were carriers of the RIF1 variants 










Figure 5-9 Linkage conditional on the measured genotype of the RIF1 variants versus the 
measured genotype of the RIF1, NEB and FMNL2 variants common to 19 members of Family 
98002. Location (cM) = centimorgan location along each chromosome, LOD = logarithm of the odds, 
with the grey dashed line indicating a significance level of 1.86 
 
Of the four variants identified in family 98002 in the chromosome 2 linkage interval, three 
were predicted to possibly affect mRNA splicing (Table 5-4), with only the RIF1 exonic SNP 
with no predicted effect. RIF1, NEB and FMNL2 are all expressed in the ciliary body and 
trabecular meshwork tissues of the eye, with NEB demonstrating a much greater expression in 
the trabecular meshwork than the ciliary body in both the OTD and our in-house RNAseq data 
(Table 5-5). The expression of NEB in the trabecular meshwork is the greatest of all the genes 
in this study which were assessed in the OTD, with a plier score of 129. The IPA gene 
interaction analysis revealed an interaction at the protein level between FMNL2 and CDH1 
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[253]. CDH1 is a member of the Type 1 classical cadherin group, involved with cell adhesion 
(https://www.genenames.org/).  
When variants in the region encompassing RIF1, NEB and FMNL2 were assessed for 
significance in the IOP and glaucoma meta-analyses [248], genome-wide significance, at 
p < 5x10-8, was reached within FMNL2. The lead SNP in FMNL2 (rs1579050) was highly 
significant at p = 1.39x10-25. Figure 5-10 shows a plot of the chromosome 2 linkage interval 
encompassing RIF1, NEB and FMNL2. The lead SNP is located in the first intron of FMNL2 
and the risk allele was associated with an increase in IOP (beta-value = 0.13mmHg). In the 
glaucoma GWAS, this locus did not quite reach genome-wide significance, with rs1579050 
reaching p = 2.90x10-7. The glaucoma odds ratio for the risk allele was 1.08 (95% CI = 1.05, 
1.11). 
 
Figure 5-10 LocusZoom plot of part of the chromosome 2 linkage interval from the IOP 
GWAS, encompassing RIF1, NEB and FNML2. The purple diamond represents the top statistically 
associated SNP. Pairwise correlations (r2) between the top SNP and neighbouring SNPs are illustrated 







A SNP each in TTC21B (rs572065013) and DLX1 (rs186854626) were identified in the same 
nine GTAS54 family members (Table 5-3). These variants were not common in the gnomAD 
database, observed at a frequency of less than 0.005. These variants contribute to nearly 4% of 
the IOP trait variance and were associated with a 5mmHg increase in IOP in these family 
members. The DLX1 variant was predicted to affect splicing and is at an evolutionarily 
conserved site, with a GERP score of 3.7, whereas the TTC21B variant was not predicted to 
affect splicing and is not evolutionarily conserved (Table 5-4). These two variants are over 6 
million bp apart, and as these variants were found in the same family members, it is impossible 
to determine from the MGA and linkage results which variant to prioritise over the other. But 
it does suggest that there may be a large haplotype in this family which may contribute to 
IOPmed variance. 
Another variant which was present only in Family GTAS54, with an MGA p-value less than 
0.05 was in PKP4 (rs148782148, Table 5-7). This variant was not prioritised with TTC21B and 
DLX1, as when linkage was conducted conditional on the measured genotype of the PKP4 
variant, the maximum LOD was reduced by 0.7, not quite reaching the threshold required for 
prioritisation of variants. This SNP is over 7 million bp away from TTC21B and was found in 
eight out of the nine GTAS54 family members who carry the prioritised variants in TTC21B 
and DLX1. This non-synonymous SNP had the highest CADD score of all the assessed variants 
in all of the linkage intervals, at 28.3. It was also at a highly evolutionarily conserved site, and 
with a GERP score of 5.5, was the most conserved of all the assessed variants (Table 5-4). This 
variant was also predicted to affect mRNA splicing with the insertion of a new exonic splicing 
silencer (ESS) site as well as breaking an exonic splicing enhancer (ESE) site (Table 5-4). The 
PKP4 variant contributed to more of the IOPmed trait variance than the TTC21B and DLX1 
variants, at nearly 6%, and had a similar associated effect size. The expression of PKP4 was 
the highest in the ciliary body of all the genes assessed, across all the linkage regions, in both 
the OTD (plier score of 158) and our in-house RNAseq data (184 counts per million) (Table 
5-5). TTC21B and DLX1 showed lower expression in the OTD and a much lower expression 
level in our RNAseq dataset, with DLX1 with only minimal expression (< 1 count per million). 
In the IPA gene interaction analysis, a protein interaction between PKP4 and CDH1 was 
identified [254]. CDH1 was the same gene identified as interacting with FMNL2, from family 
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98002 described above. None of these genes identified in Family GTAS54 reached significance 
in the published IOP and glaucoma meta-analyses. 
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Table 5-7 Additional variant identified in the same individuals as the TTC21B and DLX1 variants in Family GTAS54 
                         The variant in bold is additional to those already shown in Table 5-3 (not bold) 




Variant ID Gene 
Gene 
region 


































2 159,536,990 rs148782148 PKP4 
exonic 
p(Asp>Val) 
A T 28.3    0.005 0.016 0.0013 4.6 5.76 8    8 
2 166,810,232 rs572065013 TTC21B 5' UTR G A   6.4    0.004 
0.018 0.0079 5.02 3.96 9    9 
2 172,953,525 rs186854626 DLX1 3' UTR C T   9.9    0.002 
 
Chr = chromosome, bp = base pair 
3’ UTR - 3’ untranslated region, 5’ UTR - 5’ untranslated region, exonic = protein coding region 
Ref = reference allele, Alt = alternate allele 
CADD = combined annotation dependent depletion phred scores (version 1.4) 
gnomAD genome NFE = variant allele frequency in non-Finnish Europeans in the gnomAD genome database.  
AF = frequency of the variant allele in the 5 families 
MGA = measured genotype association analysis 
beta-value = effect size per allele; pressure inside the eye measured in mmHg,  
MAC = minor allele copies as used for MGA analysis.  





5.3.4.5 Chromosome 3p13-12.1 linkage interval 
Family GTAS54 was predicted to contribute most to the chromosome 3 linkage peak, followed 
by family 93001 and 95002 (Table 5-2). Two variants, in PDZRN (rs61732653) and FAM86DP 
(rs184945375), fulfilled the criteria for prioritisation (Table 5-3). These SNPs were found in 
the same nine GTAS54 family members, with an additional family member carrying the 
FAM86DP variant, and a family 98002 individual carrying the PDZRN variant. These two 
variants are located 2 million base pairs apart, with no other variants found predominantly in 
the same GTAS54 family members within the chromosome 3 linkage interval. Both variants 
were associated with a similar increase in IOP, over 4mmHg per allele, with the PDZRN variant 
explaining slightly more of the variance. When linkage was conducted conditional on the 
measured genotypes of these variants, the PDZRN variant demonstrated a larger reduction in 
the maximum LOD (Figure 5-11). Excluding the family 98002 individual from the analysis 






















Figure 5-11 Linkage conditional on the measured genotype of the a) PDZRN variant and b) 
FAM86DP variant. Location (cM) = centimorgan location along each chromosome, LOD = 
logarithm of the odds, with the grey dashed line indicating a significance level of 1.86 
 
When assessing other features of these two variants, both were predicted to affect mRNA 
splicing and both sites were not evolutionarily conserved (Table 5-4). PDZRN was more highly 
expressed than FAM86DP in both the ciliary body and trabecular meshwork ocular tissues in 
both the OTD and the RNAseq dataset (Table 5-5). Neither of these genes demonstrated any 





neither of them demonstrated any significant associations in the IOP and glaucoma meta-
analyses. 
5.3.4.6 Chromosome 6q24.2-25.1 linkage interval 
The chromosome 6 linkage peak did not have a major contribution by a single family (Table 
5-2). Family 95002 was shown to contribute most to this peak, albeit a small contribution. 
When this linkage interval was investigated to prioritise variants, only three variants were 
found predominantly in family 95002. Two of these variants had MGA p-value ≤ 0.05 
(Appendix E), and six of the eight family members were common to the two variants. However, 
when tested for linkage conditional on their measured genotype, the best of these two variants, 
rs143818607 in PLEKHG1, only demonstrated a maximum LOD reduction of 0.4. No variants 






Six QTLs for medication adjusted IOP were identified in five families as described in the 
previous chapter. The purpose of the analyses described in this chapter was to identify the 
variants driving the peaks and propose genes which may be involved in IOP regulation in the 
families of this study. Variants were prioritised within the linkage peaks by firstly, restricting 
the analysis to variants present in the families making the major contribution to each peak with 
the most significant MGA results. Variants meeting these criteria and reducing the LOD score 
by at least 1 LOD unit in conditional linkage analysis were considered prioritised. Additional 
variants, found in the majority of the same family members as prioritised variants, were also 
assessed to determine whether there could be alternative risk variants within a haplotype. In 
total, 15 variants in 13 genes across all of the QTLs, had a major influence on the magnitude 
of the peak linkage when adjusted for in the linkage model. No variants affecting peak linkage 
were identified in the chromosome 6 linkage region whereas eight variants affecting linkage 
were found in the chromosome 2 linkage region. 
One of the most important findings in this study is the chromosome 15 linkage region. This 
was one of the two peaks which reached full statistical significance, with a maximum LOD 
score of 3.40 after correction for the ascertainment of POAG families and adjustment for the 
non-normal distribution of the IOPmed trait (detailed in Chapter 4). This is the only linkage 
region in our study which overlaps a previously published linkage region. The peak identified 
in this study completely overlaps the GLC1I region, identified by ordered subset analysis in 15 
families with early onset POAG [177]. The fact that 15 families contributed to that linkage 
peak suggests a more common variant was involved or possibly several rare variants across 
multiple families. The HERC2 variant identified in our study is so rare that it has not been 
observed in the gnomAD database in any population. The linkage region in our study was 
driven predominantly by one family (Table 5-2 and Figure 5-1f), which contributed a LOD 
score of 2 to this peak. A variant in HERC2, identified in five members of family 95002, 
accounted for the whole contribution to the peak (Figures 5-3 and 5-4). As a potentially private 
variant in family 95002, it is highly unlikely to be the same functional variant driving the 
linkage peak at the GLC1I locus. However, there may be other rare variants in HERC2 in the 




The MGA results in our study demonstrated association of the HERC2 variant with a large 
effect on the average IOP in these five family members and which accounted for over 4.5% of 
the trait variance (Table 5-3). In the meta-analysis conducted by MacGregor et al. (2018) [248], 
the HERC2 locus reached suggestive significance for association with IOP (p = 2.56x10-6 for 
the lead SNP, rs12913832). Although that study identified the HERC2 locus as associated with 
increased IOP, it does not confirm this gene as important in IOP regulation. Our study has 
identified a coding variant within the HERC2 gene itself and is a step towards confirming the 
possible involvement of HERC2 with IOP regulation. Comparing the common lead SNP in the 
meta-analysis (MAF=0.56) and its associated effect of increasing IOP by 0.07mmHg, with the 
rare variant identified in our study, associated with over 10mmHg increase in IOP, 
demonstrates the benefit of using families to look for rare variants with large effect sizes.  
HERC2 was highly expressed in both the ciliary body and trabecular meshwork of our RNAseq 
database. This gene is involved in DNA repair [255] and some variants in HERC2 are involved 
with eye, skin and hair pigmentation [256-258] and others are associated with intellectual 
disability [259, 260]. In the gene interaction analysis, a protein interaction between HERC2 
and TP53 was identified. TP53 was previously associated with POAG [261-264], although 
results have been conflicting, with other researchers not finding an association [265, 266]. 
Tumour protein 53 (p53) is an important transcription factor which regulates the cellular 
response to stress [267] and the previous studies which found an association with POAG 
suggested that the role of p53 in apoptosis may be relevant to the retinal ganglion cell death 
which is characteristic of POAG pathogenesis [261-264]. The HERC2 protein has been 
proposed to regulate p53 signalling by binding to the protein and activating p53 
oligomerisation, an integral part of regulating the transcription of target genes [252, 268]. 
However, a possible role that HERC2 and TP53 may play in apoptosis together is still to be 
elucidated. Although TP53 has been associated with POAG, no role for this gene in IOP 
regulation has been proposed. HERC2 is a novel gene for IOP identified in our current study, 
and very recently the locus has been (independently) identified by GWAS [83], however, its 
mechanism of action in IOP regulation is unknown. 
Figure 5-13 shows the POAG disease status of family 95002 and identifies the HERC2 variant 
carriers. Of these five individuals who carry the HERC2 variant, four of them were diagnosed 
with POAG when clinically assessed. Only one of the five variant carriers did not have a POAG 
diagnosis at their last clinical assessment. However, this person (9500217) had high IOP 
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(27mmHg, well above the ascertainment correction population average of 15mmHg), and may 
well have developed POAG since the study concluded as they were only 55yrs old at their last 
clinical assessment. Although this is not enough evidence to state a link between this variant 
or gene with POAG, it is a promising finding and worthy of further investigation. 
 
Figure 5-12 Family 95002 indicating POAG disease status and carriers of the novel HERC2 
variant, at 15:28474713 (chr:pos hg19) Blue arrows indicate variant carriers, red curved line 
indicates the same individual. Identification number = the first string of numbers I = IOP measurement 




Although the HERC2 variant identified here is exonic, associated with a large increase in IOP 
and the gene is expressed in relevant ocular tissues, it may not be a functional variant itself. 
The CADD score of 10 does not predict this variant to be highly deleterious, but functional 
research on this gene would be required to determine which variants affect gene function. The 
gnomAD database proposes HERC2 as a highly constrained gene, intolerant of missense and 
loss of function variants. Other, more deleterious, variants may be present on the same 
haplotype in the same five family members as the identified variant and further sequencing of 
other HERC2 regions in these five individuals may lead to other variants of interest.  
As with the chromosome 15 linkage region, variants with the potential to affect IOP regulation 
have also been identified within the chromosome 2 QTL. However, where the chromosome 15 
peak was obviously driven by one family, the chromosome 2 peak is more complex and 
influenced by multiple families. Excluding individual families from the linkage analysis 
suggested Families 95002, 98002 and GTAS54 as contributing to this region (Table 5-2). The 
ERMN variant, carried by 6 members of family 95002, had the largest effect on reducing the 
maximum LOD (Figure 5-7a). Although this 3’ UTR variant demonstrated association with 
increased IOP in these family members in the MGA results (Table 5-3) the CADD score did 
not predict it to be deleterious. ERMN was not highly expressed in the relevant ocular tissues 
(Table 5-5) and a link with IOP is difficult to determine. The true functional variant behind this 
family’s effect on the linkage peak may be on the same haplotype as this ERMN variant, but at 
this stage, cannot be identified.  
The family 98002 contribution to the chromosome 2 linkage peak was identified as a presumed 
haplotype encompassing at least the RIF1, NEB and FMNL2 genes. The RIF1 variants were 
prioritised based on their MGA results and reduction in maximum LOD when included in the 
linkage model. Additional variants were identified in NEB and FMNL2 which were carried by 
many of the same individuals as the RIF1 variants. Nineteen members of family 98002 carried 
variants in all three of these genes and the measured genotype of only these individuals reduced 
the linkage peak by a greater amount than the 34 RIF1 carriers alone (Figure 5-9). Further 
analysis will need to be undertaken to confirm whether this region on chromosome 2 is indeed 
the same haplotype in these 19 individuals. Currently, the region identified here encompasses 
over 1 million base pairs and includes the genes; ARL5A, CACNB4 and STAM2, which did not 
have any prioritised variants in this study. The presumed haplotype could well extend beyond 
the genes identified here. 
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RIF1 was the original gene with the identified variants from Family 98002 in the chromosome 
2 linkage interval. However, although this gene is expressed in the eye (Table 5-5), it has not 
been associated with any eye diseases. NEB is expressed in the IOP relevant tissues of the eye 
and particularly in the trabecular meshwork more so than the ciliary body (Table 5-5). This 
gene is a component of muscle tissue and is a causative gene of nemaline myopathy, a 
neuromuscular disorder [269]. Interestingly, an association was found between a non-
synonymous NEB variant and primary angle closure glaucoma (PACG) in a breed of dog 
susceptible to this form of glaucoma [270]. PACG is also associated with an increase in IOP, 
and the mechanism of involvement with glaucoma in the dog study is believed to be due to an 
effect on the ciliary muscle of the eye which is necessary to retain normal structure of the 
anterior chamber of the eye including regulating the outflow of aqueous humour. However, 
there is currently no evidence that NEB is involved with IOP regulation in humans. 
FMNL2 is the most likely candidate gene to affect IOP out of the three identified in Family 
98002. Although the particular variant identified here was not prioritised based on the MGA 
results and it barely contributed to the variance of IOP in the families of this study (Table 5-6), 
FMNL2 has already been associated with IOP [111, 171] and POAG [111] (also see Appendix 
B). The two published variants were identified from large GWAS and although not proposed 
to be the functional variants themselves, the authors proposed FMNL2 as a potentially 
important IOP and POAG gene [111]. After association with this gene was found, functional 
studies were conducted to determine whether FMNL2 affects trabecular meshwork function 
which could potentially affect the regulation of aqueous humour outflow [111]. That study 
suggested that knockdown of the FMNL2 gene indirectly affected the assembly of actin fibres, 
via cell-adhesion based means, which induced morphological changes in human trabecular 
meshwork cells. They proposed that the effect on the contractile properties of trabecular 
meshwork cells could affect aqueous humour outflow, with a resultant increase in IOP as the 
mechanism of POAG pathogenesis. Strengthening this link between FMNL2 and cell adhesion 
mechanisms of action were the results of the gene interactions analysis conducted in our study. 
The IPA analysis identified a direct protein-protein interaction between FMNL2 and CDH1, 
also known as E-cadherin. These two proteins together are an important component of the cell-
cell adhesion complex [253]. Other studies have reported the importance of cadherins in cell-
cell adhesion in trabecular meshwork tissues, the possible dysfunction of which is involved in 
IOP dysregulation and glaucoma, although these studies focused on K-cadherin [271] and N- 
and OB-cadherins [272]. The CDH1 gene was found to be upregulated in retinal ganglion cells 
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in a rat model with ocular hypertension [273] and was proposed as an important gene in the 
pathogenesis of POAG [13]. 
FMNL2 is also a promising candidate gene for IOP regulation and POAG pathogenesis when 
the significance of this locus was assessed in the meta-analysis conducted by MacGregor et al. 
(2018) [248]. That study identified the FMNL2 locus as highly significantly associated with 
IOP (Figure 5-19) as well as being associated with glaucoma. The evidence surrounding 
FMNL2 as a gene involved in IOP regulation and glaucoma is encouraging and supports the 
proposal of this gene as the most likely candidate in the chromosome 2 linkage region for 
Family 98002. Although the variant identified from Family 98002 in this current study is 
unlikely to be the functional variant itself, it is only 70kb away from the two variants discussed 
above [111, 171]. Unfortunately, poor sequencing quality around this region in our study 
resulted in several variants being excluded from the MGA analysis, and resequencing this 
region may identify other variants with potentially functional consequences. 
Along with Families 95002 and 98002, GTAS54 also contributed to the chromosome 2 QTL 
and potentially supplies a novel and interesting candidate gene. Of the three variants shown in 
Table 5-7, the PKP4 variant is prioritised over the TTC21B and DLX1 variants. This is the only 
non-synonymous protein coding variant, predicted to be highly deleterious, with the highest 
CADD score of all the variants identified, in any of the linkage regions. It is predicted to 
potentially affect splicing of the mRNA and is the most evolutionarily conserved of the three 
variants. PKP4 is the most highly expressed gene, of assessed genes in this study, in the ciliary 
body in both the OTD and our in-house RNAseq database, far exceeding the expression levels 
of the other genes in this tissue (Table 5-5), and it is also expressed in the trabecular meshwork, 
with its expression in the OTD the second highest of the genes assessed. 
PKP4 is a member of the catenin protein family, which are involved with intercellular adhesion 
through the stabilisation of cadherins, the molecules which bind cells together [274, 275]. K-
cadherin is highly expressed in normal trabecular meshwork tissues and is regulated by the 
wnt/β-catenin signalling pathway. K-cadherin contributes to cell-cell adhesion in the trabecular 
meshwork is believed to be important in the regulation of IOP. Blocking of the wnt/β-catenin 
pathway led to an increase in IOP in a mouse model of glaucoma [271]. Although a direct 
relationship between PKP4 and K-cadherin in the trabecular meshwork has not yet been 
established, PKP4 is known to interact with other types of cadherins and is believed to be 
important in cell-cell adhesion as well as other cellular functions [274]. The IPA gene 
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interactions analysis conducted in our study supports a cell adhesion effect model, with an 
interaction between PKP4 and CDH1 (E-cadherin) identified [254], which is the same protein 
identified as interacting with FMNL2 discussed above. As PKP4 expression in the ciliary body 
is higher than even the trabecular meshwork, there may also be a role in this tissue, which 
produces the aqueous humour responsible for maintaining IOP in the eye. In a study based on 
a mouse knock-down model of p120 catenin, a member of the same protein family as PKP4 
(the p120 catenin family), severe developmental defects were observed in the anterior segment 
of the eye, including ciliary body and trabecular meshwork tissues [276]. Further research on 
PKP4 and its role in cell adhesion and IOP regulation in both the ciliary body and trabecular 
meshwork is necessary. There are five isoforms of PKP4 (NM_003628.5, NM_001005476.3, 
NM_001304969.2, NM_001304970.2 and NM_001304971.1) and the variant identified in this 
study only affects four of them (not NM_001304971.1). The summary RNAseq data available 
to our study did not provide the level of detail necessary to confirm which transcripts were 
present in the ocular tissues. It is necessary to identify which mRNA transcripts are expressed 
in the relevant tissues of the eye to determine whether the PKP4 variant could potentially play 
a functional role in IOP regulation.  
Figure 5-14 shows the POAG disease status of family GTAS54 and identifies the PKP4 variant 
carriers. Of the eight people identified in family GTAS54 who carry this PKP4 variant, four 
had a confirmed POAG diagnosis, three were suspected to have POAG and one had no 
diagnosis at their last clinical examination. This person (1158644) had elevated IOP of 
24mmHg (well above the ascertainment correction population mean of 15mmHg), but was not 
yet exhibiting optic nerve damage characteristic of glaucoma. At 49 years old at their last 
clinical examination, this person may have since developed POAG, but this is currently 
unknown. Although this is not enough evidence to state a link between this variant or gene with 















Figure 5-13 Family GTAS54 indicating POAG disease status and carriers of the PKP4 variant,  
rs148782148. Blue arrows indicate variant carriers. Identification number = the first string of numbers 




The chromosome 2 QTL is complex, with three families contributing to the observed linkage 
signals. This peak reached the suggestive significance threshold (LOD=1.86), which was used 
to select linkage regions identified in Chapter 4, due to the contribution of the three families 
together. Although the families’ linkage signals did not reach suggestive significance 
individually, that does not mean the linkage peak is not worth further consideration. Lander 
and Kruglyak (1995), propose that linkage peaks are still worth investigating with a nominal 
p-value = 0.05 which is equivalent to a LOD score of 0.59, as long as it is understood that there 
will be false positive results obtained [232]. Using the reduction in LOD, when linkage was 
conducted conditional on the measured genotype of these variants, as a proxy for the LOD 
score of that family’s contribution, allows each of these families’ contributions to be assessed. 
At least one variant was identified in each family which reduced the LOD score by at least 1 
LOD unit (Table 5-3). This linkage region may represent a true and coincidental finding of 
three families with IOP regulating genes within close proximity to each other. Conversely, this 
region may represent one or more false positive signals. Further research is necessary to 
confirm whether each of the three families do indeed provide a true linkage signal in this region. 
When each of the families were analysed separately, promising candidate genes were identified 
in two of the families. FMNL2 in Family 98002 has already been associated with IOP and 
PKP4, in Family GTAS54, is a novel, but plausible candidate for IOP. 
Of the other linkage regions assessed in this study, there is less evidence for the identification 
of candidate genes than for the chromosome 2 and 15 regions. The chromosome 9 linkage peak 
was the most significant, reaching a LOD score of 4.25. Family 93001 was predicted to 
contribute most to this peak and two variants identified in the same members of this family, 
over a million bp apart, were responsible for the largest reduction in the linkage peak (Figure 
5-2). Thus there is still part of this family’s contribution to the peak which is unaccounted for. 
Of the two genes in which variants were identified; NSMF and ENTR1, the variant in NSMF 
had the highest CADD score and this gene had greater expression in the ciliary body and 
trabecular meshwork in our RNAseq database (NSMF was not included in the OTD). NSMF 
has a well-recognised role in growth and migration of specific neuronal cells [277], but as yet, 
no involvement with the eye. The fact that two variants spanning a region over 1Mb, including 
over 50 genes, were identified in the same individuals suggests that these variants could be 
tagging the true functional variant which has not been sequenced in the WES of this study. No 
IOP or POAG genes have been identified in this region of chromosome 9 previously and further 
analysis is necessary. 
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The QTL on chromosome 7 was the only one driven by a single family (Table 5-2 and Figure 
5-1d). Two variants in CALN1, a SNP and an indel around 240bp apart, identified in the same 
14 individuals of family 98002, had the greatest reduction on the linkage peak (Figure 5-6). 
Although their CADD scores do not predict deleterious functional consequences, the sites are 
evolutionarily conserved (Table 5-4), suggesting a selection pressure against changes at these 
sites. CALN1 showed only minimal expression in the ciliary body and trabecular meshwork in 
our RNAseq database and the OTD plier scores were the lowest of the genes with OTD 
expression results (Table 5-5). The expression of CALN1 is highest in the brain and it may play 
a role in the physiology of neurons [278], however, there is no link to eye physiology. Taken 
together, it is unlikely that CALN1 itself is the functional gene driving the chromosome 7 
linkage peak. Further sequencing in the 14 individuals of family 98002, who carry this variant 
which drives the linkage peak, may yield more promising results in finding a candidate gene 
for IOP regulation. The closest gene to CALN1 associated with POAG is ELN, around 2Mb 
away, which was identified along with other novel loci in a large multi-ethnic GWAS [111], 
although this variant from the GWAS was not associated with IOP. It is possible that Family 
98002 carry a variant in a novel IOP gene which is yet to be identified and further research is 
necessary to confirm this. 
Two variants in the same nine members of family GTAS54 were prioritised in the chromosome 
3 linkage interval. One of these variants is in FAM86DP, a pseudogene which codes for non-
coding RNA. This gene is not highly expressed in the ciliary body or trabecular meshwork and 
its function is unknown. The other variant is in PDZRN3, a gene which is more highly 
expressed in the relevant ocular tissues than FAM86DP and many of the other genes assessed 
in this study (Table 5-4). PDZRN3 may be involved in the development of blood vessels [279] 
and the differentiation of other cell types [280-282], but currently, a role for this gene in IOP 
or glaucoma has not been established. It is possible that these variants are on the same 
haplotype as the true functional variant, which has not been sequenced in the WES of this 
study. Further investigation with family GTAS54 is necessary to identify possible IOP 
candidate genes in this linkage region. 
The chromosome 6 linkage region did not provide any prioritised variants or genes. This was 
the least significant linkage peak of all the identified linkage regions in this study. This region 
of chromosome 6 had poor sequence quality in this study and would need to be re-sequenced 
to confirm the linkage region identified here and to identify possible variants and genes of 
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interest. Currently it is premature to propose possible IOP candidate genes from this linkage 
peak. 
Although this study has not conclusively identified variants with functional relevance involved 
in IOP regulation, linkage analysis has narrowed down the genome-wide search space to QTLs 
across six chromosomes. Potential candidate genes have been identified on chromosomes 2 
and 15. Two interesting candidate genes, worthy of further consideration, have been proposed 
from the chromosome 2 QTL. FMNL2 has already been associated with IOP and may be 
important in IOP regulation in Family 98002. PKP4 is a novel IOP gene proposed in our study, 
with the identified SNP, rs148782148, itself a possible functional variant in family GTAS54. 
HERC2, on chromosome 15, is also proposed as a gene which may be involved in IOP 







The research presented in this thesis represents a novel contribution to our understanding of 
the genetic influences to POAG risk in large families. This study utilised whole exome 
sequencing data from large, extended families with clinical intermediate traits of glaucoma to 
identify variants involved with susceptibility to POAG. The families were large, 
multigenerational, enriched for POAG and were a valuable resource enabling this study to be 
conducted. In total, the five families consisted of over 500 family members with the older 
generations linking multiple branches of the later generations. Over 300 participants provided 
clinical data with 249 of these providing DNA samples, from which WES was conducted. This 
study analysed IOP and VCDR which are genetically correlated endophenotypes for POAG, 
as well as CCT, a POAG risk factor. The core analyses of this study were conducted blind to 
the POAG disease status which was only revealed after all analyses were completed. 
The main focus was to identify novel variants and genes which influence POAG risk in the 
families. Before this could be undertaken, it was important to determine whether previously 
identified variants and loci affect the POAG risk in these families. A comprehensive database 
was established (Appendix B) with loci associated with POAG and its clinical intermediate 
traits identified from GWAS, candidate gene association studies and linkage studies. These loci 
were tested for association in the families using measured genotype association (MGA), a 
family-based association test conducted within a variance components framework using 
SOLAR. Significant association results were only obtained from within the linkage region loci, 
with no variants reaching significance from the previously associated SNPs or 20kb windows 
around these SNPs. Within the linkage regions, rs114429531 in MST1 and three variants on a 
presumed haplotype in FLRT3, with large effect size and contribution to IOP variance, are 
worthy of further consideration. Overall, the published loci were not significantly associated 
with the clinical traits in these families. This analysis was only able to be conducted within 
WES regions due to the restricted coverage of whole exome sequencing.  
With the recent advancement of polygenic risk score (PRS) analysis, it would be possible to 
genotype these family members for identified POAG or IOP risk loci and assess their genetic 
risk more broadly. Although PRS analysis is generally applied in case-control cohorts [81, 
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283], its use within families could be beneficial for identifying the common genetic risk 
background upon which the effects of rare variants might contribute [284]. In glaucoma, PRS 
analysis is a recent development [83-85] and has only been tested in case-control cohorts. The 
study by Craig et al. (2020) [83], tested for differences in the penetrance of the MYOC mutation, 
p.Gln368Ter (rs74315329), in different PRS groups and found that this mutation was more 
highly penetrant in those with high PRS scores, which has important implications for families 
carrying this mutation. Understanding the background PRS scores of the families in this study 
may enable a better understanding of the effects of the rare variants identified. 
The research presented in this thesis focussed on identifying rare variants with large effect sizes 
affecting POAG endophenotypes, with the potential to be involved in POAG pathogenesis. 
Linkage analysis using the WES data was conducted to narrow down the genome search space 
and identify relevant variants in these families. Conducting linkage analysis using WES data 
is a more novel, but potentially more cost-effective strategy than conducting linkage using 
microsatellite or SNP array data followed by deeper sequencing [151, 219]. There are very few 
studies which have been published using linkage directly from exome sequencing data and 
these studies have been conducted on much smaller pedigrees than those of our study (for 
example [221, 234]). The use of such large pedigrees to conduct linkage analysis directly from 
exome sequencing data on the clinical intermediate traits of POAG was a novel approach. 
One of the most important factors when conducting linkage analysis is to consider how to 
estimate identity by descent (IBD). The inheritance of alleles shared with a common ancestor 
is the key to linkage analysis. Our study chose to use the IBDLD program [152, 226], which 
was specifically designed for dense genotyping data, and was able estimate IBD between all 
the individuals in the pedigrees. Multipoint IBD matrices were generated and used for linkage 
analysis. Linkage disequilibrium (LD) is problematic in linkage analysis, as if it is not 
accounted for, there may be inflated LOD scores and false positive results [218, 285]. The 
IBDLD program incorporates LD into the estimation tool, rather than requiring LD pruning. 
Other studies conducting linkage directly from sequencing data have inferred genotypes at the 
locations of HapMap SNPs specifically to include common variants in linkage equilibrium 
[221, 234]. Those two studies involve much smaller pedigrees to those used in our study and it 
would be interesting to compare these two approaches to IBD estimation in large pedigrees.  
Multipoint variance components linkage analysis was conducted using SOLAR and corrected 
for ascertainment of the POAG enriched families and the non-normal distribution of the IOP 
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and IOPmed traits, using an empirical LOD adjustment. Not only do these families have more 
POAG individuals than in the general population, but there are more individuals with extremely 
high IOP measures, causing the skewed distribution of IOP phenotype data compared to the 
general population. The VCDR measures were normally distributed and did not require 
ascertainment correction for the linkage analysis. The LOD adjustment conducted for IOPmed 
used a correction constant of 0.59, recognising the inflation of this trait in these families and 
the potential identification of false positive linkage regions. This provided confidence that the 
QTLs which were identified represented true linkage signals. 
The analysis of the IOPmed trait identified six QTLs reaching at least suggestive significance 
(LOD score ≥ 1.86), on chromosomes 2, 3, 6, 7, 9 and 15. Two peaks, those on chromosomes 
9 and 15, reached full significance (LOD score ≥ 3.3). All of the QTLs, other than that on 
chromosome 15, were novel for POAG and its endophenotypes. The chromosome 15 QTL 
identified here completely overlapped the GLC1I locus, with our linkage region and the 
published region displaying very similar shaped peaks [177]. The analysis of VCDR only 
resulted in one suggestive significant peak on chromosome 7. The lack of a significant QTL 
for this trait meant VCDR was not prioritised for further investigation in this study. 
Reanalysing this trait as a dichotomous trait, rather than quantitative, and trying different 
analysis approaches (as discussed in Chapter 5) which may be more suitable to this distribution 
of data, may improve the linkage signals for this trait within these families.  
The IOPmed QTLs were analysed individually, by prioritising variants based on their presence 
in families contributing to the peak, their MGA results and then conducting linkage conditional 
on the measured genotype of the variants. Variants on the presumed haplotype as other 
prioritised variants were also included in downstream analysis. The QTLs on chromosomes 15 
and 2 provided the most promising candidate variants and genes. A variant in HERC2, 
unobserved in the full gnomAD database (located at chr15: 28474713), is proposed as a novel 
variant influencing IOP in this study. This variant was identified in five members of Family 
95002 and was associated with over 10mmHg increase in IOP and contributed to nearly 5% of 
the IOPmed variance. This is a very large increase in IOP when considered that the normal IOP 
is ≤ 21mmHg. 
This is a private variant to Family 95002 and demonstrates the value in using families to 
identify rare variants with large effect sizes. Very recently, the HERC2 locus was associated 
with POAG in a GWAS [83], and as the first reference of HERC2 in the POAG literature, lends 
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additional weight to our findings. Two IOP genes are proposed from the chromosome 2 QTL, 
PKP4 and FMNL2. PKP4 is novel for IOP and POAG, with the identified variant 
(rs148782148) of potential functional relevance itself. This non-synonymous SNP was 
identified in 8 members of Family GTAS54 and was associated with an almost 5mmHg 
increase in IOP and nearly 6% of the IOPmed variance. Although not as rare as the HERC2 
variant, it has only been observed in 0.5% of the European population of the gnomAD database. 
FMNL2 is proposed as the most likely functional gene for IOP on a haplotype identified in 
Family 98002. The same 19 members of this family carry variants in RIF1, NEB and FMNL2. 
FMNL2 has already been associated with IOP and POAG [111, 171], and recently with VCDR 
[83]. Functional studies have proposed this gene’s involvement with IOP, with a knockdown 
of FMNL2 in a human trabecular meshwork cell line inducing morphological changes in the 
cells [111]. That research proposed that the effect on the contractile properties of trabecular 
meshwork cells could affect aqueous humour outflow, with a resultant increase in IOP as the 
mechanism of POAG pathogenesis. 
As FMNL2 variants had previously been identified in the literature, the question might be asked 
as to why the variant identified in this study (rs138926754) did not appear in Aim1 (Chapter 
3), when published SNP loci and 20kb windows around SNP loci were examined for 
association in the families of this study. The variant in our study was in the 20kb window of 
one of the published variants (rs55692468) [171], however, it did not meet the MGA p-value 
nominal significance threshold (p-value = 0.19). Only nominally significant variants were 
discussed in Chapter 3. However, in Chapter 5, this FMNL2 variant was identified on a 
presumed haplotype in the same individuals who also carried the RIF1 variants, which were 
prioritised based on MGA p-value. The FMNL2 SNP identified here is not proposed as the 
functional variant itself, but suggests the gene as a possible IOP regulating gene. Further 
sequencing and functional studies would need to be undertaken to identify possible functional 
variants, including those in regions not sequenced with WES, such as enhancers, long non-
coding RNA and other non-coding regions. 
The use of MGA served different purposes as described in Chapters 3 and 5. For Aim 1 
(Chapter 3), this family-based association test was used to indicate whether previously 
published POAG loci impacted the clinical intermediate traits of POAG in the families of this 
study. For Aim 3 (Chapter 5) this test was used to prioritise variants in the newly identified 
linkage regions. In Aim 1, published POAG linkage regions spanning over 300 million base 
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pairs were tested for association using MGA and only 15 SNPs within 8 loci reached full 
statistical significance after correction for multiple testing. The most significant association 
identified was p = 5.74x10-6 (for rs3755809 with CCT).  
By narrowing the search space to the QTLs identified by linkage analysis, MGA could be used 
as a tool for prioritising variants within these regions, as demonstrated in Chapter 5. A nominal 
significance threshold of p = 0.05 was set for this analysis. Using the MGA results as a 
prioritisation tool, rather than prioritising using CADD scores and other in silico functional 
tools, retains the kinship information inherent in these families. This is an analysis designed 
for quantitative traits in families and it was important to retain as much familial information as 
possible. In diseases with a clear cut affected/unaffected diagnosis, the segregation of 
functional variants with disease is a first line prioritisation tool, which can then be followed by 
using CADD scores and other measures of deleteriousness. However, our study has used 
quantitative traits, rather than a discrete POAG diagnosis, and it was important to use the 
kinship information of the families to follow the inheritance of haplotypes which influence the 
proportion of trait variation in these families. These haplotypes can then be analysed further 
with targeted sequencing to identify variants with potential functional relevance. This is 
exemplified with the identification of the risk haplotype, spanning RIF1, NEB and FMNL2 in 
the same 19 members of Family 98002. Some of the variants in these genes had MGA p-values 
above the nominal threshold, but reduced the linkage peak to similar levels as variants with p-
values less than 0.05 when included in the linkage as covariates. So although MGA was a 
valuable tool in prioritising variants, it was necessary to also look beyond the p-values when 
selecting variants and genes of interest. 
The identification of variants of interest relied on the reduction of the linkage peak when 
linkage was conducted conditional on the measured genotype of the variants being tested. If 
the linkage peak was reduced when the variant was included as a covariate, that variant was 
prioritised within that linkage region. One of the limitations with this approach is that this is 
not a sensitive method for testing each variant. Firstly, any variant in the same combination of 
individuals and with the same dosage of this allele, will produce the same results when included 
in the linkage model. This was observed, for example, in nine members of Family GTAS54 
with the variants identified in TTC21B (rs572065013) and DLX1 (rs186854626), which are 
located over 6 million bp apart on chromosome 2. This is likely to be the same haplotype in 
these individuals, although this would need to be validated. 
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Another limitation of linkage conditional on measured genotype, is that an additive model is 
assumed, with the heterozygous variant carrier halfway between the two homozygotes [246]. 
This model may not necessarily be appropriate for all variants; however, it is a practicable 
model when the true underlying model is unknown. Linkage conditional on measured genotype 
is a coarse method for identifying variants of interest which then need to be followed up with 
supporting evidence. Other factors need to be assessed, for example the measured genotype 
association results, including whether the variant accounts for much of the trait’s variance and 
the effect on IOP (beta-value) as well as whether they are predicted to have functional 
consequences. 
There are several strengths and limitations to be recognised in this body of research. A major 
strength is the families which were recruited into this study. They are large, both in depth and 
width, and enriched for glaucoma, with a higher rate of POAG than the general population. 
Recruitment of families such as these, with a complex, late-onset disease, is difficult. By the 
time the disease has manifested, many family members, such as parents and siblings, may 
already have died, while offspring may still be too young to manifest disease. To have access 
to both clinical and DNA data from so many individuals in these multigenerational families 
has provided a strong foundation for this research. Although clinical and DNA data were 
predominantly available for the younger members, these families were linked by 
comprehensive and well curated genealogical information, which provided more power to 
estimate trait heritabilities and to conduct linkage analysis [286]. Over 300 of these family 
members provided clinical data, however, CCT measures were only obtained from 186 of these 
(148 also with sequencing data), due to these measurements commencing routinely later in the 
study, limiting the power to use this trait for linkage analysis. The highly significant 
heritabilities for all of the traits obtained in these families, provided the power to conduct the 
association and linkage analyses. However, the p-values for trait heritabilities were not 
significant when families were modelled individually. Hence, to determine family contribution 
to the QTLs and retain power (significant heritability p-values), four families were tested at a 
time, with one family excluded in turn. 
The use of quantitative traits was a strength of this study. A POAG diagnosis can be subjective, 
when a certain threshold of vision loss and nerve damage is reached. But the use of objective 
quantitative traits, which can be measured in individuals with and without POAG, provides 
more power for linkage and association [42, 220, 287]. The fact that these clinical 
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measurements were taken over multiple time-points for most of the family members in this 
study improves the chance that more representative measures for these traits were used, rather 
than just a single measurement at one time-point (described in Chapter 2.3). The use of 
intermediate traits to study complex disease is now well recognised [37, 42, 68, 127] and 
provides a strategy to simplify the genetic architecture. The use of a variance components 
framework for the linkage analysis allowed a decomposition of the total trait variance into QTL 
specific variances and provided confidence that the linkage signals for IOPmed were 
independent and not the result of false signals. 
The WES sequencing data provided both strengths and limitations to this study. The strength 
in using WES sequencing rather than microsatellite markers or SNP arrays is that variants of 
potential functional significance within coding regions can be identified from the linkage 
regions, without the need for further sequencing. The PKP4 variant within the chromosome 2 
linkage region is a potentially functional variant involved in IOP regulation, which was 
identified directly from the QTL. However, most of the variants which were prioritised within 
the linkage peaks were not necessarily good functional candidates themselves. The identified 
variants may be tagging the true functional variants on the same haplotype. Either these variants 
were not sequenced in the WES, or they were sequenced, but did not meet quality thresholds 
(80% high confidence calls). Although the sequencing quality may have affected a few 
variants, we believe that many of the true functional variants lie in non-coding regions of the 
genome and were not sequenced in this study, as evidenced by the predominance of significant 
non-coding hits in recent GWAS (for example, [83, 85, 111]).  
The importance of non-coding variants in complex disease is becoming better understood as 
research has increased in this area.. In POAG, the most replicated locus is CDKN2B-AS1, a 
long non-coding RNA [91, 99] (Appendix B). In a study on another highly replicated POAG 
locus, a variant in the enhancer of SIX6 resulted in increased expression of the gene and 
dysregulation of protein expression [108]. In a study assessing variants in miRNA coding genes 
in POAG, an association was found with a common variant in MIR182, particularly in the high-
tension glaucoma subset [288]. In another study using data extracted from a GWAS in which 
variants were identified in miRNAs as well as 3’UTRs in miRNA binding sites, associations 
were identified with two miRNA variants and VCDR and cup area, as well as associations 
between 47 3’UTR sites with VCDR, IOP and cup area [289]. That study exemplifies not only 
that SNPs identified in GWAS may represent tagging of the true functional variant in LD but 
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that the GWAS SNPs themselves may be the true functional variants in non-coding regions 
[290]. If the variants identified in our study are not the true functional variants themselves, 
targeted sequencing of the candidate gene is required to identify more plausible candidates.  
Following on from the research presented in this thesis, there are several areas for further 
investigation. The first task is to use Sanger sequencing [291] to validate the variants identified 
in HERC2, PKP4 and FMNL2 (from Aim 3) as well as the MST1 and FLRT3 variants (from 
Aim 1). Once accurate genotyping has been confirmed, screening these variants, and other 
variants in the same genes, in large case/control cohorts, for example the Australian and New 
Zealand Registry of Advanced Glaucoma (ANZRAG) cohort [292] may identify differences in 
allele frequency between cases and controls and indicate promising variants and genes. This is 
exemplified in a study which screened GWAS identified POAG and endophenotype genes in 
the WES sequencing data of the ANZRAG cohort and compared it with sequencing data from 
controls [147]. Rare, predicted pathogenic variants within CARD10, a gene associated with 
VCDR and optic disc parameters, were found to be enriched in the POAG cohort. Testing for 
enrichment of the variants and other variants in the genes identified in our study in the 
ANZRAG cohort may be able to prioritise genes for further analysis. Targeted sequencing of 
genes identified in the families of this study may also lead to the identification of more 
promising variants, including non-coding variants. Promising candidate genes could be taken 
into cell lines of appropriate ocular tissues, such as trabecular meshwork, ciliary body, and 
retinal ganglion cells and knocked down or mutated to investigate their effects. The FMNL2 
functional research discussed above, involving gene silencing, was conducted in a human 
trabecular meshwork cell line [111]. Although retinal ganglion cells are difficult to grow in 
culture, promising research has been conducted on OPTN mutations inducing cell death in a 
cell line expressing markers of retinal ganglion cells [293, 294]. 
The WES data generated for our study provided rich information which can be used further to 
enhance the research presented here. Copy number variants (CNVs) were not assessed in our 
study, and with recent advances in tools for detecting CNVs [295], may prove to be a valuable 
pathway to follow. The TBK1 CNV is well recognised in causing 1% of NTG cases [57, 61, 
62]. Other, as yet unidentified CNVs may be involved with the clinical intermediate traits of 
POAG in the families of this study. The WES data could also be used as a scaffold to impute 
data in non-coding regions of the genome. Linkage analysis could then be conducted on the 
expanded dataset, which may lead to the identification of novel peaks for IOP and/or VCDR. 
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Any identified peaks would need targeted sequencing to identify variants of interest. As WES 
data is only rarely used in linkage analysis, imputing from WES data prior to linkage analysis 
would provide an innovative strategy to search for linkage regions in non-coding regions. 
Although not a linkage analysis methodology, imputation from WES data was successful in 
identifying uncommon variants involved with quantitative traits of blood cell disorders [296].  
Another strategy for enhancing the WES data of this study would be to phase the genotypes 
and search for compound heterozygous variants in these families. CYP1B1 is a gene important 
in the pathogenesis of glaucoma [65-67] and compound heterozygotes have been associated 
with more severe forms of POAG [297], JOAG [298] and PCG [299]. Identifying compound 
heterozygous variants would be novel for the clinical intermediate traits of POAG and worthy 
of further investigation. 
The research conducted in this study was based on a linkage analysis methodology to identify 
rare variants. Non-linkage based methods are also suitable for rare variant identification with 
the WES data presented here. Software such as; RVTESTS [300], famSKAT [301], gskat [302] 
and MONSTER [303] were designed to detect association of rare variants with quantitative 
traits in family based data. Recently, RVTESTS was used, in conjunction with other software, 
to identify novel loci associated with IOP, VCDR and POAG [304]. Although that study was 
a meta-analysis of GWAS data, and not family based, RVTESTS was also designed to detect 
association of rare variants in related individuals [300]. The use of such software, with the 
WES data from our study, will provide a complementary approach to the linkage analysis 
presented in this dissertation, in searching for rare variants associated with POAG. 
The ultimate goal of genetics research on POAG is to improve the diagnosis and treatment for 
this complex disease. Considering that 50% of Australians currently living with POAG are 
undiagnosed [6], improved screening for this disease is necessary to prevent permanent vision 
loss. Genetic screening has the potential to identify at risk individuals, preferably before vision 
loss occurs. With our current understanding of glaucoma genetics, with a few rare causative 
mutations along with hundreds of variants each associated with a slightly increased risk, there 
is no justification for genetic testing of POAG at the population level [305]. However, for at 
risk populations, such as family members of those with POAG, or those with high IOP, 
polygenic risk score analysis is providing potential for predicting the chances of developing 
this disease, the severity and even the need for surgery [83-85, 248]. For those families carrying 
a MYOC mutation, there is much promise with predictive genetic testing, identifying at risk 
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family members at an earlier stage than those who presented through clinical pathways [54, 
80]. Potentially, if the variants or genes identified in our study prove to be of functional 
importance in regulating IOP, genetic testing could be offered to the members of that family, 
allowing for more regular monitoring of IOP and possibly an earlier intervention with pressure 
reducing medication.  
Finding novel genes involved with IOP as well as confirming genes already identified, can only 
improve our understanding of the biological pathways involved with the pathogenesis of 
POAG. This study has proposed a novel gene for IOP, PKP4, as well as a gene already 
identified as involved with IOP, FMNL2. In the gene interaction analysis, there were identified 
protein interactions between CDH1 with both FMNL2 and PKP4. All three of these proteins 
are involved with cell-cell adhesion complexes [111, 253, 274], however, PKP4 is novel to 
IOP and glaucoma. The interaction of PKP4 with CDH1, which itself has an interaction with 
FMNL2 and which are both recognised IOP genes, is a promising finding. The novel HERC2 
variant is also a promising finding, not only because of its associated effect on IOP in the 
variant carriers, but this locus has also recently been associated with POAG [83]. Although no 
mechanisms of involvement were suggested in that study, the research conducted here may 
propose an IOP mediated pathway. 
A better understanding of the genetics of POAG and the biological pathways in which these 
genes act, will allow for a greater variety of treatments in the future [78]. Exciting 
developments using CRISPER-Cas9 technology [306] have the potential for targeted and 
permanent genetic therapies. For example, mutant MYOC genes have been knocked down in 
human trabecular meshwork cells and in a mouse model to reduce IOP, and has the potential 
to revolutionise treatment for those carrying MYOC mutations [307]. A less personalised 
approach, but perhaps more beneficial to a larger group of individuals, is the promising 
research on using the same technology to knock down the aquaporin 1 gene (AQP1), involved 
with aqueous humour secretion from the ciliary body [308]. Although variants in this gene 
were tested but found not to be associated with POAG [309], this gene is believed to be 
involved with actin fibre reorganisation with possible effects to trabecular meshwork cell 
contractility [310]. FMNL2 is also believed to affect actin fibres in trabecular meshwork cells 
[111] and future research may possibly find a biological link between these two genes. The 
aquaporin knockdown study [308] demonstrated successful trials in mouse models and human 
tissue culture and propose that a single injection into the eye can target the ciliary body to 
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permanently reduce IOP. As more genes involved with POAG and it endophenotypes are 
uncovered, a better understanding of the pathogenesis of this complex disease will be 




This novel study has investigated the genetic susceptibility to POAG by searching for rare 
variants with large effect sizes in the whole exome sequencing data of extended families. 
Several rare variants associated with IOP increase were identified, demonstrating enrichment 
in the families of this study and validating the use of extended pedigrees in complex disease 
research. These rare variants may not yet be useful targets for population-wide screening as 
POAG risk alleles, but they are useful within the families themselves, allowing family members 
who are carriers earlier and more frequent IOP monitoring. The variants identified in this study 
propose novel genes for involvement with IOP; MST1, FLRT3, PKP4 and HERC2, whilst also 
proposing FMNL2 which had previously been associated with IOP and POAG. The recent 
association of the HERC2 locus with POAG in an independent study, in parallel with our study, 









Appendix A General Methods Scripts 
A.1 Configuration file for bcbio variant calling 
# Template for whole genome Illumina variant calling with GATK pipeline 
# Saved as config_file-template.yaml 
 details: 
   - analysis: variant2 
     genome_build: hg19 
# to do multi-sample variant calling, assign samples the same metadata / batch 
# metadata: 
# batch: allvariants 
 
     algorithm: 
       aligner: false 
       recalibrate: false 
       bam_clean: remove_extracontigs 
       variantcaller: gatk-haplotype 
       jointcaller: gatk-haplotype-joint 
# for targeted projects, set the region 
variant_regions: ~/TruSeq-Exome-Targeted-Regions.bed 
 resources: 
   samtools: 
     cores: 1 
   sambamba: 




A.2 Vcf annotations 
A.2.1 Script to add GATK filtering tags to genotype calls 
java -Xmx4g -jar /gd/apps/GATK/GenomeAnalysisTK.jar \ 
-R /gd/apps/gatk-bundle/hg19/ucsc.hg19.fasta \ 
-T VariantFiltration \ 
-o output_file_name.vcf \ 
--variant input_file_name.vcf \ 
--genotypeFilterExpression "DP >= 10 && GQ >= 20" --genotypeFilterName 
"High_Confidence" \ 
--genotypeFilterExpression "DP < 10 && GQ < 20" --genotypeFilterName 
"Low_Confidence" \ 
--genotypeFilterExpression "DP < 10 && GQ >= 20" --genotypeFilterName 
"Low_coverage_High_quality" \ 
--genotypeFilterExpression "DP >= 10 && GQ < 20" --genotypeFilterName 
"High_coverage_Low_quality" 
 
A.2.2 ANNOVAR annotation of vcf file 
table_annovar.pl input_file_name.vcf \ 
/gd/apps/annovar-2018Apr16/humandb -buildver hg19 \ 
-out input_file_name_annotated.vcf \ 







-operation g,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f,f \ 
-nastring . -vcfinput  
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A.3 R script converting bcbio called vcf to dosage file for MGA 
# Script to convert bcbio SNPs and indels vcf files (un-annotated) to dosage file suitable for 
running MGA in SOLAR 
# All columns need names.  
library(tidyr) 
library(dplyr) 
# Remove the # before the CHROM in the heading, or it won't be read in 
POAG <- read.table(file = "input_file_name.vcf", 
                   sep="\t",header=TRUE,as.is=TRUE,na.strings=".",  
                   stringsAsFactors = FALSE, colClasses = "character")  
# Convert ./. reads to blank cells. Note the . needs to be "escaped" and the . at the end will 
match any character. 
POAG <- as.data.frame(sapply(POAG,gsub,pattern="[.]/[.].*",replacement=""))  
# To filter variants to get rid of the really rare ones. 
# Count the number of heterozygous variant calls each variant in the file and add this as a new 
column in the vcf file 
# The ^ is to only count the genotypes at the beginning of the each cell (the info column has 
"unwanted" genotypes in it) 
# The [/|] is to pick up both unphased and phased genotypes. Prob won't make a difference 
here, but might for future runs 
POAG$het_counts <- apply(POAG, 1, function(x) 
                   sum(grepl('^[1-9][/|]0|^0[/|][1-9]', x))) 
# Count the number of homozygote variant calls each variant in the file and add this as a new 
column in the vcf file 
POAG$hom_counts <- apply(POAG, 1, function(x)  
                   sum(grepl('^[1-9][/|][1-9]', x))) 
# Create another column which adds 1 per het count and 2 per homozygous count 
POAG$total_counts <- (POAG$het_counts + 2*POAG$hom_counts) 




filtered_between <- filter(POAG,  
                    (POAG$total_counts >= 5 & POAG$total_counts <= 494)) 
# After filtering, delete the 3 columns which I added in to do the counts (columns 259 to 261) 
filtered_POAG <- filtered_between[, -c(259:261)] 
# Replace remaining variant strings with counts 
  ## the ^ ensures that the genotype at the start of the cell is replaced. 





# But some indels (not many though) are multiallelic. So anything which is 0/* or */0 will be 





# And for the homozygous multiallelics 
filtered_POAG <- as.data.frame(sapply(filtered_POAG,gsub,pattern="^[1-
9]/[1-9].*",replacement="2")) 
# Make the dosage file of all variants 
# adds a new ID column into the data.frame which is what will be used for the variant ID for 
SOLAR 
filtered_POAG$New_ID <- paste(filtered_POAG$CHROM, filtered_POAG$POS, 
sep="_") 
# Subsets out just the genotypes (dosages) for the samples, 
POAG_subset <- subset(filtered_POAG, select = 10:258) 
# Make the row names of the subset be the new variant idenifier made above, prefixed by snp_ 
which is required in SOLAR 
rownames(POAG_subset) <- paste("snp_",filtered_POAG$New_ID, sep="") 
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# Flip the data.frame around so samples are now rows instead of columns and genotypes are 
columns instead of rows 
transpose_POAG_subset <- as.data.frame(t(POAG_subset)) 
# remove the X from the row names 
row.names(transpose_POAG_subset) <- 
gsub("X","",row.names(transpose_POAG_subset)) 
# Quality control step 
## we work with a matrix (because nchar not vectorized for data.frame ) 
## nchar returns 0 for "" and 1 for "0" "1" or "2" 
test <- nchar(as.matrix(transpose_POAG_subset)) 
## plot the sums so we get a sense 
plot(colSums(test)) 
## create a logical vector to identify columns to keep 
## colSums is a vector of counts of TRUE based on test above 
keep <- colSums(test) >= (nrow(test) * 1/2) 
## finally apply our identifier to extract the columns to keep (≥ 50% dosages per variant) 
clean <- transpose_POAG_subset[, keep] 
# write out to csv for SOLAR input 
write.table(clean, file = "trait_dosages_date.csv", quote = FALSE, sep = 
",", na = "NA", row.names = TRUE, col.names = TRUE) 





A.4 Measured genotype association analysis in SOLAR 
# load pedigree and phenotype files 
## full pedigree and phenotype files used (531 family members) 
load ped pedigree_file.ped 




# covariates to be included 
# abbreviation of interactions of age and age2 with sex 
covar age^1,2#sex study 
# to run variance components modelling, only including the significant covariates 
polygenic -screen 
# to run measured genotype association analysis 




A.5 Example linkage diagram R script 
# This script is to create plots with multiple lines superimposed and a legend on the bottom. 
# For all the chromosomes in a grid pattern 
 




# Read in file (5 columns - Chromosome, Location 3 different LODs)  
trait <- read.table("table_with_multipoint_results.txt", \ 
header = TRUE, sep = "\t") 
# Adjust data into "long format"  
trait_long <- gather (trait, IOP, LOD, 3:5, -Chromosome) 
 
# Draw graphs - 1 box for each autosome. Comparing 3 traits in the same graph 
ggplot(data=trait_long, 
      aes(x=Location, y=LOD, colour=IOP, linetype=IOP)) +  
      theme(legend.position = c(0.45, 0.05), 
      legend.title = element_blank(), 
      axis.title.x = element_text(hjust=0.18)) + xlab('Location (cM)') +  
      facet_wrap( ~ Chromosome, switch = "x") + 
      scale_colour_manual(values = c('blue','magenta', 'green4')) + 
      scale_linetype_manual(values = c(1,1,1)) + 
      geom_line(size = 0.5) + 
      geom_hline(yintercept=3, lty="solid", colour = "grey50, size=0.5") + 





Appendix B POAG loci database 
 
Key - column headings: 
SNP/indel = single nucleotide polymorphism / insertion or deletion 
MIM number = genotype or phenotype number from the Online Mendelian Inheritance in 
Man catalogue (http://omim.org/) 
Locus = location of the nearest gene 
Chr = chromosome number 
Chr. position (bp) = base pair position of each SNP in the two most recent human genome 
assemblies as found in the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/). 
POAG = primary open-angle glaucoma 
IOP = intraocular pressure 
VCDR = vertical cup to disc ratio 
CCT = central corneal thickness 
ODA = optic disc area 
OCA = optic cup area 
 
 
Key – body of table 
1 = association found between SNP and POAG or endophenotype. 
0 = no association found between SNP and POAG or endophenotype. 
J = juvenile open angle glaucoma 
N = normal tension glaucoma 
 
C = control cohort 
D = discovery cohort 
R = replication cohort 
NTG = normal tension glaucoma cohort 
HTG = high tension glaucoma cohort 
AS = association study using a candidate gene approach  
GWAS = genome-wide association study 
GWAS (Ped.) = genome-wide association study using pedigrees 
LS = linkage study 
































NIES Norfolk Island Eye Study 
NL Netherlands 
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indel PRDM16 PR domain containing 16 605557 1p36.32 1 3,046,430 3,129,866   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs12028027 PRDM16 PR domain containing 16 605557 1p36.32 1 3,050,331 3,133,767   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs2252865 RERE RE repeats-encoding gene 605226 1p36.23 1 8,422,676 8,362,616 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs301801 RERE RE repeats-encoding gene 605226 1p36.23 1 8,495,945 8,435,885   1   EU, AS GWAS 27,878 





607093 1p36.3 1 11,856,378 11,796,321 1     GE AS 218 





607093 1p36.3 1 11,856,378 11,796,321 0     IR AS 248 





607093 1p36.3 1 11,856,378 11,796,321 1     SA AS 210 Al-Shahrani et al., 2016 





1     AU AS 113 Tunny et al., 1996 [181] 
rs873458 MFN2 mitofusin 2 608507 1p36.2 1 12,046,089 11,986,032 N     GE AS 567 Wolf et al., 2009 [313] 
rs2295281 MFN2 mitofusin 2 608507 1p36.2 1 12,059,412 11,999,355 N     GE AS 567 Wolf et al., 2009 [313] 
rs11588779 MFN2 mitofusin 2 608507 1p36.2 1 12,082,881 12,022,824 N     GE AS 567 Wolf et al., 2009 [313] 
rs3924048 DHRS3 
short-chain dehydrogenase / 
reductase family, member 3 






Springelkamp et al., 
2015 [134] 
rs274754 COL8A2 collagen, type VIII, alpha-2 120252 1p34.2 1 36,565,617 36,100,016    1  US-Cau AS 100 
Desronvil et al., 2010 
[314] 
rs96067 COL8A2 collagen, type VIII, alpha-2 120252 1p34.2 1 36,571,920 36,106,319    1  US-Cau AS 100 
Desronvil et al., 2010 
[314] 
rs96067 COL8A2 collagen, type VIII, alpha-2 120252 1p34.2 1 36,571,920 36,106,319    1  





Vithana et al., 2011 
[315] 






Cornes et al.,  2012 [316] 






Hoehn et al., 2012 [198] 







Ulmer et al., 2012 [196] 
rs96067 COL8A2 collagen, type VIII, alpha-2 120252 1p34.2 1 36,571,920 36,106,319    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs96067 COL8A2 collagen, type VIII, alpha-2 120252 1p34.2 1 36,571,920 36,106,319    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1866758 HIVEP3 
human immunodeficiency virus 
type 1 enhancer-binding protein 3 
606649 1p34.2 1 42,318,868 41,853,197  1    
D: US, LA, AS, AA 
























































  2   AU LS 
 1 large 
family 
Charlesworth et al., 
2005 [189] 
rs1925953 RPE65 retinoid isomerohydrolase 180069 1p31.3 1 68,848,681 68,382,998 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1192414 CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,075,134 91,609,577 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 





R: 4455  
Ramdas et al., 2010 [99] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540 1     EU AS 45998 Ramdas et al., 2011 [69] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 





R: 9326  
Khor et al., 2011 [317] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540     1 D:NL GWAS D: 23000 
Axenovitch et al., 2011 
[104] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540 0     AF AS 437 Cao et al., 2012 [96] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540     1 AU, NZ AS 1759 Dimasi et al., 2012 [29] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540 1     AS, AF, EU GWAS 
D: 13250 
R: 35953 
Li et al., 2015 [100] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540   1 1  IN AS 468 
Philomenadin et al., 
2015 [105] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 






Springelkamp et al., 
2015 [134] 
rs1192415  CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,097 91,611,540 1     US, L, AS, AA AS 63,412 
Choquet et al., 
2018[111] 
rs4658101 CDC7/TGFBR3 
cell division cycle 7/transforming 
growth factor, beta receptor III 
603311/ 
600742 
1p22.1 1 92,077,409 91,611,852   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs4658101 CDC7/TGFBR 
cell division cycle 7/transforming 





1 92,077,409 91,611,852 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs148639588 COL11A1 collagen, type XI, alpha 1 120280 1p21.1 1 103,272,424 102,806,868 1    1 EU GWAS 
OAG:3071 
C:6750 
Gharahkhani et al., 2018 
[131] 





1     ES AS 452 
Juronen et al., 2000 
[318] 





1     IT AS 87 Izzotti et al., 2003 [319] 





0     SW AS 400 
Jansson et al., 2003 
[320] 





1     TU AS 312 




















































1     SA AS 169 
Abu-Amero et al., 2008 
[323] 





0     CH AS 606 Fan et al., 2010 [264] 













Matovinovic et al., 2017 
[133] 
rs4656461 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,687,205 165,717,968 1     
D: AU, NZ 




Burdon et al., 2011 [91] 
rs4656461 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,687,205 165,717,968 1 1 0 0  AU, NZ AS 1420 
Sharma et al., 2012 
[109] 
rs4656461 TMCO1 
transmembrane and coiled-coil 
domains 1 






Gharahkhani et al.,  
2014 [89] 
rs4656461 TMCO1 
transmembrane and coiled-coil 
domains 1 






Hysi et al., 2014 [86] 
rs4656461 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,687,205 165,717,968 1     BMES AS 
OAG: 67 
C: 1919 
Burdon et al 2015 [95] 
rs4656461 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,687,205 165,717,968 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs7555523 TMCO1 
transmembrane and coiled-coil 
domains 1 






Hysi et al., 2014 [86] 
rs6668108 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24.1 1 165,691,320 165,722,083 1 1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs7524755 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24.1 1 165,694,897 165,725,660 1 1    
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs10918274 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,714,416 165,745,179 1 1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs7555523 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,718,979 165,749,742 1 1    
D: NL 
R: UK, AU, NZ,CA 






van Koolwijk et al.,  
2012 [66] 
rs7518099 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,736,880 165,767,643 1     
D: AU, NZ 




Burdon et al., 2011 [91] 
rs7518099 TMCO1 
transmembrane and coiled-coil 
domains 1 






Gibson et al., 2012 [93] 
rs7518099 TMCO1 
transmembrane and coiled-coil 
domains 1 






Hysi et al., 2014 [86] 
rs7518099 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,736,880 165,767,643  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs7518099 TMCO1 
transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,736,880 165,767,643 1     
Meta-analysis 
US, AU, EU, SC 















































transmembrane and coiled-coil 
domains 1 
614123 1q24 1 165,739,598 165,770,361 1     
D: multi ethnic 





Choquet et al., 2018 
[111] 
rs2239854 F5 coagulation factor V 612309 1q24.2 1 169,525,808 169,556,570   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
indel F5 coagulation factor V 612309 1q24.2 1 169,530,520 169,561,282   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 






Springelkamp et al., 
2015 [134] 
rs10753787 F5 coagulation factor V 612309 1q24.2 1 169,549,775 169,580,537   1  1 EU, AS MA 
IGGC 
>79,000 






induced glucocorticoid response 
protein 











 1 family 
  
Locus: 
Sheffield et al., 1993 [46] 
Gene: 
Stone et al., 1997 [55] 
  OPTC opticin 605127 1q32.1 1     1     IN AS 300 
Acharya et al., 2007 
[325] 
rs4846476 TGFB2 transforming growth factor beta 2 190220 1q41 1 218,526,228 218,352,886    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs596169 MIR548F3 microRNA 548f-3  1q41 1 219,147,419 218,974,077  1    
D: US, LA, AS, AA 









tumor protein p53 binding 
protein 2 
602143 1q41 1 
223,967,595 
 - 224,033,674  
 223,779,893 
- 223,845,972  
1     NL LS 1 family 
Michael, et al., 2017 
[146] 
rs6671926 CDC42BPA 
CDC42 binding protein kinase 
alpha 






Springelkamp et al., 
2015 [134] 






Nakano et al., 2009 [76] 
rs547984 ZP4 zona pellucida glycoprotein 4 613514 1q43 1 238,096,886 237,933,586 0     AF AS 437 Cao et al., 2012 [96] 






Nakano et al., 2009 [76] 






Nakano et al., 2009 [76] 
rs693421 ZP4 zona pellucida glycoprotein 4 613514 1q43 1 238,099,090 237,935,790 0     CH AS 1039 Chen et al., 2012b [326] 
rs693421 ZP4 zona pellucida glycoprotein 4 613514 1q43 1 238,099,090 237,935,790 1     KO AS 1115 Kim et al., 2014 [327] 






Nakano et al., 2009 [76] 
rs13016883 TRIB2 tribbles pseudokinase 2 609462 2p24.3 2 12,877,307 12,737,181 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 






















































latent transforming growth factor 
beta binding protein 1 
150390 2p22.3 2 33,348,494 33,123,427    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs115179432 LTBP1 
latent transforming growth 
factor-beta-binding protein 1 
150390 2p22.3 2 33,348,679 33,123,612  1    
D: US, LA, AS, AA 

















1      TU  LS 
 17 
families 
Sarfarazi et al., 1995 [50] 
rs1800440 CYP1B1 
cytochrome P450, subfamily 1, 
polypeptide 1 
601771 2p22.2 2 38,298,139 38,070,996 1     PA AS 330 Micheal et al., 2015[182] 
rs1800440 CYP1B1 
cytochrome P450, subfamily 1, 
polypeptide 1 
601771 2p22.2 2 38,298,139 38,070,996 1     Mixed MA 8 studies Wang et al., 2015 [183] 
rs1056827 CYP1B1 
cytochrome P450, subfamily 1, 
polypeptide 1 
601771 2p22.2 2 38,302,177 38,075,034 1     PA AS 330 
Micheal et al., 2015 
[182] 
rs1056827 CYP1B1 
cytochrome P450, subfamily 1, 
polypeptide 1 
601771 2p22.2 2 38,302,177 38,075,034 1     Mixed MA 8 studies Wang et al., 2015 [183] 
rs10012 CYP1B1 
cytochrome P450, subfamily 1, 
polypeptide 1 
601771 2p22.2 2 38,302,390 38,075,247 1     PA AS 330 
Micheal et al., 2015 
[182] 
rs2617266 CYP1B1 
cytochrome P450, subfamily 1, 
polypeptide 1 
601771 2p22.2 2 38,302,544 38,075,401 1     PA AS 330 
Micheal et al., 2015 
[182] 
rs3213787 SRBD1 S1 RNA binding domain 1 – 2p21 2 45,646,824 45,419,685 N     D: JA GWAS D: 660 Meguro et al., 2010 
[328] 
rs3213787 SRBD1 S1 RNA binding domain 1 – 2p21 2 45,646,824 45,419,685 1     JA AS 561 Mabuchi et al., 2011 
[329] 
rs3213787 SRBD1 S1 RNA binding domain 1 – 2p21 2 45,646,824 45,419,685 0     AF AS 437 Cao et al., 2012 [96] 





Gibson et al., 2012 [93] 








1      AC, UK LS 
 several 
families 
Suriyapperuma et al., 
2007 [176] 
rs1533428 LOC730100 uncharacterized LOC730100 – 2p16.3 2 51,959,258 51,732,120 1     CH AS 1039 Chen et al., 2012b [326] 
rs7426380 EFEMP1 
EGF containing fibulin-like 
extracellular matrix protein 1 
601548 2p16.1 2 56,095,010 55,867,875  1    
D: US, LA, AS, AA 








extracellular matrix protein 1 
601548 2p16.1 2 56,096,892 55,869,757   1  1 EU, AS MA 
IGGC 
>79,000 




extracellular matrix protein 1 






Springelkamp et al., 
2015 [134] 





1     US LS  sibpairs Wiggs et al., 2000 [190] 
rs6732795 ANTXR1 anthrax toxin receptor 1 606410 2p13.3 2 69,411,517 69,184,385  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs678350 HK2 hexokinase 2 601125 2p12 2 75,062,870 74,835,743 
1 
N 






















































1       LS 
 Several 
families 
Stoilova et al., 1996 
[175] 
rs2033008 NCK2 NCK adaptor protein 2 604930 2q12 2 106,502,585 105,886,129 N     JA AS 246 
Akiyama et al., 2008 
[331] 
rs2033008 NCK2 NCK adaptor protein 2 604930 2q12 2 106,502,585 105,886,129 N     JA AS 1108 Shi et al., 2013 [330] 
rs1800587 IL1A interluekin 1 alpha 147760 2q14 2 113,542,960  112,785,383 1     CH AS 323 Wang et al., 2006a [184] 
rs1143634 IL1B interluekin 1 beta 147720 2q14 2 113,590,390  112,832,813  1     CH AS 163 Lin et al., 2003b [332] 





R: 9014  
Osman et al., 2012 [90] 
rs7588567 NCKAP5 NCK-associated protein 5 608789 2q21.2 2 134,363,032 133,605,461 0     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs56117902 FMNL2 formin-like 2 616285 2q23.3 2 153,304,730 152,448,216 1 1    
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs55692468 FMNL2 formin-like 2 616285 2q23.3 2 153,361,375 152,504,861  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 








1     AC LS 
 several 
families 
Nemesure et  al., 2003 
[187] 
rs56335522 IKZF2 IKAROS family zinc finger 2 606234 2q34 2 213,758,234 212,893,510 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 






Springelkamp et al., 
2015 [134] 
rs1035673 TNS1 tensin 1 600076 2q35 2 218,675,533 217,810,810  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs10189064 USP37 ubiquitin specific peptidase 37  2q35 2 219,327,500 218,462,777    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs121908120 WNT10A 
wingless-type MMTV integration 
site family, member 10A 






Cuellar-Partida et al., 
2015 [333] 
rs121908120 WNT10A 
wingless-type MMTV integration 
site family, member 10A 
606268 2q35 2 219,755,011 218,890,289    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs4608502 COL4A3 collagen, type IV, alpha-3 120070 2q36.3 2 228,134,155 227,269,439    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs7606754 COL4A3 collagen, type IV, alpha-3 120070 2q36.3 2 228,135,180 227,270,464    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs143937055 COL4A3 collagen, type IV, alpha-3 120070 2q36.3 2 228,143,967 227,279,251  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs7599762 COL6A3 collagen, type VI, alpha-3  120250 2q37.3 2 238322885  237,414,242  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs1801282 PPARG 
peroxisome proliferator activated 
receptor gamma 
601487 3p25.2 3 12,393,125 12,351,626 1     IN AS 122 
Chandra et al., 2016 
[334] 



























































Springelkamp et al., 
2015 [134] 
rs11129176 RARB retinoic acid receptor, beta 180220 3p24.2 3 25,049,310 25,007,819   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 







-  54,445,739 
1      AU LS  1 family Baird et al., 2005 [174] 
rs2710323 ITIH1 
inter-alpha-trypsin inhibitor, 
heavy chain 1 






Gharahkhani et al., 2014 
[89] 






Springelkamp et al., 
2015 [134] 
rs6764184 FLNB filamin b 603381 3p14.3 3 58,006,266 58,020,539 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs12494328 FLNB filamin b 603381 3p14.3 3 58,035,497 58,049,770 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs13093086 FOXP1 forkhead box P1 605515 3p13 3 71,055,162 71,006,011  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs34201102 CADM2 cell adhesion molecule 2 609938 3p12.1 3 85,137,499 85,088,348 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs3749260 GPR15 G protein-coupled receptor 15 601166 3q11.2 3 98,250,862 98,532,018    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs2623325 COL8A1 collagen, type VIII, alpha-1 120251 3q12.1 3 99,131,755 99,412,911   1   EU  AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs6804624 COL8A1 collagen, type VIII, alpha-1 120251 3q12.1 3 99,159,147 99,440,303   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1997404 COL8A1 collagen, type VIII, alpha-1 120251 3q12.1 3 99,161,022 99,442,178   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs9860250 ABI3BP 
ABI family, member 3 (NESH) 
binding protein 






Springelkamp et al., 
2015 [134] 
rs9843102 ABI3BP 
ABI family, member 3 (NESH) 
binding protein 
606279 3q12.2 3 100,650,929 100,932,085 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 








1      US LS  1 family Wirtz et al., 1997 [153] 
indel STAG1 stromal antigen 1 604358 3q22.3 3 136,138,073 136,419,231    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 




Wirtz & Keller, 2016 
[336] 
rs1164313 SLC9A9 
solute carrier family 9 member 
A9 




Matovinovic et al., 2017 
[133] 






















































long intergenic non-protein 
coding RNA 1214 / TSC22 domain 
family, member 2 
?/617724 3q25.1 3 150,065,280 150,347,493  1    
D: US, LA, AS, AA 










polymerase / Long intergenic 
non-protein coding RNA 886 




Matovinovic et al., 2017 
[133] 
rs9822953 TIPARP 
TCDD-inducible poly (ADP-ribose) 
polymerase 
612480 3q25.31 3 156,472,071 156,754,282    1  EU, AS GWAS >20,000 Lu et al., 2013 [200] 
rs9822953 TIPARP 
TCDD-inducible poly (ADP-ribose) 
polymerase 
612480 3q25.31 3 156,472,071 156,754,282    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs7636836 FNDC3B 
fibronectin domain III-containing 
protein 3B 
611909 3q26.31 3 171,765,125 172,047,335 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs4894796 FNDC3B 
fibronectin domain III-containing 
protein 3B 
611909 3q26.31 3 171,780,763 172,062,973 1     AS, AF, EU GWAS 
D: 13250 
R: 35953 
Li et al., 2015 [100] 
rs6445046 FNDC3B 
fibronectin domain III-containing 
protein 3B 
611909 3q26.31 3 171,933,252 172,215,462    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs7635832 FNDC3B 
fibronectin domain III-containing 
protein 3B 
611909 3q26.31 3 171,989,276 172,271,486  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs7635832 FNDC3B 
fibronectin domain III-containing 
protein 3B 
611909 3q26.31 3 171,989,276 172,271,486 1 1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs6445055 FNDC3B 
fibronectin domain III-containing 
protein 3B 






Hysi et al., 2014 [86] 
rs4894535 FNDC3B 
fibronectin domain III-containing 
protein 3B 
611909 3q26.31 3 171,995,605 172,277,815    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs7620503 TBL1XR1 transducin-beta-like 1 receptor 1 608628 3q26.32 3 177,304,298 177,586,510    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
indel TBL1XR1 transducin-beta-like 1 receptor 1 608628 3q26.32 3 177,306,757 177,588,969    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs2111534 MFN1 mitofusin 1 608506 
3q25–
3q26 
3 179,090,772 179,372,984 N     GE AS 567 Wolf et al., 2009 [313] 
rs1000002 PARL/ABCC5 
presenilin associated, rhomboid 
like protein / ATP-binding 
cassette, subfamily C, member 5 
607858 
/605251 
3q27 3 183,635,768 183,917,980 N     GE AS 567 Wolf et al., 2009 [313] 
rs1402003 PARL/ABCC5 
presenilin associated, rhomboid 
like protein / ATP-binding 
cassette, subfamily C, member 5 
607858 
/605251 
3q27 3 183,642,879 183,925,091 N     GE AS 567 Wolf et al., 2009 [313] 
rs9853115 DGKG diacylglycerol kinase, gamma  601854 3q27.3 3 186,131,600 186,413,811  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs9853115 DGKG diacylglycerol kinase, gamma  601854 3q27.3 3 186,131,600 186,413,811 1     
D: multi ethnic 






















































long intergenic non-protein 
coding RNA 2052 / crystallin, 
gamma-S 
-/123730 3q27.3 3 186,200,223 186,482,434 1  1   EU GWAS 
OAG:3071 
C:6750 
Gharahkhani et al.,  
2018 [131] 
rs13076750 LPP 
LIM domain-containing preferred 
translocation partner in lipoma 
600700 3q28 3 188,059,443 188,341,655  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs166850  OPA1 optic atrophy 1 605290 3q29 3 193,355,074 193,637,285 N     UK AS 276 Aung et al., 2002 [338] 
rs166850  OPA1 optic atrophy 1 605290 3q29 3 193,355,074 193,637,285 0     Korea AS 166 Woo et al., 2004 [339] 
rs166850  OPA1 optic atrophy 1 605290 3q29 3 193,355,074 193,637,285 1     AF AS 157 Yao et al., 2006 [340] 
rs166850  OPA1 optic atrophy 1 605290 3q29 3 193,355,074 193,637,285 0     GE AS 567 Wolf et al., 2009 [313] 
rs166850  OPA1 optic atrophy 1 605290 3q29 3 193,355,074 193,637,285 0     CH AS 606 Fan et al., 2010 [264] 
rs166850  OPA1 optic atrophy 1 605290 3q29 3 193,355,074 193,637,285 1     UK AS 212 
Yu-Wai-Man et al.,  
2010 [341] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 N     UK AS 276 Aung et al., 2002 [338] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 1     UK AS 110 Powell et al., 2003 [342] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 0     KO AS 166 Woo et al., 2004 [339] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 1     AF AS 157 Yao et al., 2006 [340] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 1     JA AS 570 
Mabuchi et al., 2007 
[343] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 0     GE AS 567 Wolf et al., 2009 [313] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 0     CH AS 606 Fan et al., 2010 [264] 
rs10451941 OPA1 optic atrophy 1 605290 3q29 3 193,355,102 193,637,313 1     UK AS 212 
Yu-Wai-Man et al.,  
2010 [341] 
rs6855176 AFAP1 actin filament-associated protein 1 608252 4p16.1 4 7,753,403 7,751,676 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 






Gharahkhani et al., 2014 
[89] 
rs4619890 AFAP1 actin filament-associated protein 1 608252 4p16.1 4 7,853,160 7,851,433 1     US, L, AS, AA AS 63,412 Choquet et al., 2018 [111] 
rs9330348 AFAP1 actin filament-associated protein 1 608252 4p16.1 4 7,883,887 7,882,160 1     
D: multi ethnic 




Choquet et al., 2018 
rs28795989 AFAP1 actin filament-associated protein 1 608252 4p16.1 4 7,891,545 7,889,818 1 1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs59521811 AFAP1 actin filament-associated protein 1 608252 4p16.1 4 7,909,772 7,908,045 1 1    
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs11732100 AFAP1 actin filament-associated protein 1 608252 4p16.1 4 7,924,690 7,922,963 1     
Meta-analysis 
US, AU, EU, SC 
















































transcription factor 2 
601542 4q25 4 111,963,719 111,042,563  1    
D: US, LA, AS, AA 








matrix protein 3 
608946 4q31.21 4 144,542,213 143,621,060  1    US-Cau GWAS D: 1660 Chen et al., 2015 [143] 
rs5335 EDNRA Endothelin receptor, type A 131243 4q31.2 4 148,463,840 147,542,688 N     JA AS 650 
Ishikawa et al., 2005 
[344] 
rs28789690 NR3C2 
Nuclear receptor subfamily 3, 
group C, member 2 
600983 4q31.23 4 149,077,899 148,156,748    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs3931397 NR3C2 
Nuclear receptor subfamily 3, 
group C, member 2 
600983 4q31.23 4 149,079,497 148,158,346    1  EU, AS MA >20,000 Lu et al., 2013 [200] 








1      UK LS 1 family  Porter et al., 2011 [345] 
rs76325372 ANKH ankylosis,  homolog (mouse) 605145 5p15.2 5 14,837,332 14,837,223 1     
D: multi ethnic 





Choquet et al., 2018 
[111] 
rs72759609 PDZD2 PDZ domain-containing 2 610697 5p13.3 5 31,952,051 31,951,945 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs4865762 MOCS2/FST 
molybdenum cofactor synthesis 
gene 2 / Follistatin 
603708 
/136470 
5q11.2 5 52,582,931 53,287,101  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs61275591 ANKRD55 ankyrin repeat domain 55 615189 5q11.2 5 55,775,556 56,479,729 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs1309531 CWC27 
CWC27 spliceosome associated 
protein homolog 
617170 5q12.3 5 64,306,311 65,010,484    1  
Meta-analysis 
EU, AS 




CWC27 spliceosome associated 
protein homolog / A disintegrin-
like and metalloproteinase with 
thrombospondin type 1 motif, 6 
-/605008 5q12.3 5 64,389,665 65,093,838    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs10471310 ADAMTS6 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 6 
605008 5q12.3 5 64,548,961 65,253,134    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs2307121 ADAMTS6 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 6 
605008 5q12.3 5 64,625,512 65,329,685    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs10064391  ADAMTS6 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 6 
605008 5q12.3 5 64,686,659 65,390,832    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs7717697 VCAN versican 118661 
5q14.2-
5q14.3 
5 82,744,604 83,448,785   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs73220188 FBXL17/FER 
F-box and leucine-rich repeat 
protein 17 / FER tyrosine kinase 
609083 
/176942 
5q21.3 5 108,053,612 108,717,911  1    
D: US, LA, AS, AA 






































































    US  LS 
1 large 
family 
Locus and gene: 
Monemi et al., 2005 [73] 
rs249767 FGF1 fibroblast growth factor 1 131220 5q31.3 5 141,918,585 142,539,020    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1042714 ADRB2 beta-2-adrenergic receptor 109690 
5q32–
5q34 
5 148,206,473 148,826,910  1    JA Gene 745 
Inagaki et al., 2006b 
[186] 
rs17658229 DUSP1 dual-specificity phosphatase 1 600714 5q35.1 5 172,191,052 172,764,049   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs35084382 DUSP1 dual-specificity phosphatase 1 600714 5q35.1 5 172,197,039 172,770,036   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs35028368* ADAMTS2 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 2 
604539 5q35.3 5 178,671,146 179,244,145    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs17756712 EXOC2 exocyst complex component 2 615329 6p25.3 6 625,071 625,071   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs2073006 EXOC2 exocyst complex component 2 615329 6p25.3 6 637,465 637,465 1     
D: multi ethnic 




Choquet et al., 2018 
rs2745572 FOXC1 forkhead box C1 601090 6p25.3 6 1,548,369 1,548,134 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 
rs2745572 FOXC1 forkhead box C1 601090 6p25.3 6 1,548,369 1,548,134 1     US, L, AS, AA AS 63,412 





forkhead box F2 / FOXC1 
upstream transcript, noncoding 
603250 
/ 615976 
6p25.3 6 1,548,369 1,548,134 1 1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 






Gharahkhani et al., 2014 
[89] 
rs11969985 GMDS GDP-mannose 4,6-dehydratase 602884 6p25.3 6 1,922,907 1,922,673 1     US, L, AS, AA AS 63,412 Choquet et al., 2018 
rs4960295 RREB1 
ras responsive element binding 
protein 1 
602209 6p24.3 6 7,205,796 7,205,563   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs4645836 TNFα tumour necrosis factor 191160 6p21.33 6 31,542,476 31,574,699 1     CH AS 464 Wang et al., 2012 [346] 
rs1800629 TNFα tumour necrosis factor 191160 6p21.33 6 31,543,031 31,575,254 1     CH AS 163 Lin et al., 2003 [347] 
rs1800629 TNFα tumour necrosis factor 191160 6p21.33 6 31,543,031 31,575,254 0     AU AS 342 
Mossbock et al., 2006 
[348] 
rs1800629 TNFα tumour necrosis factor 191160 6p21.33 6 31,543,031 31,575,254 1     Iran AS 289 
Razeghinejad et al., 2009 
[349] 
rs1800629 TNFα tumour necrosis factor 191160 6p21.33 6 31,543,031 31,575,254 1     CH AS 606 Fan et al., 2010 [264] 
rs1800629 TNFα tumour necrosis factor 191160 6p21.33 6 31,543,031 31,575,254 1     TU AS 279 















































rs1800629 TNFα tumour necrosis factor 191160 6p21.33 6 31,543,031 31,575,254 1     CH AS 464 Wang et al., 2012 [346] 
rs1043618 HSPA1A Heat shock 70-KD protein 1A 140550 6p21.33 6 31,783,507 31,815,730   1   PO AS 769 Nowak et al., 2015 [351] 
exon 4 TAP1 
transporter, ATP-binding 
cassette, major 
histocompatibility complex 1 





1      CH AS 171  Lin et al., 2004 [352] 
exon 10 TAP1 
transporter, ATP-binding 
cassette, major 
histocompatibility complex 1 





1      CH AS 171  Lin et al., 2004 [352] 
rs72852338 CDKN1A 
cyclin dependent kinase inhibitor 
1A 
116899 6p21.2 6 36,554,240 36,586,463   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs67530707* CDKN1A 
cyclin dependent kinase inhibitor 
1A 
116899 6p21.2 6 36,592,986 36,625,209 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs67530707* CDKN1A 
cyclin dependent kinase inhibitor 
1A 
116899 6p21.2 6 36,592,986 36,625,209 1     US, L, AS, AA AS 63,412 Choquet et al., 2018 
rs6913530 CDKN1A 
cyclin dependent kinase inhibitor 
1A 
116899 6p21.2 6 36,598,209 36,630,432 1     
D: US, L, AS, AA 




Choquet et al., 2018 
rs1801270 CDKN1A 
cyclin dependent kinase inhibitor 
1A 
116899 6p21.2 6 36,651,971 36,684,194 1     CH AS 118 Tsai et al., 2004 [353] 
rs13191376 RUNX2 
runt-related transcription factor 
2 
600211 6p21.1 6 45,522,139 45,554,402    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1396046 PKHD1 
polycystic kidney and hepatic 




6 51,536,992 51,672,194  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs2025751 PKHD1 
polycystic kidney and hepatic 
disease 1 gene 
606702 6p12.3 6 51,622,449 51,757,651  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs735860 ELOVL5 
elongation of very long chain 
fatty acids-like 5 
611805 6p12.1 6 53,123,118 53,258,320 N     D: JA GWAS D: 660 
Meguro et al., 2010 
[328] 
rs1412710 COL12A1 collagen, type XII, alpha-1 120320 
6q13-
q14 
6 75,837,203 75,127,487    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1931656 FAM46A 
family with sequence similarity 
46, member a 
611357 6q14.1 6 82,610,188 81,900,471    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs2875087 TENT5A/IBTK 
terminal nucleotidyltransferase 





6q14.1 6 82,616,083 81,906,366  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs9361886 IBTK 
inhibitor of Bruton 
agammaglobulinemia tyrosine 
kinase 
606457 6q14.1 6 82,778,502 82,068,785    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1538138 IBTK 
inhibitor of Bruton 
agammaglobulinemia tyrosine 
kinase 





















































inhibitor of Bruton 
agammaglobulinemia tyrosine 
kinase 







Ulmer et al., 2012 [196] 
rs1538138 IBTK 
inhibitor of Bruton 
agammaglobulinemia tyrosine 
kinase 
606457 6q14.1 6 82,794,594 82,084,877    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs141917145* RFPL4B ret finger protein-like 4B  6q21 6 113,375,847 113,054,645  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 






Springelkamp et al., 
2015 [134] 
rs868153 HSF2 heat shock transcription factor 2 140581 6q22.31 6 122,389,955 122,068,809   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs2684249 HSF2 heat shock transcription factor 2 140581 6q22.31 6 122,392,511 122,071,365 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs9494457 PDE7B phosphodiesterase 7B 604645 6q23.3 6 136,474,794 136,153,656 1     
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs560713 PDE7B phosphodiesterase 7B 604645 6q23.3 6 136,505,036 136,183,898  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs190298731 UST uronyl 2-sulfotransferase 610752 6q25.1 6 149,059,291 148,738,155 1     
D: AA 
D: HI 
GWAS D: 10,961 
Hoffmann et al., 2014 
[172] 
rs6917589 SOD2 
superoxide dismutase 2, 
mitochondrial 
147460 6q25.3 6 160,099,260 159,678,228 1     CH AS 1413 Zhou et al., 2015 [354] 
rs5746136 SOD2 
superoxide dismutase 2, 
mitochondrial 
147460 6q25.3 6 160,103,084 159,682,052 1     CH AS 1413 Zhou et al., 2015 [354] 
rs4880 SOD2 
superoxide dismutase 2, 
mitochondrial 
147460 6q25.3 6 160,113,872 159,692,840 1 1 1   SA AS 629 
Abu-Amero et al., 2014 
[355] 
  -  6q27 6 
164,500,000 
- 171,115,067  
164,100,000 
- 170,805,979 
 1    BDES LS  Duggal et al., 2005 [188] 
rs41269593 RNASET2 ribonuclease T2 612944 6q27 6 167,343,204 166,929,716  1    US-Cau GWAS D: 1660 Chen et al., 2015 [143] 
indel THBS2 thrombospondin II 188061 6q27 6 169,553,553 169,153,458    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs59072263 GLCCI1/ICA1 
glucocorticoid-induced transcript 
1 / islet cell autoantigen 1 
614283 
/147625 






Blue Mountains Eye 
Study, 2013 [356] 
rs12699251 THSD7A 
thrombospondin type 1 domain 
containing 7A 
612249 7p21.3 7 11,679,113 11,639,486 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs10274998 DGKB diacylglycerol kinase beta 604070 7p21.2 7 14,245,377 14,205,752   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs11763147 VKORC1L1 
vitmain K epoxide reductase 
complex, subunit 1-like 1 
608838 7q11.21 7 65,326,821 65,861,834    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
indel RABGEF1 
rab guanine nucleotide exchange 
factor 1 
609700 7q11.21 7 66,262,284 66,797,297    1  
Meta-analysis 
EU, AS 




















































Cornes et al.,  2012 [316] 
rs4718428 TMEM248 transmembrane protein 248   7q11.21 7 66,421,446 66,956,459    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs149154973 ELN elastin 130160 7q11.23 7 73,322,211 73,907,882 1     
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs1509922 SEMA3C/HGF 




7q21.11 7 80,858,944 81,229,628  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs1045642 ABCB1 
ATP binding cassette subfamily B 
member 1 
171050 7q21.12 7 87,138,645 87,509,329 1 1    CH AS 250 Liu, H. et al., 2016 [357] 
rs2032582 ABCB1 
ATP binding cassette subfamily B 
member 1 
171050 7q21.12 7 87,160,618 87,531,302 1 1    CH AS 250 Liu, H. et al., 2016 [357] 
rs2106166 SAMD9 
sterile alpha motif domain-
containing protein 9 
610456 7q21.2 7 92,668,332 93,039,018    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs662 PON1 paraoxonase 1 168820 7q21.3 7 94,937,446 95,308,134 N     JA AS 839 
Inagaki et al., 2006a 
[358] 
rs6968419 TFEC/TES 




7q31.2 7 115,823,384 116,183,330 1 1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs1052990 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,148,370 116,508,316 1     
D: IC 





R2: 879  
Thorleifsson et al.,  
2010 [77] 
rs1052990 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,148,370 116,508,316 1     US-Cau AS 2183 Wiggs et al., 2011 [87] 
rs10258482 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 






Hysi et al., 2014 [86] 
rs10262524 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 






Hysi et al., 2014 [86] 
rs10281637 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,151,338 116,511,284 1 1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs17588172 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,154,015 116,513,961 1     US-Cau AS 6538 Loomis et al., 2014 [88] 
rs17588172 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,154,015 116,513,961 1 1    KO AS 1161 Kim et al., 2015 [359] 
rs6969706 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,154,831 116,514,777 1     
D: multi ethnic 








CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 1 1    
D: IC 





R2: 879  
Thorleifsson et al., 
2010 [77] 
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 0     US AS 842 Kuehn et al., 2011 [360] 
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 














































rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 0     AF AS 437 Cao et al., 2012 [96] 
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 0     SA AS 625 
Abu-Amero et al., 2012 
[361] 
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 






Gharahkhani et al.,  
2014 [89] 
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 1     US-Cau AS 6538 Loomis et al., 2014 [88] 
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 0     BMES AS 
Cases: 67 
C: 1919 
Burdon et al 2015 [95]  
rs4236601 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 
7q31.2 7 116,162,729 116,522,675 1     US, L, AS, AA AS 63,412 Choquet et al., 2018 
rs7795356 CAV1/CAV2 caveolin 1/caveolin 2 
601047 
/601048 





R: 9014  
Osman et al., 2012 [90] 
rs76481776 MIR182 microRNA 182 611607 7q32.2 7 129,770,387 129,410,227 1 1    EU AS 37,063 Liu, Y. et al., 2016 [288] 
rs2070744 NOS3 nitric oxide synthase 3 163729 7q36 7 150,690,079 150,992,991 1     EG AS 270 Emam et al., 2014 [362] 





1     AU AS 156 Tunny et al., 1998 [363] 
  ASB10 (GLC1F) 
ankyrin repeat- and SOCS box-









1       LS   
Locus: 
Wirtz et al., 1999 [71] 
Gene: 
Pasutto et al., 2012 [72] 
rs3800791 ASB10 
ankyrin repeat- and socs box- 
containing protein 10 
615054 7q36.1 7 150,873,246 151,176,159 1     PA AS 389 
Micheal at al., 2015b 
[364] 
rs2253592 ASB10 
ankyrin repeat- and socs box- 
containing protein 10 
615054 7q36.1 7 150,878,260 151,181,173 1     PA AS 389 
Micheal at al., 2015b 
[364]  
rs3808520 LOXL2 lysyl oxidase-like 2 606663 8p21.3 8 23,164,773 23,307,260    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs11759831 CRISPLD1 
cysteine-rich secretory protein 
LCCL domain containing 1 
- 8q21.11 8 48,896,220 48,928,583   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
indel PKIA 
protein kinase (cAMP-dependent, 
catalytic) inhibitor alpha 
606059 8q21.13 8 78,380,944 77,468,708  1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs7815043 PKIA 
protein kinase (cAMP-dependent, 
catalytic) inhibitor alpha 
606059 8q21.13 8 78,932,025 78,019,790  1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs6468996 DCAF4L2 
DDB1 and CUL4 associated factor 
4-like 2 
- 8q21.3 8 88,735,337 87,723,109   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
indel DCAF4L2 
DDB1 and CUL4 associated factor 
4-like 2 
- 8q21.3 8 88,744,441 87,732,213   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs9969524 DCAF4L2 
DDB1 and CUL4 associated factor 
4-like 2 
























































assembly factor 6 
612392 8q22.1 8 95,969,322 94,957,094    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs284489 ZFPM2/LRP12 
zinc finger protein multitype 2/ 
low density lipoprotein receptor-
related protein 12 
603693/- 8q22.3 8 105,958,020 104,945,792 
1 
N 
    D: EU GWAS D: 6633 Wiggs et al., 2012 [94] 





1      US LS 
1 large 
family  
Trifan et al., 1998 [173] 
rs2514884 ANGPT1 Angiopoietin 1 601667 8q23.1 8 108,276,873 107,264,645 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs10105844 ANGPT1 Angiopoietin 1 601667 8q23.1 8 108,290,872 107,278,644  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs7815720 SLC30A8 
solute carrier family 30 (zinc 
transporter), member 8 
611145 8q24.11 8 118,089,513 117,077,274  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 




607187 8q24.22 8 134,615,750 133,603,507  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs2920293 PSCA prostate stem cell antigen 602470 8q24.3 8 143,765,414 142,683,996   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs189033490 FAM83H 
family with sequence similarity 
83, member H 
611927 8q24.3 8 144,811,340 143,729,170  1    US-Cau GWAS D: 1660 Chen et al., 2015 [143] 
rs7026684 GLIS3 GLIS family zinc finger 3 610192 9p24.2 9 4,215,308 4,215,308    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs2224492 GLIS3 GLIS family zinc finger protein 3 610192 9p24.2 9 4,237,546 4,237,546  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs1324183 MPDZ/NFIB 
multiple PDZ domain 
protein/nuclear factor 1/B 




long intergenic non-protein coding 
RNA 1235 / long intergenic non-
protein coding RNA 583 
 9p23 9 13,558,317 13,558,318  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs66720556 MPDZ Multiple PDZ domain protein 603785 9p23 9 13,559,717 13,559,718    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1063192  CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,003,367 22,003,368   1   
D: NL 
R: NL, UK 
GWAS 
D: 7360 
R: 4455  
Ramdas et al., 2010 [99] 
rs1063192  CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,003,367 22,003,368 1  1   US-Cau AS 875 Fan et al., 2011 [97] 
rs1063192  CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,003,367 22,003,368 1     EU AS 45998 Ramdas et al., 2011 [69] 
rs1063192  CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,003,367 22,003,368 1     AF AS 437 Cao et al., 2012 [96] 














































rs1063192  CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,003,367 22,003,368 N  1   JA AS 616 
Mabuchi et al., 2012 
[98] 





R: 9014  
Osman et al., 2012 [90] 
rs1063192  CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,003,367 22,003,368 1     BMES AS 
OAG: 67 
C: 1919 
Burdon et al 2015 [95] 




D: 1519 R: 
700  
Nakano et al., 2012 
[101] 





R: 697  
Takamoto et al., 2012 
[102] 
rs7049105 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,028,801 22,028,802 N 1 1   AU, NZ AS 2027 Burdon et al., 2012 [92] 
rs7049105 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,028,801 22,028,802 N     US-Cau GWAS 6633 Wiggs et al., 2012 [94] 






Nakano et al., 2012 
[101] 
rs7865618 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,031,005 22,031,006   1   EU  AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs2157719 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,033,366 22,033,367 N     US-Cau GWAS 6633 Wiggs et al., 2012 [94] 
rs2157719 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,033,366 22,033,367 1     AS, AF, EU GWAS 
D: 13250 
R: 35953 
Li et al., 2015 [100] 
rs2157719 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,033,366 22,033,367 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1333037 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,040,765 22,040,766 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 






Burdon et al., 2011 [91] 
rs1412829 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,043,926 22,043,927 1     BMES AS 
OAG: 67 
C: 1919 
Burdon et al 2015 [95] 
rs1360589 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,045,317 22,045,318 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs10811645 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,049,656 22,049,657 
1 
N 
    
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs944800 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,050,898 22,050,899 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs7866783 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,056,359 22,056,360 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 






Burdon et al., 2011 [91] 




















































Gibson et al., 2012 [93] 
rs10120688 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,056,499 22,056,500 N     US-Cau GWAS 6633 Wiggs et al., 2012 [94] 






Burdon et al., 2011 [91] 
rs4977756 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,068,652 22,068,653 0     AF AS 437 Cao et al., 2012 [96] 
rs4977756 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,068,652 22,068,653 N     US-Cau GWAS 6633 Wiggs et al., 2012 [94] 






Gharahkhani et al.,  
2014 [89] 
rs4977756 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,068,652 22,068,653 1     BMES AS 
OAG: 67 
C: 1919 
Burdon et al 2015 [95] 
rs4977756 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,068,652 22,068,653 1     JA AS 523 Kimura et al., 2015 [365] 
rs4977756 CDKN2B-AS1 CDKN2B antisense RNA 1 613149 9p21.3 9 22,068,652 22,068,653 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 





J      US LS 
 several 
families 
Wiggs et al., 2004 [47] 
rs2487048 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,691,823 104,929,542 1     EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs2472496 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,695,353 104,933,072  1 1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs2472494 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,695,539 104,933,258 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs2472493 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 






Gharahkhani et al.,  
2014 [89] 
rs2472493 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 






Hysi et al., 2014 [86] 
rs2472493 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,695,848 104,933,567 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 
rs2472493 ABCA1 
ATP binding cassette subfamily A 
member 1  
600046 9q31.1 9 107,695,848 104,933,567 1 1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs2472493 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,695,848 104,933,567 1 1    
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs2472493 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,695,848 104,933,567 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs2472493 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 
600046 9q31.1 9 107,695,848 104,933,567 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs2487032 ABCA1 
ATP-Binding cassette, subfamily 
A, member 1 




















































rs10980623 LPAR1 lysophosphatidic acid receptor 1 602282 9q31.3 9 113,660,537 110,898,257    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1007000 LPAR1 lysophosphatidic acid receptor 1 602282 9q31.3 9 113,662,681 110,900,401    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs2149356 TLR4 toll-like receptor 4 603030 9q33.1 9 120,474,199 117,711,921 1     JA AS 765 Takano et al., 2012 [367] 
rs7037117 TLR4 toll-like receptor 4 603030 9q33.1 9 120,483,663 117,721,385 N     JA AS 568 
Shibuya et al., 2008 
[368] 
rs7037117 TLR4 toll-like receptor 4 603030 9q33.1 9 120,483,663 117,721,385 0     AF AS 437 Cao et al., 2012 [96] 
rs7037117 TLR4 toll-like receptor 4 603030 9q33.1 9 120,483,663 117,721,385 1     CH AS 1039 Chen et al., 2012b [326] 




multivesicular body subunit 12B   9q33.3 9 129,246,487 126,484,208  1    UK AS 2774 Nag et al., 2014 [129]  
rs6478746 LMX1B 
LIM homeobox transcription 
factor 1, beta 
602575 9q33.3 9 129,367,398 126,605,119 1    1 EU GWAS 
OAG:3071 
C:6750 
Gharahkhani et al.,  
2018 [131] 
rs10819187 LMX1B 
LIM homeobox transcription 
factor 1, beta 
602575 9q34.1 9 129,369,971 126,607,692 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs55770306 LMX1B 
LIM homeobox transcription 
factor 1, beta 
602575 9q34.1 9 129,388,033 126,625,754 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs7854658 LMX1B 
LIM homeobox transcription 
factor 1, beta 
602575 9q34.1 9 129,414,938 126,652,659 1     UK AS 643 Park et al., 2009 [369] 






Hysi et al., 2014 [86] 
rs8176741 ABO ABO glycosyltransferase 110300 9q34.2 9 136,131,461 133,256,074  1 1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs3094339 VAV2/BRD3 
vav 2 guanine nucleotide 
exchange factor / bromodomain 
containing protein 3 
600428 
/ 601541 
9q34.2 9 136,884,738 134,019,616    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs4841899 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,424,412 134,532,566    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs3132306 RXRA/COL5A1 
retinoid X receptor alpha / 











Cornes et al.,  2012 [316] 
rs3132306 RXRA/COL5A1 
retinoid X receptor alpha / 











Hoehn et al., 2012 [198] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,440,528 134,548,682    1  
D: CR, SCL 




Vitart et al., 2010 [201] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,440,528 134,548,682    1  





Vithana et al., 2011 
[315] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 


























































retinoid X receptor alpha / 





9 137,440,528 134,548,682    0  AU, NZ AS 1759 Dimasi et al., 2012 [29] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 











Hoehn et al., 2012 [198] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 












Ulmer et al., 2012 [196] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,440,528 134,548,682    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs1536482 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,440,528 134,548,682    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs3118520 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,440,528 134,548,682    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs3132303 RXRA/COL5A1 
retinoid X receptor alpha / 





9 137,444,298 134,552,452    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs7032489 COL5A1 collagen, type V, alpha-1 120215 9q34.3 9 137,559,775 134,667,929    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs7044529 COL5A1 collagen, type V, alpha-1 120215 9q34.3 9 137,568,051 134,676,205    1  





Vithana et al., 2011 
[315] 
rs7044529 COL5A1 collagen, type V, alpha-1 120215 9q34.3 9 137,568,051 134,676,205    0  AU, NZ AS 1759 Dimasi et al., 2012 [29] 







Ulmer et al., 2012 [196] 
rs7044529 COL5A1 collagen, type V, alpha-1 120215 9q34.3 9 137,568,051 134,676,205    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs7040970 LCN12/PTGDS 




9q34.3 9 139,859,013 136,964,561    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs11145951 LCN12/PTGDS 




9q34.3 9 139,860,264 136,965,812    1  EU, AS MA >20,000 Lu et al., 2013 [200] 










 1 large 
family  
Locus: 
Sarfarazi et al., 1998 [70] 
Gene: 
Rezaie et al., 2002 [59] 








1     AC LS 
 several 
families 
Nemesure et  al.,  
2003 [187] 
rs7098387 PLXDC2 plexin domain containing 2 606827 10p12.31 10 20,623,473 20,334,544 1     KO AS 1115 Kim et al., 2014 [327] 
rs7081455 PLXDC2 plexin domain containing 2 606827 10p12.31 10 20,638,885 20,349,956 0     AF AS 437 Cao et al., 2012 [96] 
rs7081455 PLXDC2 plexin domain containing 2 606827 10p12.31 10 20,638,885 20,349,956 0     CH AS 1039 Chen et al., 2012b [326] 






Nakano et al., 2012 
[101] 
rs11014632 GPR158 g protein-coupled receptor 158 614573 10p12.1 10 25,877,651 25,588,722  1    
D: US, LA, AS, AA 






















































610973 10p12.1 10 28,405,411 28,116,482 1     IN GWAS 
D: 729 
R: 714 
Vishal et al., 2016 [370] 
rs7090871 ARID5B AT rich interactive domain 5B 608538 10q21.2 10 63,830,286 62,070,527    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs35809595 ARID5B AT-rich interactive domain 5B 608538 10q21.2 10 63,831,928 62,072,169    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs5785510* ARID5B 
AT-rich interaction domain-
containing protein 5B 
608538 10q21.2 10 63,837,290 62,077,531  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 




Matovinovic et al., 2017 
[133] 
rs61854782 ATOH7 atonal homolog 7 609875 10q21.3 10 69,991,749 68,231,992   1   CH AS 431 Chen et al., 2012a [371] 
rs7916697 ATOH7 atonal homolog 7 609875 10q21.3 10 69,991,853 68,232,096 0     US-Cau AS 875 Fan et al., 2011 [97] 






Khor et al., 2011 [317] 
rs7916697 ATOH7 atonal homolog 7 609875 10q21.3 10 69,991,853 68,232,096 1     AF AS 437 Cao et al., 2012 [96] 
rs7916697 ATOH7 atonal homolog 7 609875 10q21.3 10 69,991,853 68,232,096 0     CH AS 431 Chen et al., 2012a [371] 
rs7916697 ATOH7 atonal homolog 7 609875 10q21.3 10 69,991,853 68,232,096   1  1 AU, UK AS 3599 
Venturini et al., 2014 
[130]  
rs7916697 ATOH7 atonal homolog 7 609875 10q21.3 10 69,991,853 68,232,096   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs7916410 ATOH7 atonal homolog 7 609875 10q21.3 10 69,995,667 68,235,910   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1900005 ATOH7 atonal homolog 7 609875 10q21.3 10 69,998,055 68,238,298   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 






Macgregor et al., 2010 
[335] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124  1 1   IN AS 468 
Philomenadin et al., 
2015 [105] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124     1 D:NL GWAS D: 23000 
Axenovich et al., 2011 
[104] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124 0     African AS 437 Cao et al., 2012 [96] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124 0     CH AS 431 Chen et al., 2012a [371] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124     0 AU, NZ AS 1759 Dimasi et al., 2012 [29] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124     1 US-Cau AS 875 Fan et al., 2011 [97] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124 N     JA AS 616 





















































Ramdas et al., 2010 [99] 
rs1900004 ATOH7 atonal homolog 7 609875 10q21.3 10 70,000,881  68,241,124 1     EU AS 45998 Ramdas et al., 2011 [69] 






Springelkamp et al., 
2015 [134] 






Macgregor et al., 2010 
[335] 
rs3858145 ATOH7 atonal homolog 7 609875 10q21.3 10 70,011,838  68,252,081   0   US-Cau AS 875 Fan et al., 2011 [97] 
rs3858145 ATOH7 atonal homolog 7 609875 10q21.3 10 70,011,838  68,252,081 0     AF AS 437 Cao et al., 2012 [96] 
rs3858145 ATOH7 atonal homolog 7 609875 10q21.3 10 70,011,838  68,252,081   1   CH AS 431 Chen et al., 2012a [371] 
rs3858145 ATOH7 atonal homolog 7 609875 10q21.3 10 70,011,838  68,252,081 0     AU, NZ AS 1759 Dimasi et al., 2012 [29] 






Gibson et al., 2012 [93] 






Springelkamp et al., 
2015 [134] 
rs12571093 ATOH7/PBLD 
atonal homolog 7/phenazine 










Macgregor et al. 2010 
[335] 





 1    AU LS 
 1 large 
family 





cytochrome P450, family 26, 




10q23.33 10 94,963,391 93,203,634 1  1   EU GWAS 
OAG:3071 
C:6750 





cytochrome P450, family 26, 




10q23.33 10 95,049,398 93,289,641  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
indel PLCE1 phospholipase C, epsilon 1 608414 10q23.33 10 96,008,348 94,248,591   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs3891783 PLCE1 phospholipase C, epsilon 1 608414 10q23.33 10 96,015,793 94,256,036   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1830890 PLCE1 phospholipase C, epsilon 1 608414 10q23.33 10 96,019,501 94,259,744   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs7072574 PLCE1 phospholipase C, epsilon 1 608414 10q23.33 10 96,036,306 94,276,549   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs2274224 PLCE1 phospholipase C, epsilon 1 608414 10q23.33 10 96,039,597 94,279,840 1     
D: multi ethnic 




Choquet et al., 2018 
rs2419835 HABP2 hyaluronan binding protein 2 603924 10q25.3 10 115,296,564 113,536,805    1  
Meta-analysis 
EU, AS 














































rs1801253 ADRB1 beta-1-adrenergic receptor 109630 
10q24–
10q26 
10 115,805,056 114,045,297 N     JA AS 745 
Inagaki et al., 2006b 
[186] 
rs1681739 HSPA12A heat shock 70kDa protein 12A 610701 10q25.3 10 118,563,329 116,803,818   1  1 EU, AS MA 
IGGC 
>79,000 






617231 10q26.13 10 126,247,468 124,558,899 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 





1     CH AS 164 Tsai et al., 2003 [372] 
rs2030324 BDNF brain-derived neurotrophic factor 113505 11p14.1 11 27,726,915 27,705,368 1  1   PO AS 769 Nowak et al., 2015 [351] 
rs542340 DNAJC24 
DnaJ/Hsp40 homolog, subfamily 
C, member 24 
611072 11p13 11 31,409,438 31,387,891 1     
D: AA 
D: HI 
GWAS D: 10,961 
Hoffmann et al., 2014 
[172] 
rs542340 DNAJC24 
DnaJ/Hsp40 homolog, subfamily 
C, member 24 
611072 11p13 11 31,409,438 31,387,891 0     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs1223068 IMMP1L 
inner mitochondrial membrane 
peptidase subunit 1 
612323 11p13 11 31,480,349 31,458,802   1  1 EU, AS MA 
IGGC 
>79,000 




complex, subunit 4 
606985 11p13 11 31,532,959 31,511,412 1     
D: AA 
D: HI 
GWAS D: 10,961 




complex, subunit 4 






Springelkamp et al., 
2015 [134] 






Gasten et al., 2012 [373] 






Gasten et al., 2012 [373] 






Gasten et al., 2012 [373] 
rs3026398 PAX6 paired box gene 6 607108 11p13 11 31,808,775 31,787,227    1  AU-Cau AS 956 Dimasi et al., 2010 [374] 
rs1001179 CAT catalase 115500 11p13 11 34,460,231 34,438,684 1     SA AS 628 
Abu-Amero et al., 2013 
[375] 
rs79390637 PSMC3/RAPSN 
proteasome 26S subunit, ATPase, 




11p11.2 11 47,456,867 47,435,316  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs12419342 RAPSN 
receptor-associated protein of 
the synapse 






























11p11.2 11 47,955,608 47,934,056 1 1    EU, AS MA 
IGGC 
>79,000 

















































receptor type J 






Hysi et al., 2014 [86] 
rs7946766 PTPRJ 
Protein-tyrosine phosphatase, 
receptor type J 






Hysi et al., 2014 [86] 










606044 11q13.1 11 65,337,251 65,569,780   1   EU, AS GWAS 27,878 





606044 11q13.1 11 65,337,251 65,569,780 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 




Matovinovic et al., 2017 
[133] 
rs1799750 MMP1 matrix metalloproteinase 1 120353 11q22.2 11 102,670,496 102,799,765 1     PO AS 449 





Rho GTPase activating protein 20 
/ chromosome 11 open reading 
frame 53 




Rho GTPase activating protein 20 
/ chromosome 11 open reading 
frame 53 
609568/- 11q23.1 11 110,913,240 111,042,516    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs12806740 TMEM136 transmembrane protein 136 - 11q23.3 11 120,203,628 120,332,919 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs58073046 ARHGEF12 
Rho guanine nucleotide exchange 
factor 12 
604763 11q23.3 11 120,248,493 120,377,784  1    D: EU GWAS 
D: 8015 
R: 7471 
Springelkamp et al., 
2015 [106] 
rs58073046 ARHGEF12 
Rho guanine nucleotide exchange 
factor 12 
604763 11q23.3 11 120,248,493 120,377,784 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs12794618 ARHGEF12 
Rho guanine nucleotide exchange 
factor 12 
604763 11q23.3 11 120,289,699 120,418,990  1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs2276035 ARHGEF12 
Rho guanine nucleotide exchange 
factor 12 






Gharahkhani et al.,  
2014 [89] 
rs199800298* ARHGEF12 
Rho guanine nucleotide exchange 
factor 12 
604763 11q23.3 11 120,348,584 120,477,875  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
indel ARHGEF12 
Rho guanine nucleotide exchange 
factor 12 
604763 11q23.3 11 120,357,425 120,486,716 1 1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs4936099 ADAMTS8 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 8 
605175 11q24.3 11 130,280,725 130,410,830   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs4936099 ADAMTS8 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 8 
605175 11q24.3 11 130,280,725 130,410,830   1  1 EU, AS MA 
IGGC 
>79,000 
















































a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 8 
605175 11q24.3 11 130,284,041 130,414,146  1    EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs56009602 ADAMTS8 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif, 8 
605175 11q24.3 11 130,289,612 130,419,717    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 







Ulmer et al., 2012 [196] 
rs151326733 DERA deoxyribose-phosphate aldolase can't find 12p12.3 12 16,189,478 16,036,544 1     
D: AA 
D: HI 
GWAS D: 10,961 
Hoffmann et al., 2014 
[172] 
rs4931170 FAR2 fatty acyl CoA reductase 2 616156 12p11.22 12 29,388,772 29,235,839  1    US-Cau GWAS D: 1660 Chen et al., 2015 [143] 
rs7977237 
LOC105369739 
 / ADAMTS20 
uncharacterized LOC105369739 / 
a disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif 20 
-/611681 12q12 12 43,700,341 43,306,538  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs11168187 RPAP3 
RNA polymerase II-associated 
protein 3 
611477 12q13.11 12 48,044,011 47,650,228   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103]  











 1 family 
  
Locus: 
Fingert et al., 2011 [61] 
Gene: 
Fingert et al., 2014 [75] 









Awadalla et al., 2015 [62] 
rs343093 HMGA2 high mobility group AT-hook 2 600698 12q14.3 12 66,255,005 65,861,225 1     Japan GWAS 
POAG:7378 
C:36385 


























615856 12q21.31 12 83,922,912 83,529,133   1   EU, AS GWAS 27,878 






615856 12q21.31 12 83,946,450 83,552,671 1     
D: US, L, AS, AA 























































615856 12q21.31 12 83,978,117 83,584,338   1  1 EU, AS MA 
IGGC 
>79,000 






615856 12q21.31 12 83,979,286 83,585,507 1  1  1 EU, AS MA 
IGGC 
>79,000 






615856 12q21.31 12 84,003,866 83,610,087 1  1  1 EU, AS MA 
IGGC 
>79,000 
























Springelkamp et al., 
2015 [134] 
rs7308752 DCN decorin 125255 12q21.33 12 91,527,181 91,133,404    1  
Meta-analysis 
EU, AS 




- 12q23.3 12 104,008,707 104,008,707    1  
Meta-analysis 
EU, AS 




611076 12q23.3 12 104,210,992 103,817,214    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs11553764 GLT8D2 
glycosyltransferase 8 domain 
containing 2 
- 12q23.3 12 104,415,244 104,021,466    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs1564892 GLT8D2 
glycosyltransferase 8 domain 
containing 2 
- 12q23.3 12 104,445,742 104,051,964    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs74481774 TMEM119 transmembrane protein 119 - 12q3.3 12 108,987,230 108,593,454  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs7137828 ATXN2 ataxin 2 601517 12q24.12 12 111,932,800 111,494,996 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 
rs7137828 ATXN2 ataxin 2 601517 12q24.12 12 111,932,800 111,494,996 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs7311936 FAM101A 
family with sequence similarity 
101, member A 
615927 12q24.31 12 124,631,597 124,147,051   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs11613189 FAM101A 
family with sequence similarity 
101, member A 
615927 12q24.31 12 124,642,803 124,158,257   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs10846617 FAM101A 
family with sequence similarity 
101, member A 






Springelkamp et al., 
2015 [134] 
rs1034200 BASP1P1 
brain abundant, membrane 
attached signal protein 1 
pseudogene 1 
- 13q12.12 13 23,228,691 22,654,552    1  
D: CR, SCL 



















































brain abundant, membrane 
attached signal protein 1 
pseudogene 1 
- 13q12.12 13 23,228,691 22,654,552    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs9552680 BASP1P1 
brain abundant, membrane 
attached signal protein 1 
pseudogene 1 
- 13q12.12 13 23,235,285 22,661,146  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs10161679 BASP1P1 
brain abundant, membrane 
attached signal protein 1 
pseudogene 1 
- 13q12.12 13 23,243,645 22,669,506    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
indel DCLK1 doublecortin-like kinase  1 604724 13q13 13 36,629,905 36,055,768   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs7323428 DCLK1 doublecortin-like kinase  1 604724 13q13 13 36,643,601 36,069,464   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 






Ramdas et al., 2010 [99] 






Springelkamp et al., 
2015 [134] 
rs2755237 FOXO1 forkhead box O1 136533 13q14.11 13 41,109,429 40,535,292    1  AU, UK GWAS D: 5058 Lu et al., 2010 [199] 
rs2721051 FOXO1 forkhead box O1 136533 13q14.11 13 41,110,884 40,536,747    1  AU, UK GWAS D: 5058 Lu et al., 2010 [199] 
rs2721051 FOXO1 forkhead box O1 136533 13q14.11 13 41,110,884 40,536,747    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
indel FOXO1 forkhead box O1 136533 13q14.11 13 41,112,152 40,538,015    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs11616662 FOXO1 forkhead box O1 136533 13q14.11 13 41,119,466 40,545,329  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs9530458 LMO7 LIM domain 7 604362 13q22.2 13 76,249,275 75,675,139 1     EU GWAS 
OAG:3071 
C:6750 
Gharahkhani et al., 2018 
[131] 
 –   13q31.1 13 
79,074,135 
 - 87,752,255 
78,500,000 
- 87,100,000 
 1    BDES LS 
multiple 
families 
Duggal et al., 2005 [188] 








1     US LS  sibpairs Wiggs et al., 2000 [190] 
rs718433 TRAJ17 
T-cell receptor alpha chain 
joining gene cluster 
615443 14q11.2 14 22,235,890 21,767,650  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs3794453 RBM23 RNA binding motif protein 23 – 14q11.2 14 23,386,875 22,917,666   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
indel RBM23 RNA binding motif protein 23 – 14q11.2 14 23,388,793 22,919,584   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 








1     US LS  sibpairs Wiggs et al., 2000 [190] 
rs10130556 DDHD1/BMP4 
DDHD domain-containing protein 
1/ Bone morphogenetic protein 4 
614603 
/ 112262 






















































DDHD domain-containing protein 
1/ Bone morphogenetic protein 4 
614603 
/ 112262 
14q22.1 14 53,988,050 53,521,332   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs4901977 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
601205 
/ 606326 
14q23.1 14 60,789,176 60,322,458   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs6573307 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,798,009 60,331,291 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs4436712 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,808,002 60,341,284 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs8015152 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,811,999 60,345,281 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs146737847 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,976,501 60,509,783 1  1   
D: NL, UK 




Iglesias et al., 2014 [107] 
rs33912345 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,976,537 60,509,819 1     US-Cau AS 518 Carnes et al., 2014 [108] 
rs33912345 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,976,537 60,509,819 1  1   
D: NL, UK 




Iglesias et al., 2014 [107] 
rs33912345 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,976,537 60,509,819 
1 
N 
    CH AS 1132 Sang et al., 2016 [377] 
rs33912345 SIX6 
sine oculis homeobox, 
drosophila, homolog of,  6 
606326 14q23.1 14 60,976,537 60,509,819 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157   1   
D: NL 




Ramdas et al., 2010 [99] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157   1   D: NL GWAS D : 23000 
Axenovich et al., 2011 
[104] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 1  1   US-Cau AS 875 Fan et al., 2011 [97] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 1     EU AS 45998 Ramdas et al., 2011 [69] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 0     AF AS 437 Cao et al., 2012 [96] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 1  1   AU, NZ AS 1759 Dimasi et al., 2012 [29] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 






Gibson et al., 2012 [93] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 N  0   JA AS 616 
Mabuchi et al., 2012 
[98] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 






Osman et al., 2012 [90] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 















































sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 






Gharahkhani et al.,  
2014 [89] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 1     BMES AS 
OAG: 67 
C: 1919 
Burdon et al 2015 [95] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157   1   IN AS 468 
Philomenadin et al., 
2015 [105] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 






Springelkamp et al., 
2015 [134] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 
1 
N 
    CH AS 1132 Sang et al., 2016 [377] 
rs10483727 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,072,875 60,606,157 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs34935520 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,091,401 60,624,683 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs34935520 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,091,401 60,624,683 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs35155027 SIX1/SIX6 
sine oculis homeobox, 
drosophila, homolog of,  1/6 
601205 
/ 606326 
14q23.1 14 61,095,174 60,628,456 1     
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs56223983 STON2 stonin 2 608467 14q31.1 14 81,814,754 81,348,410    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs754203 CYP46A1 
cytochrome P450, family 46, 
subfamily A, polypeptide 1 
604087 14q32.1 14 100,157,967 99,691,630 1     FR AS 268 
Fourgeux et al., 2009 
[378] 
rs754203 CYP46A1 
cytochrome P450, family 46, 
subfamily A, polypeptide 1 
604087 14q32.1 14 100,157,967 99,691,630 1     IN AS 122 
Chandra et al., 2016 
[334] 








1      US, AA, HI LS 
 multiple 
families 
Allingham et al., 2005 
[177] 
rs785422 TJP1 tight junction protein 1 601009 15q13.1 15 30,173,885 29,881,682    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs785422 TJP1 tight junction protein 1 601009 15q13.1 15 30,173,885 29,881,682    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs28480457 MEIS2 MEIS1, mouse, homolog of, 2 601740 15q14 15 37,171,641 36,879,440 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs587847 MEIS2 MEIS1, mouse, homolog of, 2 601740 15q14 15 37,660,049 37,367,848  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 
rs17352842 FBN1 fibrillin 1 134797 15q21.1 15 48,694,211 48,402,014    1  AU AS 956 Dimasi et al., 2010 [374] 
rs8030753 FBN1 fibrillin 1 134797 15q21.1 15 48,801,935 48,509,738    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs2593221 TCF12 transcription factor 12 600480 15q21.3 15 57,501,414  1     
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 








J     CH  LS 
 1 large 
family 














































rs12912010 SMAD3 SMAD family member 3 603109 15q22.33 15 67,467,143 67,174,805    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs12912045 SMAD3 SMAD family member 3 603109 15q22.33 15 67,467,297 67,174,959  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs12913547 SMAD3 SMAD family member 3 603109 15q22.33 15 67,467,507 67,175,169    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs1048661 LOXL1 lysyl oxidase-like 1 153456 15q24.1 15 74,219,546 73,927,205 1     Mixed AS 5293 Wu et al., 2015 [379] 
rs1048661 LOXL1 lysyl oxidase-like 1 153456 15q24.1 15 74,219,546 73,927,205 1     Japan GWAS 
POAG:7378 
C:36385 
Shiga et al., 2018 [337] 
rs3825942 LOXL1 lysyl oxidase-like 1 153456 15q24.1 15 74,219,582 73,927,241 1     Mixed AS 5293 Wu et al., 2015 [379] 
rs2165241 LOXL1 lysyl oxidase-like 1 153456 15q24.1 15 74,222,202 73,929,861 1     Mixed AS 5293 Wu et al., 2015 [379] 
rs2165241 LOXL1 lysyl oxidase-like 1 153456 15q24.1 15 74,222,202 73,929,861 1     Spain AS 658 
Zanon-Moreno et al., 
2015 [380] 
rs6496932 AKAP13 A-kinase anchor protein 13 604686 15q25.3 15 85,825,567 85,282,336    1  
D: CR, SCL 




Vitart et al., 2010 [201] 






Cornes et al.,  2012 [316] 






Gibson et al., 2012 [93] 







Ulmer et al., 2012 [196] 
rs6496932 AKAP13 A-kinase anchor protein 13 604686 15q25.3 15 85,825,567 85,282,336    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs4843040 AKAP13 A-kinase anchor protein 13 604686 15q25.3 15 85,838,636 85,295,405    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 






Cornes et al.,  2012 [316] 







Ulmer et al., 2012 [196] 
rs8034595 NR2F2 
nuclear receptor subfamily 2, 
group F, member 2 






Springelkamp et al., 
2015 [134] 
rs6598351 FAM169B 
family with sequence similarity 
169, member B 
- 15q26.3 15 98,808,111 98,264,882   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs72755233 ADAMTS17 
A disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif 17 
607511 15q26.3 15 100,692,953 100,152,748  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs11247230 ASB7 
ankyrin repeat- and SOCS box-
containing protein 7 






Springelkamp et al., 
2015 [134] 
rs60779155 ASB7 
ankyrin repeat- and SOCS box-
containing protein 7 






















































ankyrin repeat- and SOCS box-
containing protein 7 
615052 15q26.3 15 101,200,873 100,660,668   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs4299136 ASB7 
ankyrin repeat- and SOCS box-
containing protein 7 
615052 15q26.3 15 101,201,604 100,661,399   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs2034809 LRRK1 leucine-rich repeat kinase 1 610986 15q26.3 15 101,555,399 101,015,194    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs2034809 LRRK1 leucine-rich repeat kinase 1 610986 15q26.3 15 101,555,399 101,015,194    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs930847 LRRK1 leucine-rich repeat kinase 1 610986 15q26.3 15 101,558,562 101,018,357    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs930847 LRRK1 leucine-rich repeat kinase 1 610986 15q26.3 15 101,558,562 101,018,357    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 






Cornes et al.,  2012 [316] 
rs752092 CHSY1 chondroitin sulfate synthase 1 608183 15q26.3 15 101,781,934 101,241,729    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs752092 CHSY1 chondroitin sulfate synthase 1 608183 15q26.3 15 101,781,934 101,241,729    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs192917960 RBFOX1 
RNA-binding protein FOX1, C 
elegans, homolog of, 1 
605104 16p13.3 16 5,919,655 5,869,654 1     
D: AA 
D: HI 
GWAS D: 10,961 
Hoffmann et al., 2014 
[172] 
rs192917960 RBFOX1 
RNA-binding protein FOX1, C 
elegans, homolog of, 1 
605104 16p13.3 16 5,919,655 5,869,654 0     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs1906060 RBFOX1 
RNA-binding protein FOX1, C 
elegans, homolog of, 1 
605104 16p13.3 16 6,108,430 6,058,429  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 






Chen et al., 2014 [366] 
rs3785176 PMM2 phosphomannomutase 2 601785 16p13.2 16 8,896,931 8,803,074 0     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 






Springelkamp et al., 
2015 [134] 
rs11646917 SALL1 sal-like 1 602218 16q12.1 16 51,428,908 51,394,997   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 






Ramdas et al. 2010 [99] 






Springelkamp et al., 
2015 [134] 
indel SALL1 sal-like 1 602218 16q12.1 16 51,461,915 51,428,004 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs4784295 SALL1 sal-like 1 602218 16q12.1 16 51,471,432 51,437,521   1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs1345467 SALL1 sal-like 1 602218 16q12.1 16 51,482,321 51,448,410   1   EU, AS GWAS 27,878 















































rs1345467 SALL1 sal-like 1 602218 16q12.1 16 51,482,321 51,448,410 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
 3’UTR CDH-1 cadherin 1 192090 16q22.1 16 
68,867,398 
 - 68,869,440 
68,833,495 
- 68,835,537 




A disintegrin-like and 
metalloproteinase with 
thrombospondin type 1 motif 18 
/ nudix hydrolase 7 
607512/6
09231 
16q23.1 16 77,591,935 77,558,038  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs12447690 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,298,124 88,264,518    1  D: AU, UK GWAS D: 5058 Lu et al., 2010 [199] 
rs12447690 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,298,124 88,264,518    1  
D: CR, SCL 




Vitart et al., 2010 [201] 






Vithana et al., 2011 
[315] 






Cornes et al.,  2012 [316] 
rs12447690 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,298,124 88,264,518    0  AU, NZ AS 1759 Dimasi et al., 2012 [29] 






Hoehn et al., 2012 [198] 







Ulmer et al., 2012 [196] 
rs6540223 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,321,436 88,287,830    1  EU, AS MA >20,000 Lu et al., 2013 [200] 
rs35193497 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,324,821 88,291,215    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs28687756 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,328,928 88,295,322    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs12926024 ZNF469 zinc finger protein 469  612078 16q24.2 16 88,331,309 88,297,703  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs9938149 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,331,640 88,298,034    1  D: AU, UK GWAS D: 5058 Lu et al., 2010 [199] 






Vithana et al., 2011 
[315] 
rs9938149 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,331,640 88,298,034    0  AU, NZ AS 1759 Dimasi et al., 2012 [29] 






Hoehn et al., 2012 [198] 
rs9938149 ZNF469 zinc finger protein  469 612078 16q24.2 16 88,331,640 88,298,034    1  EU, AS MA >20,000 Lu et al., 2013 [200] 








1     US LS  sibpairs Wiggs et al., 2000 [190] 
rs4790881 SMG6 
SMG6, nonsense mediated 
mRNA decay factor 
610963 17p13.3 17 2,068,932 2,165,638  1    
D: US, LA, AS, AA 




















































inhibitor of CDK, cyclin A1 
interacting protein 1  
617374 17p13.2 17 4,829,560 4,926,265  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs1042522 TP53 tumour protein p53 191170 17p13.1 17 7,579,472 7,676,154 1     CH AS 117 Lin et al., 2002 [261] 
rs1042522 TP53 tumour protein p53 191170 17p13.1 17 7,579,472 7,676,154 1     IR AS 130 
Neamatzadeh et al., 
2015 [262] 
rs1042522 TP53 tumour protein p53 191170 17p13.1 17 7,579,472 7,676,154 N     CH AS 606 Fan et al., 2010 [264] 
rs1042522 TP53 tumour protein p53 191170 17p13.1 17 7,579,472 7,676,154 1     Cau US AS 358 
Daugherty et al., 2009 
[263] 
rs9897123 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,020,501 10,117,184 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs9897123 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,020,501 10,117,184 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 
rs12150284 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,031,090 10,127,773  1    D: EU GWAS D: 6236 Ozel et al., 2014 [110] 






Hysi et al., 2014 [86] 
rs9913911 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,031,183 10,127,866 1 1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs9913911 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,031,183 10,127,866 1 1 1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs9913911 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,031,183 10,127,866 1 1    
D: US, L, AS, AA 




Choquet et al., 2018 
[111] 
rs9913911 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,031,183 10,127,866 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs11656696 GAS7 growth arrest-specific 7 603127 17p13.1 17 10,033,679 10,130,362 1 1    
D: NL 
R: UK, AU, NZ, 
Canada 



















604058 17p12 17 14,565,130 14,661,813    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 






Springelkamp et al., 
2015 [134] 
rs11867840 BCAS3 
breast carcinoma amplified 
sequence 3 
607470 17q23 17 59,273,265 61,195,904 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs11651885 BCAS3 
breast carcinoma amplified 
sequence 3 






















































breast carcinoma amplified 
sequence 3 






Ramdas et al., 2010 [99] 













606006 17q25.1 17 73,238,508 75,242,427  1    US-Cau GWAS D: 1660 Chen et al., 2015 [143] 
rs11659764 TCF4 transcription factor 4  602272 18q21.2 18 53,335,512 55,668,281  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 





 1    BDES LS  Duggal et al., 2007 [191] 
 c.431G→A 
Arg144Gln 
OLFM2 olfactomedin 2 – 19p13.2 19 9,968,088 9,857,412 1     JA AS 770 
Funayama et al., 2006 
[382] 





1     US LS sibpairs  Wiggs et al., 2000 [190] 
rs25487 XRCC1 
X-ray cross-complementing 
group  1 
194360 19q13.31 19 44,055,726 43,551,574 1     PA AS 516 Yousaf et al., 2011 [383] 
rs449647 APOE apolipoprotein  E 107741 19q13.2 19 45,408,564 44,905,307 1     PO AS 769 Nowak et al., 2015 [351] 
rs429358 
rs7412 





1     AU, NZ AS 193 Vickers et al., 2002 [384] 
rs429358 
rs7412 





0     UK AS 504 Lake et al., 2004 [385] 
rs429358 
rs7412 





0     UK AS 212 









1     JA AS 681 Fan et al., 2005 [387] 
rs429358 
rs7412 





1 1    JA AS 489 









1     CH AS 700 Lam et al., 2006 [389] 
rs429358 
rs7412 





0     ES AS 429 









1     SA AS 190 









0     TU AS 194 Saglar et al., 2009 [392] 
rs13181 XPD 
xeroderma pigmentosum 
complementation group  D 
278730 19q13.32 19 45,854,919 45,351,661 1     PA AS 516 Yousaf et al., 2011 [383] 






















































natural killer cell group 7 
sequence 
606008 19q13.41 19 51,879,034 51,375,780 1     
D: AA 
D: HI 
GWAS D: 10,961 
Hoffmann et al., 2014 
[172] 
rs1279683 SLC23A2 
solute carrier family 23,  
member 2 
603791 20p13 20 4,983,092 5,002,446 1     ME AS 500 
Zanon-Moreno et al., 
2013 [393] 





J      US LS 
several 
families  
Wiggs et al., 2004 [47] 
rs6054374 BMP2 bone morphogenic protein 2 112261 20p12.3 20 6,578,556 6,597,909   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs6054375 BMP2 bone morphogenic protein 2 112261 20p12.3 20 6,578,629 6,597,982 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs6107845 BMP2 bone morphogenic protein 2 112261 20p12.3 20 6,578,741 6,598,094 1  1  1 EU, AS MA 
IGGC 
>79,000 





long intergenic non-protein 
coding RNA 1734 / long 
intergenic non-protein coding 
RNA 1370 
 20q12 20 37,912,667 39,284,024  1    
D: US, LA, AS, AA 








receptor type T 









collagen type VI alpha 1 chain / 
collagen type VI alpha 2 
120220 
/ 120240 
21q22.3 21 47,442,334 46,022,420  1    
D: US, LA, AS, AA 




Choquet et al., 2017 
[171] 
rs8133436 COL6A2 collagen type VI alpha 2 120240 21q22.3 21 47,519,535 46,099,621    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 
rs58714937 TXNRD2 thioredoxin reductase 2 606448 22q11.21 22 19,856,710 19,869,187 1     
D: multi ethnic 




Choquet et al., 2018 
[111] 
rs35934224 TXNRD2 thioredoxin reductase 2 606448 22q11.21 22 19,872,645 19,885,122 1     US, L, AS, AA AS 63,412 
Choquet et al., 2018 
[111] 
rs35934224 TXNRD2 thioredoxin reductase 2 606448 22q11.21 22 19,872,645 19,885,122 1     
Meta-analysis 
US, AU, EU, SC 
GWAS 37333 Bailey et al., 2016 [12] 
rs71313931 ARVCF 
armadillo repeat gene deleted in 
velocardiofacial syndrome 
602269 22q11.21 22 19,960,184 19,972,661    1  
Meta-analysis 
EU, AS 
GWAS 25,910 Iglesias et al., 2018 [179] 





1     TU AS 265 Unal et al., 2007 [322] 
rs1547014 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,100,711 28,704,723   1   
D: NL 




Ramdas et al., 2010 [99] 
rs1547014 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,100,711 28,704,723 0     EU AS 45998 Ramdas et al., 2011 [69] 
rs1547014 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,100,711 28,704,723   0   AU, NZ AS 1759 Dimasi et al., 2012 [29] 
rs1547014 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,100,711 28,704,723   1   JA AS 616 
Mabuchi et al., 2012 
[98] 














































rs1547014 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,100,711 28,704,723   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 
rs5762752 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,100,977 28,704,989 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs5752773 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,105,415 28,709,427 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs738722 CHEK2 checkpoint kinase 2 604373 22q12.1 22 29,130,012 28,734,024 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 






Springelkamp et al., 
2015 [134] 






Springelkamp et al., 
2015 [134] 
rs737723 SEC14L2 SEC14-like 2  607558 22q12.2 22 30,802,029 30,406,040 1     ME AS 500 




containing protein 10 
607209 22q13.1 22 37,907,069 37,511,062   1  1 EU, AS MA 
IGGC 
>79,000 




containing protein 10 
607209 22q13.1 22 37,909,539 37,513,532   1  1 EU, AS MA 
IGGC 
>79,000 




containing protein 10 
607209 22q13.1 22 37,919,267 37,523,260 0     AF AS 437 Cao et al., 2012 [96] 
rs9607469 CARD10 
caspase recruitment domain-
containing protein 10 





R: 9326  
Khor et al., 2011 [317] 
rs9607469 CARD10 
caspase recruitment domain-
containing protein 10 





R: 344  
Gibson et al., 2012 [93] 
rs9607469 CARD10 
caspase recruitment domain-
containing protein 10 
607209 22q13.1 22 37,919,267 37,523,260   1   IN AS 468 




containing protein 10 






Springelkamp et al., 
2015 [134] 
rs1074407 TRIOBP TRIO- and F-actin binding protein 609761 22q13.1 22 38,156,183 37,760,176 1  1  1 EU, AS MA 
IGGC 
>79,000 
Springelkamp et al., 
2017 [136] 
rs5756813 TRIOBP TRIO- and F-actin binding protein 609761 22q13.1 22 38,175,477 37,779,470   1   EU, AS GWAS 27,878 
Springelkamp et al., 
2014 [103] 






Springelkamp et al., 
2015 [134] 
rs7291444 PKDREJ 
polycystin and sea urchin REJ 
homolog-like 





Appendix C Scripts for MGA  
C.1 Subset vcf file and join to MGA data file 
C.1.1 Subset vcf file to same regions as extracted from MGA file 
# bed file used for this is identical to bed file for extracting mgassoc results except no column 
headings in the bed file here. 
 
module load bcftools 
bcftools view -R BED_FILE_for_vcf.txt -O v -o 
extracted_vcf_section_SNPs_.vcf full_vcf_file.vcf.gz 
 
C.1.2 Join extracted MGA results to extracted and annotated vcf files 
library(tidyr) 
library(dplyr) 
# Read in extracted mgassoc file 
trait_mgassoc <- read.csv(file = "extracted_mgassoc_file.csv", header = TRUE, sep = ",") 
# Need to make sure that the bp column is read as numbers 
trait_mgassoc$bp <- as.numeric(as.character(trait_mgassoc$bp)) 
# to remove the chr and bp columns which aren't needed anymore - although sometimes handy 
to leave for data sorting. 
trait_final <- select(trait_mgassoc, -Chr, -bp) 
# to join on to annotated, peaks extracted vcf file (NOTE: vcf file needs prep work before this 
stage) 
annotatedVCFfile <- read.table("annotatedVCFfile.txt", header = TRUE, sep = 
"\t", as.is = TRUE, quote="") 
# to turn it into a table 
annotatedVCFfile_table <- tbl_df(annotatedVCFfile) 
# to combine columns to make it look like the mgassoc file 
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  ## need to join by POS rather than Start as indels become "normalised" once annotated, 
affecting the starting positions of deletions) 
     ## some deletions also in SNP file, so joining by POS is better for both SNPs and indels 
combined_columns_annotatedVCFfile <- unite(annotatedVCFfile_table, SNP, 
Chr, POS, sep = "_") 
## To combine the mgassoc file with annotated vcf file (mgassoc on left) 
joined <- inner_join(trait_mgassoc, combined_columns_annotatedVCFfile, by = 
"SNP") 
 
# To write the final, joined table as a new file 
write.csv(joined, 
          file = "output_file_mgassoc_annotated.vcf.csv", 










Appendix D Linkage analysis scripts 
D.1 R script for removing rare variants and setting low quality calls to 
“missing” 
# Using full vcf file, NOT annotated 
library(tidyr) 
library(dplyr) 
# Read in vcf 
full_vcf <- read.table(file = "full_vcf_file.vcf", 
            sep="\t", header=FALSE, quote = "", as.is=TRUE,na.strings=".",  
            stringsAsFactors = FALSE, colClasses = "character") 




# Count the number of heterozygous variant calls each variant in the file and add this as a new 
column in the vcf file 
## The ^ is to only count the genotypes at the beginning of the each cell (the info column has           
"unwanted" genotypes in it) 
## The [/|] is to pick up both unphased and phased genotypes. Prob won't make a difference 
here, but might for future runs 
full_vcf_cleaned$het_counts <- apply(full_vcf_cleaned, 1, function(x) 
sum(grepl('^1[/|]0|^0[/|]1', x))) 
# Count the number of homozygote variant calls each variant in the file and add this as a new 
column in the vcf file 
full_vcf_cleaned$hom_counts <- apply(full_vcf_cleaned, 1, function(x) 
sum(grepl('^1[/|1]', x))) 
# Create another column which adds 1 per het count and 2 per homozygous count 
full_vcf_cleaned$total_counts <- (full_vcf_cleaned$het_counts + 
2*full_vcf_cleaned$hom_counts) 
        # to check whether everything is looking ok 
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      head <- full_vcf_cleaned[1:200,] 
      write.table(head, file = "head.txt",sep = "\t", row.names = F 
      col.names = F, quote = F,na = ".") 
# Filter vcf file to get rid of rare or too common SNPs (filter is a dplyr function, so make sure   
it's loaded) 
filtered_between <- filter(full_vcf_cleaned, (full_vcf_cleaned$total_counts 
>= 8 & full_vcf_cleaned$total_counts <= 490)) 
        # to check whether everything is looking ok 
      top <- filtered_between[1:200,] 
      write.table(top, file = "top.txt",sep = "\t", row.names = F, 
      col.names = T, quote = F, na = ".") 
# After filtering, delete the 3 columns which I added in to do the counts (columns 259 to 261) 
final_vcf <- filtered_between[, -c(259:261)] 
# If this file is going to be used to blank out PedCheck error SNPs, need to have some form of 
ID no. in ID column 
  # Just copy bp position from column 2 to column 3 to use as ID 
final_vcf$V3 <- final_vcf$V2 
# Write table for remerging with the vcf header 
write.table(final_vcf,file = output_cleaned_filtered_vcf_file.vcf", 
            sep = "\t", row.names = F, col.names = F, quote = F, 
            na = ".") 
 
D.2 PLINK command to remove SNPs with missing genotype calls, 
deviation from Hardy-Weinberg Equilibrium, presence on sex 
chromosomes and recode as a vcf file. 
# --geno 0.05 removes variants with missing call rates exceeding 5% 
# --hwe 0.001 removes variants with a Hardy-Weinberg exact test p-value less than 0.001 
# --chr 1-22 only retains autosomal variants 
# --recode vcf creates an output vcf file (necessary for Mendelian error checking steps) 
 
plink --vcf input_vcf_file.vcf --geno 0.05 --hwe 0.001 --chr 1-22 \ 
--recode vcf --out output_vcf_file 
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D.3  File preparation for PedCheck 
D.3.1 Subset filtered vcf into individual chromosomes (loop command) 
# Filtered vcf input file: filteredSNPs.vcf 
module load bcftools \ 
for chr in {1..22}; do bcftools view -t chr${chr} -O v -o 
chr${chr}filteredSNPs.vcf filteredSNPs.vcf & done 
# Output files: chr${chr}filteredSNPs vcf files 
 
D.3.2 Create PLINK ped and map files (loop command) 
# alleles needed numerical coding instead of alphabetic 
module load plink \ 
for chr in {1..22}; \ 
do plink --vcf chr${chr}filteredSNPs.vcf --allele1234 --recode --cm-map \ 
file_path_to/genetic_map_chr@_combined_b37.txt --out chr${chr}PLINKPed & 
done 
# Output files: chr$chrPLINKped.map and chr${chr}PLINKPed.ped 
 
D.3.3 Modification of map file for PedCheck (loop command)  
# concatenate individual chromosome map files into 1 full map file 
for chr in {1..22}; do cat chr${chr}PLINKPed.map >> all_chr_PLINKPed.map \ 
& done 
# use excel to concatenate chromosome and base pair position columns into 1 column (chr_bp).  
# delete all other columns 
# subset this full file back to individual chromosomes 





D.3.4 Modification of ped file for PedCheck (loop command) 
# R script (loop command) for joining PLINK produced ped files with extra pedigree 
information 
library(dplyr) 
# Read in ped file (family info only).This has the new ID numbers and is sorted by generations 
within families.  
# Changed .ped to .txt before doing this. 
familyPED <- read.csv(file = "PEDforPedCheck.ped.txt", header = TRUE, sep = 
"\t") 
# Start of loop command 
for (chr in 1:22) { 
# Read in PLINK.ped output file.Added a .txt to the end of the output file. 
PLINKped <- read.csv(file = paste("chr", chr, "PLINKPed.ped.txt", sep = 
''),  
FALSE, sep = " ") 
# Name column 2 in the PLINKped file as "ID" (as can't join the 2 files without named column) 
colnames(PLINKped)[2] <- "ID" 
# Join original ped file to PLINK output ped file. Inner join only retains the rows in both sets 
(ie only the people with WES info) 
JoinedPED <- left_join (familyPED, PLINKped, by = "ID") 
# Delete columns not necessary for PedCheck (ie generation, ID,SEX, V1 to V6) 
FinalPED <- select(JoinedPED, -6,-7,-V1,-V3,-V4,-V5,-V6) 
# write the output as a text file, so that I can manipulate for PedCheck  
write.table(FinalPED, file = paste("chr", chr, "PEDforPedCheck.ped.txt", 
sep = ''), 
     sep = "\t", 
     quote = FALSE, 
     na = "0", 
     row.names=FALSE, 




D.3.5 Mendelian error checking using PedCheck (loop command) 
# Loop which runs each chromosome separately (otherwise PedCheck crashes) 
# As PedCheck outputs an error file with the same name for each chromosome, need to rename 
the output file before starting on the next chromosome. Run in sequence rather than in parallel 
for this reason. 
module load pedcheck 
for chr in {1..22}; do \ 
pedcheck -p chr${chr}PEDforPedCheck.ped \ 
-n chr${chr}NAMESforPedCheck.txt -4 -e -a; \ 
mv pedcheck.err chr${chr}PedCheck.err; done 
 
D.3.6 Remove Mendelian error SNPs from vcf file (loop command) 
# SNPs to exclude files made for each chromosome. Just a list of the bp positions in a text file. 
module load plink 
for chr in {1..22}; \ 
do plink --vcf chr${chr}filteredSNPs.vcf --exclude 
chr${chr}_excludeSNPs.txt \ 
--recode vcf --out chr${chr}PLINKno_errors & done 
 
D.4 File preparation for IBDLD 
D.4.1 PLINK command for IBDLD file prep 
# default letter coding for alleles needed for this 
module load plink 
plink --vcf input.vcf --recode --cm-map \ 




D.4.2 Map file requirements for IBDLD 
# PLINK output map file needs an additional unique SNP identification number in the second 
column. Rather than using rs numbers (which not every variant has), I created a unique 
chromosome_base-pair-location number using “concatenate” with Excel. 
# Output files: MAP_file_for_IBDLD.map 
D.4.3 Modification of ped file for IBDLD 
# R script to modify PLINK ped file output for IBDLD input 
library(dplyr) 
# Read in ped file (family info only).This has the new ID numbers and is sorted by generations 
within families. Changed .ped to .txt before doing this. 
familyPED <- read.csv(file = "ped_file.ped.txt", header = TRUE, sep = "\t") 
# Read in PLINK.ped output file Added a .txt to the end of the output file. 
  ## The colClasses command is to stop R reading in a column of "T" as "True" 
PLINKped <- read.csv(file = "PLINKped_output_file.ped.txt", header = FALSE, 
            sep = " ", colClasses = "character") 
# Name column 2 in the PLINKped file as "ID" (as can't join the 2 files without named column) 
colnames(PLINKped)[2] <- "ID" 
# Join original ped file to PLINK output ped file. Inner join only retains the rows in both sets 
(ie only the people with WES info) 
JoinedPED <- inner_join (familyPED, PLINKped, by = "ID") 
# Delete columns not necessary for IBDLD (ie ID,SEX, V1 to V6) 
FinalPED <- select(JoinedPED, -6,-V1,-V3,-V4,-V5,-V6) 
# write the output as a text file, so that IBDLD can work with it 
write.table(FinalPED, file = "PED_file_for_IBDLD.ped ", 
      sep = "\t", 
      quote = FALSE, 
      row.names=FALSE, 
      col.names=FALSE) 
#Output file: PED_file_for_IBDLD.ped 
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D.4.4 IBDLD command 
# -ploci 50 -dist 2 uses 50 previous loci withing a 2cM window to calculate LD 
# -mincallrate 0.95 sets the minimum threshold for each SNP for inclusion in LD calculations 
    and IBD estimation at 95% 
# -step 0 executes both LD calculation and IBD estimation steps in order 
# -ibd 2 outputs IBD sharing at each locus and Δ7 coefficient required for SOLAR 
# -hiddenstates 9 is the appropriate setting for related individuals in a pedigree and sets the IBD 
    hidden states number to 9 
# --ibdtxt outputs ibd probabilities as a text file 
 
module load IBDLD 
ibdld -o prefix_for_IBDLD_output_files -p PED_file_for_IBDLD.ped \ 
-m MAP_file_for_IBDLD.map \ 
-ploci 50 -dist 2 -mincallrate 0.95 -step 0  -ibd 2 -hiddenstates 9 --
ibdtxt 
 
D.5 Generation of Multipoint identity by descent (MIBD) matrices 
D.5.1 To create MIBD files from ibd.txt. output files 
# awk script written by Juan Peralta 
#!/usr/bin/env awk -f 
# build solar mibd files directly from ibdld txt files  
# pass: 
# -v prefix="solar/mibd/mibd." 
# -v indexout="path/to/pedindex.out" 
# -v indexcde="path/to/pedindex.cde" 





  seen[-1]=1 
  addcrc=0 
  if (prefix == "") prefix="mibd/mibd." 
  if (indexout == "") indexout="pedindex.out" 
  if (indexcde == "") indexcde="pedindex.cde" 
  col = 1 
  len = 1 
  FS=" " 
  while(getline < indexcde) { 
    if (NR==1) continue; 
    if ($2=="ID") { len = $1; break; } 
    col = col + $1 
  } 
  while(getline < indexout){ 
    id=substr($0,col,len) 
    gsub(" ","",id) 
    ibdid[id]=$1 
  } 
  FS="\t" 
  while(getline < map){ 
    mchr[$2] = $1 
    mcm[$2] = $4 
  } 
 
} 
# map marker names to column numbers, 2 cols per name 
NR == 1 { 
  colspermarker = $1 
  chr = $3 
  j=5 
  for (i=5;i<=NF;i++){ 
    idx[$i]=j 
    j=j+colspermarker 
  } 
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  for (m in mcm) { 
    if (!(m in idx)) delete mcm[m]  
  } 
# mark mibd with crc from pedindex file 
  if (! (cm in seen) && addcrc) { 
    printf " %5i  %5i  %s %s\n",ibdid1,ibdid2,"0.1923398118",".28249" >> 
prefix""$1"."cm 
    seen[cm]=1 
  } 
} 
# ignore famids in the output 
# save each col into a different mibd file 
NR > 1{ 
  for (m in mcm){ 
    cm = int(mcm[m]) 
    i = idx[m] 
    j = i + 1; 
#print m,cm,idx[m],i,j >> prefix""chr"."cm 
    if ($2 == $4) done[$2] = y 
    printf "%5i %5i  %.7f  %0.7f\n",ibdid[$2],ibdid[$4],$i*2,$j >> 
prefix""chr"."cm 
  } 
#  if (ibdid1 == ibdid2) { 
#      diag[$1"@"cm"@"ibdid1]=1 
#  } 
#  if (! ($1 in chrs)) chrs[$1]=1 
#  if (! (cm in cms)) cms[cm]=1 
#  printf "%5i %5i  %.7f  %0.7f\n",ibdid1,ibdid2,$6*2,$7 >> prefix""$1"."cm 
} 
 
# gzip mibd files 
END { 
  for (m in mcm){ 
    cm = int(mcm[m]) 
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    # print missing diagonal elements 
    for (i in ibdid) { 
      if (! (i in done)) { 
        printf "%5i %5i  %.7f  %0.7f\n",ibdid[i],ibdid[i],1.0,1.0 >> 
prefix""chr"."cm 
      } 
    } 
    system("gzip -f "prefix""chr"."cm) 
  } 
} 
 
D.5.2 Preparation of map file for MIBD generation I - removal of SNPs not used for IBD 
estimation 
# Remove SNPs which were excluded from the IBDLD calculations 
# This info (241 SNPs) extracted from the log file generated by IBDLD and saved in 1 column 
(1 SNP per line). 
# R script used to join extracted SNPs on to map file used for IBDLD program 
library(dplyr) 
# Read in IBDLD map file (full list of variants) 
IBDLDmap <- read.csv(file = "IBDLD_map_file.map.txt",header = FALSE, 
                            sep = "\t") 
# Read in filtered SNP file (filtered out by IBDLD, want to delete from map file for MIBD) 
filteredSNPs <- read.csv(file = "filteredSNPs_IBDLD_99%.txt", header = 
FALSE) 
# Add in a column to filtered file to indicate which are the SNPs to remove 
filteredSNPs$V2 <- "to_remove" 
# Name V2 column in files to use for joining 
colnames(IBDLDmap)[2] <- "chr_bp" 
colnames(filteredSNPs)[1] <- "chr_bp" 
# Join full IBDLD file with filtered SNPs file 
fullMAP <- full_join(IBDLDmap, filteredSNPs, by = "chr_bp") 
# write the output as a text file 
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write.table(fullMAP, file = "IBDLD_map_with_SNPs_to_remove.txt", 
      sep = "\t", 
      quote = FALSE, 
      row.names=FALSE, 
      col.names=FALSE, 
      na = "") 
# Open file in Excel and sort based on “to remove” column. Delete identified rows. 
 
D.5.3 Preparation of map file for MIBD generation II - selection of 1SNP per cM markers 
# Switch cM and bp columns in excel, so new map file reads chr, chr_bp, bp,cM 
# Use INT function in excel to create a new column which rounds cM position down to the 
   nearest integer. 
# Then use “remove duplicates” while selecting the chromosome and INT columns to just 
   retain 1 marker per cM (retains the first value in the list and removes all duplicates below). 
# Remove INT column, to retain the 4 original columns. 
# Subset the full map file into files for each chromosome 
 
D.5.4 MIBD file generation (loop command) 
# loop command for using the custom awk script with individual chromosome map files, 
IBDLD output files and pedigree indexing files to generate MIBD files 
 
for chr in {1..22}; do \ 
zcat file_path_to/POAGdate_${chr}.ibdtxt.gz | awk \ 
-f ibdld2mibd.awk -v prefix=MIBD/mibd. -v indexout=pedindex.out \ 





D.5.5 MIBD file processing 
# grm program written by Juan Peralta, University of Texas Rio Grande 
# -z truncates negative values to zero 
# -m maximum number of iterations allowed for convergence 
# -t tolerance parameter removed (default is 1x10-6) 
 
for f in mibd.*; do \ 
LD_LIBRARY_PATH=. ./grm nearest_psd -z -m 400 -i linearsymmetric -o linear 
<(zcat $f | awk 'NR==1 {print "id1,id2,matrix1"} {print $1","$2","$3}') | 
awk -v mibd=$f 'BEGIN {FS=" ";cmd="zcat "mibd; while(cmd | getline){ 
d7[$1,$2]=$4};FS=","} NR>1 {printf "%5i %5i  %.7f  %0.7f\n", 
$1,$2,$3,d7[$1,$2]}' | gzip -c > processed_$f; done 
 
D.6 Empirical kinship file (phi2) preparation 
# The  prefix_genome.kinship IBDLD output file was used as the starting point for the 
phi2 file.  
# The 15th column was multiplied by 2 (in a new column). The ID numbers and new phi2 
column were retained and all other columns deleted. 
# Headers of id1, id2 and marker1 for the 3 retained columns. 
# File saved as a .csv (for the correct formatting) and then the extenstion was deleted. 




D.7 Ascertainment correction tcl script for IOP and IOPmed 
# Similar modelling commands as in Appendix A.8, except polymod and maximise are used 
instead of polygenic -screen 
# This script shows constraint of MaxIOP mean, SD and beta values for the covariates 
 
proc ACscript_TRAIT {} { 
 model new 
 trait IOP 
 covariate age^1,2#sex  
 polymod 
 constrain mean = 15.42639902 
 parameter mean = 15.42639902 
 constrain sd = 3.338103473 
 parameter sd = 3.338103473 
 constrain bage = 0.01620147599 
 parameter bage = 0.01620147599 
 constrain bsex = -0.164419209 
 parameter bsex = -0.164419209 
 constrain <bage*sex> = 0.00680895065 
 parameter bage*sex = 0.00680895065 
 constrain <bage^2> = -0.0008252308106 
 parameter bage^2 = -0.0008252308106 
 constrain <bage^2*sex> = -0.0004636277018 
 parameter bage^2*sex = -0.0004636277018 
 matrix load -sample V25_phi2.gz phi2 
 option MergeAllPeds 1 
 maximize 







D.8 Ascertainment correction tcl script for maximum VCDR 
# Similar modelling commands as in Appendix A.8, except polymod and maximise are used 
instead of polygenic -screen 
# This script shows constraint of MaxVCDR mean, SD and beta values for the covariates 
proc ACscript_VCDR {} { 
 model new 
 trait VCDR 
 covariate age^1,2#sex 
 polymod 
 constrain mean = 4.46177549 
 parameter mean = 4.46177549 
 constrain sd = 2.020809901 
 parameter sd = 2.020809901 
 constrain bsex = -0.355021133 
 parameter bsex = -0.355021133 
 constrain bage = 0.02753255984 
 parameter bage = 0.02753255984 
 constrain <bage*sex> = -0.004957120049 
 parameter bage*sex = -0.004957120049 
 constrain <bage^2> = -0.0007189157873 
 parameter bage^2 = -0.0007189157873 
 constrain <bage^2*sex> = 0.0002952706829 
 parameter bage^2*sex = 0.0002952706829 
 matrix load -sample V25_phi2.gz phi2 
 option MergeAllPeds 1 
 maximize 






D.9 Linkage analysis with ascertainment correction commands for 
SOLAR 
 
# load pedigree and phenotype files 
load ped pedigree_file.ped 




# load tcl script which includes covariates, constraints, loading phi2 and MergeAllPeds 
# no need to type .tcl at the end 








# run linkage for all the chromosomes 
chromosome 1-22    # or chromosome all 
 
# interval of 1 marker 
interval 1 
 
# run the multipoint linkage analysis for QTLs with a LOD ≥ 3 and do additional passes until 
the largest peak does not reach LOD =2 
multipoint 3 2 
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Appendix E MGA results for QTL analysis 
The following table contains the measured genotype association results for the IOPmed trait 
with p ≤ 0.05 from within the linkage intervals described in Chapter 5.3.1, broken down into 
MAC present within each family. 
chr_bp = chromosome number and base pair position (hg19) 
beta-value = effect size (mmHg), non-transformed data 
Included in MGA (MAC) = minor allele count of genotype data with accompanying phenotype data 
included in the measured genotype analysis 
Total Genotyped (MAC) = total minor allele count genotyped in the families  
Rows in bold = a single family contributing ≥ 90% of the MAC and tested for linkage conditional on 
the measured genotype 
 










































































chr2_148687731 0.03672 -3.10403 71 15 3 33 15 6 72 
chr2_149881029 0.021112 -0.31372 72 23 13 20 5 10 71 
chr2_150327599 0.009312 2.32815 11 1 0 2 0 8 11 
chr2_152220510 0.012683 -5.86676 9 0 0 1 7 2 10 
chr2_152226616 0.012683 -5.86675 9 0 0 1 7 2 10 
chr2_152300147 0.00534 -9.36015 4 0 0 0 5 0 5 
chr2_152317669 0.021508 1.71079 34 0 0 36 0 0 36 
chr2_152321091 0.032912 -6.79727 5 0 0 5 0 0 5 
chr2_152331769 0.009528 0.95387 60 5 2 43 9 4 63 
chr2_152331995 0.021508 1.71079 34 0 0 36 0 0 36 
chr2_152387592 0.051654 2.32988 16 16 0 0 0 0 16 
chr2_152658296 0.015969 3.07686 5 1 2 2 0 0 5 
chr2_152695190 0.018201 3.13282 6 0 0 1 3 2 6 
chr2_152976670 0.039887 -4.96469 10 3 1 5 0 1 10 
chr2_152976702 0.039887 -4.96469 10 3 1 5 0 1 10 
chr2_153032341 0.013664 2.03996 13 0 0 0 3 10 13 
chr2_154334499 0.047524 -0.66388 250 71 32 87 39 25 254 
chr2_155555878 0.029176 1.44245 15 2 1 0 0 12 15 
chr2_157441670 0.014453 1.74038 17 6 0 0 0 11 17 
chr2_157442354 0.033259 -6.79592 5 0 0 5 0 0 5 
chr2_158157361 0.011068 1.42136 464 111 71 179 65 46 472 
chr2_158177675 0.001213 7.99404 6 0 6 0 0 0 6 
chr2_158385315 0.047841 2.41229 15 15 0 0 0 0 15 
chr2_159166069 0.016792 1.70981 471 112 66 175 74 52 479 
chr2_159517926 0.018676 -7.17334 8 0 2 5 1 0 8 
chr2_159536990 0.001276 4.61379 8 0 0 0 0 8 8 
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chr2_159537297 0.034126 2.44277 7 1 1 0 5 0 7 
chr2_159954175 0.018085 -2.88489 115 29 16 25 19 27 116 
chr2_160569020 0.044099 1.57866 24 23 0 0 0 1 24 
chr2_160604379 0.044099 1.57866 24 23 0 0 0 1 24 
chr2_160604768 0.044099 1.57866 24 23 0 0 0 1 24 
chr2_160604812 0.030669 -2.77613 160 33 18 62 33 16 162 
chr2_160625727 0.001138 -3.52924 149 35 16 53 33 14 151 
chr2_160627317 0.005055 -3.06511 97 27 12 35 17 8 99 
chr2_160628155 0.000701 -3.57268 147 35 17 52 32 13 149 
chr2_160639970 0.000666 -3.64955 145 32 16 52 33 14 147 
chr2_160660189 0.028976 1.62844 25 23 1 0 0 1 25 
chr2_160661107 0.048186 1.53375 24 23 0 0 0 1 24 
chr2_160737622 0.005487 -9.35673 4 0 0 0 5 0 5 
chr2_160919050 0.037884 3.37375 5 0 0 0 5 0 5 
chr2_161349966 0.041938 2.16138 17 17 0 0 0 0 17 
chr2_163128824 0.026782 -3.06399 344 94 37 120 53 46 350 
chr2_165946416 0.044685 0.86674 14 1 0 0 13 0 14 
chr2_166032775 0.012 -3.67418 39 3 7 22 1 6 39 
chr2_166740469 0.033389 0.95825 32 23 5 2 0 2 32 
chr2_166810232 0.007935 3.42906 9 0 0 0 0 9 9 
chr2_167144974 0.000885 -3.44397 198 46 16 88 32 22 204 
chr2_167144995 0.002962 -3.35093 171 44 16 61 32 21 174 
chr2_167145142 0.003462 -3.26942 162 43 15 59 30 18 165 
chr2_167313451 0.033368 -3.29698 84 20 10 32 18 5 85 
chr2_167321993 0.020364 2.30886 20 20 0 0 0 0 20 
chr2_168102774 0.017428 -4.24146 28 7 12 3 2 4 28 
chr2_168104183 0.033646 -6.64238 5 1 0 4 0 0 5 
chr2_168726592 0.047905 2.64191 8 0 0 9 0 0 9 
chr2_168726659 0.00255 0.50725 102 36 7 35 15 10 103 
chr2_169952233 0.02097 -3.10096 85 16 5 29 22 13 85 
chr2_170361334 0.005038 -3.92889 56 12 12 22 6 4 56 
chr2_170367099 0.005038 -3.92889 56 12 12 22 6 4 56 
chr2_170403106 0.020682 0.60382 43 8 15 6 1 13 43 
chr2_170430388 0.026969 -0.25604 113 20 21 34 26 15 116 
chr2_170597913 0.053042 -7.18340 8 0 0 9 0 0 9 
chr2_170762566 0.053739 -0.42084 80 15 18 15 19 13 80 
chr2_171242761 0.045859 -1.64938 82 19 2 39 18 6 84 
chr2_171570151 0.039398 -1.41272 139 13 18 48 28 35 142 
chr2_171570488 0.001828 -1.79131 316 71 25 140 47 39 322 
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chr2_171573597 0.022572 4.43855 16 16 0 0 0 0 16 
chr2_171574217 0.002474 -2.06115 343 74 26 155 50 44 349 
chr2_171849612 0.010833 2.07926 112 26 30 26 19 13 114 
chr2_171910313 0.010833 2.07926 112 26 30 26 19 13 114 
chr2_172174150 0.02009 -1.34278 343 88 46 109 62 45 350 
chr2_172174151 0.02009 -1.34278 343 88 46 109 62 45 350 
chr2_172174263 0.021883 -1.41399 351 89 48 112 63 46 358 
chr2_172175068 0.026575 -1.37750 337 84 40 112 62 46 344 
chr2_172188368 0.039098 1.26829 136 25 24 67 11 10 137 
chr2_172412835 0.047152 -1.36000 104 26 18 34 21 9 108 
chr2_172412836 0.047152 -1.36000 104 26 18 34 21 9 108 
chr2_172585298 0.030574 1.89826 41 7 3 23 3 7 43 
chr2_172650165 0.026833 -3.16920 19 2 0 9 6 2 19 
chr2_172864845 0.017563 -0.99053 264 63 31 94 37 44 269 
chr2_172953525 0.007935 5.02290 9 0 0 0 0 9 9 
chr2_173352103 0.040329 -1.51678 82 9 11 43 12 10 85 
chr2_173369000 0.011837 -1.91599 76 9 9 43 11 7 79 
chr2_173461090 0.053921 2.39005 21 1 0 9 2 9 21 
chr2_173463649 0.022572 4.43855 16 16 0 0 0 0 16 
chr2_173588663 0.029383 2.20717 20 1 2 6 0 11 20 
chr2_173686569 0.024137 -8.81417 3 69 33 106 23 23 254 
chr3_71731348 0.033903 1.80156 56 3 15 10 9 19 56 
chr3_73024350 0.002121 1.63430 313 90 40 110 31 46 317 
chr3_73437185 0.011651 4.46663 10 0 0 1 0 9 10 
chr3_75471002 0.018981 4.23992 10 0 0 0 0 10 10 
chr3_75471289 0.024081 3.35708 13 4 9 0 0 0 13 
chr3_75471644 0.041758 2.70174 14 5 9 0 0 0 14 
chr3_75471832 0.041758 2.70174 14 5 9 0 0 0 14 
chr3_75476615 0.041758 2.70174 14 5 9 0 0 0 14 
chr3_75477000 0.041758 2.70174 14 5 9 0 0 0 14 
chr3_77089699 0.040147 1.31813 68 23 14 14 5 13 69 
chr6_143091769 0.010803 1.94990 75 14 29 17 8 7 75 
chr6_143780313 0.003533 6.06502 8 0 8 0 0 0 8 
chr6_143876124 0.046952 -1.18018 114 29 19 33 12 21 114 
chr6_143890039 0.002539 -1.58743 340 74 47 119 62 42 344 
chr6_143890049 0.00483 -1.45827 341 75 47 119 62 42 345 
chr6_143890097 0.006376 -1.43845 342 75 48 119 62 42 346 
chr6_144150609 0.033318 1.81971 55 12 12 20 7 5 56 
chr6_144150831 0.03243 1.80093 56 12 12 21 7 5 57 
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chr6_147887092 0.003194 6.02032 11 0 9 1 1 0 11 
chr6_147887218 0.030777 1.11850 310 53 53 129 44 37 316 
chr6_147887569 0.019099 1.23319 161 37 34 46 28 18 163 
chr6_147887890 0.002295 3.70064 24 3 16 1 2 2 24 
chr6_147888022 0.031363 1.09751 316 53 55 132 45 37 322 
chr6_147890370 0.000369 4.26638 23 3 16 1 2 1 23 
chr6_150239330 0.034563 -2.01054 69 7 6 33 5 19 70 
chr6_150240829 0.034563 -2.01054 69 7 6 33 5 19 70 
chr6_150570837 0.031942 -3.24875 13 3 0 5 3 2 13 
chr6_150570867 0.031942 -3.24876 13 3 0 5 3 2 13 
chr6_150570940 0.031942 -3.24876 13 3 0 5 3 2 13 
chr6_150719710 0.016934 -1.49973 273 79 18 95 54 32 278 
chr6_151152230 0.034745 4.45393 8 0 8 0 0 0 8 
chr6_151670690 0.026239 -2.64579 18 1 3 11 3 0 18 
chr6_151672285 0.039019 -2.42027 19 1 4 11 3 0 19 
chr6_151674270 0.026239 -2.64579 18 1 3 11 3 0 18 
chr6_151674326 0.021986 1.52424 332 81 63 108 49 37 338 
chr6_151678315 0.047685 1.33775 333 85 61 109 48 36 339 
chr6_151678385 0.044608 1.31602 331 83 62 109 46 37 337 
chr6_151678499 0.036508 1.43204 338 85 63 110 49 37 344 
chr6_151679198 0.036508 1.43204 338 85 63 110 49 37 344 
chr6_151685528 0.011532 1.61660 311 81 61 103 45 27 317 
chr6_151686905 0.012438 1.58705 312 82 61 103 45 27 318 
chr6_151726300 0.044336 -1.50777 94 17 2 47 13 16 95 
chr6_151766552 0.021243 -2.49787 41 8 4 26 3 1 42 
chr6_151773504 0.045027 -1.24940 127 28 7 56 13 24 128 
chr6_151789912 0.035681 -2.25948 42 8 4 27 3 1 43 
chr7_55238268 0.021056 1.21829 146 56 11 29 38 12 146 
chr7_55238464 0.034338 1.15142 144 54 11 28 38 13 144 
chr7_55268916 0.040816 -2.09606 38 7 4 12 7 9 39 
chr7_55539538 0.011415 4.51296 11 0 0 12 0 0 12 
chr7_55540132 0.004189 -1.89892 89 20 8 48 10 5 91 
chr7_55714282 0.015883 -1.34902 269 68 23 99 60 25 275 
chr7_55749559 0.007659 -2.02621 66 11 6 39 6 7 69 
chr7_55749603 0.017199 2.07883 120 30 21 46 13 11 121 
chr7_55862375 0.051692 1.67622 29 4 6 6 6 8 30 
chr7_56087300 0.027421 1.65745 76 29 5 23 7 13 77 
chr7_56087319 0.017133 1.76859 77 29 6 23 7 13 78 
chr7_56087364 0.017133 1.76859 77 29 6 23 7 13 78 
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chr7_56087365 0.017133 1.76859 77 29 6 23 7 13 78 
chr7_56087374 0.017133 1.76859 77 29 6 23 7 13 78 
chr7_56087379 0.017133 1.76859 77 29 6 23 7 13 78 
chr7_56087399 0.013163 1.87845 76 29 6 22 7 13 77 
chr7_56087409 0.013163 1.87845 76 29 6 22 7 13 77 
chr7_56087423 0.026111 1.70278 74 28 6 21 7 13 75 
chr7_56088811 0.024994 1.76331 72 28 5 20 7 13 73 
chr7_56088825 0.022266 1.79305 73 28 5 21 7 13 74 
chr7_56088902 0.007411 2.02720 72 29 5 21 7 11 73 
chr7_56088907 0.007411 2.02720 72 29 5 21 7 11 73 
chr7_56088908 0.007411 2.02720 72 29 5 21 7 11 73 
chr7_57528997 0.046438 0.88542 180 22 28 65 44 23 182 
chr7_57529392 0.046438 0.88542 180 22 28 65 44 23 182 
chr7_57530627 0.046438 0.88542 180 22 28 65 44 23 182 
chr7_57530731 0.043 0.91429 176 22 28 64 42 22 178 
chr7_57530733 0.043 0.91429 176 22 28 64 42 22 178 
chr7_57530786 0.033895 0.93837 219 25 29 88 47 32 221 
chr7_57531189 0.045244 0.86260 203 25 26 77 46 31 205 
chr7_57531524 0.049125 0.88860 179 22 28 65 43 23 181 
chr7_57531737 0.046438 0.88542 180 22 28 65 44 23 182 
chr7_57531922 0.048092 0.87710 181 22 28 66 44 23 183 
chr7_62809629 0.01444 5.99714 8 8 0 0 0 0 8 
chr7_63674464 0.006821 3.97540 22 0 8 15 0 0 23 
chr7_64254791 0.011112 1.26726 326 77 54 124 46 30 331 
chr7_64254901 0.008929 1.39304 333 80 56 124 47 31 338 
chr7_64292695 0.010306 -1.40817 158 36 16 58 27 25 162 
chr7_64293217 0.009827 -1.41627 158 36 17 56 27 25 161 
chr7_64293575 0.004743 -1.55064 159 36 17 57 27 25 162 
chr7_64293731 0.008494 -1.43742 160 36 17 58 27 25 163 
chr7_64311698 0.045154 3.80551 10 1 2 7 0 0 10 
chr7_64312825 0.045154 3.80551 10 1 2 7 0 0 10 
chr7_64313784 0.031492 -2.23034 453 96 70 170 73 52 461 
chr7_64389067 0.045154 3.80551 10 1 2 7 0 0 10 
chr7_64389478 0.045154 3.80551 10 1 2 7 0 0 10 
chr7_64437820 0.021674 -2.43071 459 98 72 172 73 52 467 
chr7_64437832 0.021674 -2.43071 459 98 72 172 73 52 467 
chr7_64661070 0.035846 1.72419 202 45 31 70 33 27 206 
chr7_65159983 0.041272 1.03087 203 44 36 64 36 28 208 
chr7_65425894 0.027299 -1.14825 245 67 26 97 35 23 248 
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chr7_65579838 0.011534 -4.49428 7 1 2 3 1 0 7 
chr7_65825257 0.013809 -1.86826 51 9 5 22 10 7 53 
chr7_66019649 0.023312 -1.72741 50 8 5 22 10 7 52 
chr7_66038388 0.006026 1.95280 67 12 13 28 12 3 68 
chr7_66098384 0.023312 -1.72741 50 8 5 22 10 7 52 
chr7_66107971 0.030377 -1.68291 51 8 5 22 11 7 53 
chr7_66297377 0.031411 -1.66180 52 8 5 23 11 7 54 
chr7_66421143 0.023312 -1.72741 50 8 5 22 10 7 52 
chr7_66760636 0.010972 1.27490 151 48 23 62 8 12 153 
chr7_66762277 0.024745 1.03540 205 62 27 83 12 23 207 
chr7_66764392 0.011411 -2.63992 36 7 4 16 8 1 36 
chr7_66767623 0.044782 1.28099 116 22 24 50 8 14 118 
chr7_66785137 0.025835 1.33131 188 60 27 75 11 18 191 
chr7_66786212 0.002585 -3.00772 36 5 5 19 5 2 36 
chr7_66786384 0.04138 1.28658 186 60 27 73 11 18 189 
chr7_71135043 0.01308 -3.92959 10 0 0 10 0 0 10 
chr7_71178166 0.000971 -3.26140 25 2 4 14 4 2 26 
chr7_71249529 0.014784 4.27507 13 0 0 14 0 0 14 
chr7_71249770 0.014784 4.27507 13 0 0 14 0 0 14 
chr7_72333411 0.01444 5.99714 8 8 0 0 0 0 8 
chr7_72334664 0.033018 -2.43115 21 8 0 10 2 1 21 
chr7_72338657 0.002418 2.62723 64 22 12 15 9 7 65 
chr7_72338825 0.040606 -2.42225 21 9 0 9 2 1 21 
chr7_72350159 0.025911 1.11899 288 87 54 89 40 22 292 
chr7_72350361 0.033798 1.11449 301 87 55 92 43 28 305 
chr7_72417063 0.015279 1.30693 266 75 48 82 42 23 270 
chr7_72418618 0.025961 2.33047 46 10 5 15 13 3 46 
chr7_72469999 0.052846 1.76094 140 33 27 57 7 17 141 
chr7_72476293 0.000313 6.59143 15 11 4 0 0 0 15 
chr7_72850305 0.001494 5.65415 14 10 4 0 0 0 14 
chr7_72855568 0.00498 8.45610 7 0 0 8 0 0 8 
chr7_72855662 0.029575 3.38497 12 3 2 4 3 0 12 
chr7_73020301 0.014512 -5.20449 479 112 72 173 73 56 486 
chr7_73096993 0.015851 -1.11394 159 36 29 62 16 19 162 
chr7_73097654 0.010458 -1.21946 158 36 29 61 16 19 161 
chr7_73536579 0.005095 8.43094 7 0 0 8 0 0 8 
chr7_73814702 0.038331 -3.63691 15 1 0 11 1 2 15 
chr7_74193642 0.039346 2.03234 12 2 1 8 1 0 12 
chr7_75046785 0.043941 1.45864 159 39 28 74 7 14 162 
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chr7_75048172 0.004798 -3.94712 8 0 1 6 1 0 8 
chr7_75051375 0.001166 1.69773 260 56 47 111 30 20 264 
chr7_75115535 0.03207 2.81049 20 0 0 17 3 0 20 
chr7_75141695 0.014784 4.27507 13 0 0 14 0 0 14 
chr7_75167225 0.046961 1.43214 136 34 23 65 5 12 139 
chr7_75544455 0.038538 -1.41599 172 15 40 59 39 21 174 
chr7_76038848 0.00086 4.17345 33 12 0 20 2 0 34 
chr7_76111938 0.006738 4.24846 25 12 0 13 1 0 26 
chr7_76239511 0.038826 -4.33925 6 0 0 5 2 0 7 
chr7_76610344 0.016849 -4.59266 8 0 0 8 0 0 8 
chr7_76619625 0.030922 -1.78738 76 21 7 19 11 19 77 
chr7_76629626 0.03436 -1.69654 158 44 15 60 16 25 160 
chr7_76631549 0.033471 -1.24804 114 27 10 42 22 16 117 
chr7_76669334 0.007761 -1.54339 112 26 11 40 23 16 116 
chr7_76681663 0.022883 -1.31064 96 20 11 33 24 10 98 
chr7_76681764 0.000241 -2.34286 101 22 6 39 22 15 104 
chr7_76682235 0.008884 1.86510 102 33 22 26 15 8 104 
chr7_77167371 0.0149 -3.34340 14 0 0 4 5 5 14 
chr7_77553078 0.041947 -2.72359 15 1 2 4 3 5 15 
chr9_137779026 0.041546 1.16452 171 20 36 82 17 19 174 
chr9_138012886 0.019012 -1.33445 140 24 40 39 28 12 143 
chr9_138453641 0.018304 2.69157 41 16 11 4 1 9 41 
chr9_138515632 0.020238 -4.13968 14 3 0 10 3 0 16 
chr9_138515991 0.041242 -1.89073 60 24 8 24 4 2 62 
chr9_138585419 0.010369 7.34035 7 0 0 7 0 0 7 
chr9_138586966 0.047378 2.35557 451 103 71 162 71 51 458 
chr9_138586967 0.047378 2.35557 451 103 71 162 71 51 458 
chr9_138700604 0.036658 7.00902 6 0 0 6 0 0 6 
chr9_138715799 0.026967 1.95662 31 7 3 10 11 1 32 
chr9_138836941 0.007331 1.52518 147 40 21 43 23 21 148 
chr9_138908250 0.027168 -1.87137 55 7 5 24 17 2 55 
chr9_139235606 0.010488 2.60756 35 21 1 4 3 7 36 
chr9_139256468 0.01519 2.24644 38 21 1 5 6 6 39 
chr9_139256541 0.034995 2.08737 36 21 0 5 5 6 37 
chr9_139296703 0.006599 5.18076 15 15 0 0 0 0 15 
chr9_139301708 0.000686 4.67169 22 15 0 0 1 6 22 
chr9_139351941 0.00505 3.62115 23 16 0 0 1 6 23 
chr9_139566823 0.017659 -2.29652 443 92 68 174 66 51 451 
chr9_139649934 0.03615 2.90053 15 11 4 0 0 0 15 
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chr9_139726239 0.016884 1.60980 373 97 62 117 56 46 378 
chr9_139964447 0.051812 -1.28576 133 27 8 69 26 5 135 
chr9_139975195 0.003499 3.17817 38 2 28 2 4 2 38 
chr9_140002995 0.018575 2.57932 42 21 2 1 3 15 42 
chr9_140003529 0.000044 3.19434 78 20 32 2 7 17 78 
chr9_140112447 0.018819 1.72059 70 24 5 13 8 20 70 
chr9_140194793 0.047551 -3.90527 5 1 0 2 2 0 5 
chr9_140277794 0.049938 -1.96111 35 8 3 13 8 5 37 
chr9_140342693 0.006599 5.18075 15 15 0 0 0 0 15 
chr9_140357943 0.001956 2.84684 46 17 7 7 2 13 46 
chr9_140400464 0.04592 -3.70320 7 0 5 0 2 0 7 
chr15_20777925 0.018561 1.40576 154 36 29 56 21 16 158 
chr15_20778593 0.016736 1.71828 36 14 10 5 2 5 36 
chr15_21932917 0.002253 2.34371 145 38 23 38 25 24 148 
chr15_21936054 0.002639 2.30104 145 39 23 38 24 24 148 
chr15_21936801 0.018173 2.04138 60 9 13 21 4 14 61 
chr15_21936861 0.047411 1.67117 135 35 23 33 23 24 138 
chr15_21937528 0.004425 2.19615 145 39 23 37 25 24 148 
chr15_21937536 0.002367 2.33134 146 39 23 38 25 24 149 
chr15_22014916 0.019128 3.41153 14 1 0 0 0 13 14 
chr15_22015598 0.028673 -0.89489 230 71 22 82 35 23 233 
chr15_22015940 0.028576 -1.06769 280 73 32 105 46 28 284 
chr15_22016334 0.01266 -1.73392 82 33 12 29 8 2 84 
chr15_22145400 0.049186 -1.11887 193 7 3 29 11 6 56 
chr15_22382655 0.033109 1.49971 142 56 27 101 44 34 262 
chr15_22383066 0.050809 1.08748 307 37 40 32 11 15 135 
chr15_22835939 0.017002 4.09186 11 0 0 0 0 11 11 
chr15_22863037 0.028362 -3.43487 9 0 1 8 0 0 9 
chr15_23043644 0.017002 4.09186 11 0 0 0 0 11 11 
chr15_23046770 0.011603 1.55032 338 66 58 134 48 37 343 
chr15_23052632 0.002385 1.86423 349 66 63 139 48 38 354 
chr15_23191502 0.035843 -1.16060 246 61 44 84 37 23 249 
chr15_23200323 0.012758 -1.47988 183 34 30 76 30 16 186 
chr15_23201566 0.012426 1.30457 276 63 41 97 42 37 280 
chr15_23377447 0.008723 -5.39482 5 0 0 5 0 0 5 
chr15_23377450 0.008723 -5.39481 5 0 0 5 0 0 5 
chr15_23445715 0.0154 2.23850 49 12 10 16 4 9 51 
chr15_23890600 0.034234 6.11886 6 6 0 0 0 0 6 
chr15_24410011 0.003292 2.42020 62 5 13 23 14 8 63 
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chr15_24410100 0.003292 2.42020 62 5 13 23 14 8 63 
chr15_24410204 0.007524 2.24996 60 5 12 23 13 8 61 
chr15_24412931 0.003016 3.15175 38 3 11 14 6 5 39 
chr15_24414271 0.003292 2.42020 62 5 13 23 14 8 63 
chr15_24924663 0.048426 -1.03352 106 14 17 43 22 10 106 
chr15_25101838 0.040159 1.57999 51 6 3 32 2 9 52 
chr15_25227494 0.045391 -1.01635 140 33 22 53 26 8 142 
chr15_25228550 0.023891 1.88528 203 51 32 68 33 23 207 
chr15_25362564 0.035889 1.64680 79 8 20 39 9 6 82 
chr15_25380969 0.010376 -5.84234 6 0 0 4 2 0 6 
chr15_25438493 0.010041 1.54228 107 11 3 59 14 21 108 
chr15_25925094 0.014669 -1.27939 209 54 25 68 40 26 213 
chr15_25953198 0.010223 -3.49603 15 0 3 5 3 4 15 
chr15_26790609 0.048712 3.09960 10 0 0 0 0 10 10 
chr15_28259941 0.048712 3.09960 10 0 0 0 0 10 10 
chr15_28474713 0.000491 10.34104 5 0 5 0 0 0 5 
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